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Abstract 
Transcutaneous immunisation (TCI) is a novel needle-free method of vaccine delivery, 
which involves the application of soluble antigens onto the surface of intact skin. In this 
thesis, the immunogenicity and neutralising potency of tetanus neurotoxin (TeNT) 
fragments were compared to that of tetanus toxoid (TTxd) following TCI. In addition, to 
understand the mechanisms of induction of immune response by TCI, in vitro and in vivo 
interaction of tetanus proteins with skin immune cells was also investigated. The 50kDa 
recombinant carboxyl-terminal fragment of tetanus toxin (HCWT) and a 50kDa HC mutant 
(HCM115) which is devoid of neuronal binding properties, were expressed and purified by 
affinity chromatography, and excess endotoxin removed by size exclusion 
chromatography. Mice immunized with HCWT, in the absence of adjuvant, induced the 
highest anti-toxoid and anti-HCWT antibody titers, with significant increases in the toxin 
neutralising antibody response when compared with TTxd. In vitro studies demonstrated 
that both HC fragments and TTxd were capable of up regulating the surface expression of 
activation marker ICAM-1 on murine bone-marrow derived dendritic cells (DC), but not 
on the human keratinocyte cell line HaCaT. Real-time reverse transcriptase-PCR (Real-
time RT-PCR) analysis showed that TNF-α expression was up regulated in vivo as early as 
10 minutes following TCI, and this was caused by shaving rather than by tetanus proteins 
themselves. Immunohistochemistry staining to monitor the translocation of HCWT 
fragment and TTxd through the skin following TCI showed that HCWT protein could be 
detected in both the epidermis and dermis within four hours post-application. However, 
TTxd translocation appeared to be much slower in comparison. Collectively, the results 
presented in this thesis suggest that TCI may provide an opportunity for effective delivery 
of toxin-like antigens, which harbor protective epitopes and that traditional toxoid proteins 
may not be optimal antigens for skin immunisation. 
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Vaccine preventable diseases 
Vaccination is an extremely effective and efficient method for reducing morbidity and 
mortality rates caused by infectious diseases. The introduction of routine vaccination 
schedules has led to the eradication of smallpox (Parrino and Graham, 2006) regional 
elimination of measles and polio (Featherstone et al., 2003;Hull et al., 1997) and 
substantial reductions in the mortality and morbidity of other diseases such as diphtheria, 
tetanus, pertussis, mumps, meningitis, rubella and hepatitis B (Chabot et al., 2004;Chen 
and Orenstein, 1996).  Nevertheless, despite these successes, infectious diseases still 
remain one of the highest causes of worldwide morbidity and mortality, particularly in 
developing countries where the implementation of vaccination programmes remain 
problematic.  In 2002, The World Health Organisation (WHO) estimated that over 2.1 
million deaths were caused by vaccine preventable disease, with over 213 000 due to 
tetanus (Figure 1.1). Tragically, many of these deaths could be prevented through the 
optimal use of currently available vaccines. 
 
Tetanus is a disease marked by severe muscular contractions and convulsions brought on 
by the powerful exotoxin produced by toxigenic forms of the bacterium, Clostridium tetani 
(Farrar et al., 2000). This disease is relatively rare in the developed countries since the 
introduction of the highly effective toxoid vaccine into routine immunisation schedules 
during the 1940s’ and 50s’ (Bardenheier et al., 1998). However tetanus, particularly 
neonatal and maternal tetanus, remains an important public health problem in over 48 
countries, primarily in Asia and Africa (Vandelaer et al., 2003).  
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Figure 1.1. Worldwide prevalence of deaths due to vaccine preventable disease.  (Data 
obtained from WHO, 2002; http://www.who.int/en/) 
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Tetanus: pathogenesis and disease 
C.tetani is a Gram-positive, obligate anaerobic, rod shaped, spore forming bacterium that is 
solely responsible for causing tetanus in man and animals (Figure 1.2). Spores are 
distributed worldwide in the environment and can be found in the gastrointestinal tracts of 
domestic and farm animals. C. tetani spores are extremely stable and therefore very 
difficult to eliminate once an environment becomes contaminated. Although most spores 
are killed through autoclaving at 120oC for 15 minutes, some can survive under very harsh 
and unfavourable conditions, such as prolonged exposure to temperatures below 120oC or 
exposure to chemicals such as iodine and hydrogen peroxide.  
 
Generally, tetanus infection occurs when spores from a contaminated environment enter 
the body via injury with a contaminated object, or when an open wound encounters 
infected material such as soil. Maternal and neonatal tetanus can be caused by 
environmental contamination during unhygienic abortions, births and post-natal care of 
newborn umbilical cords (Roper et al., 2007). Under favourable conditions, such as those 
found in necrotic tissues, C. tetani sporulation and vegetative growth rapidly occurs. At 
autolysis following the death of the bacterium, pathogenic strains of C.tetani release two 
toxins into the surroundings – tetanolysin and tetanospasmin. A role of tetanolysin has yet 
to be determined but studies have shown that it belongs to the cytolysins, which are a 
family of toxins that are capable of forming pores in the cytolpasmic membranes of cells 
(Bhakdi et al., 1993). In contrast, with a minimum lethal dose of 2.5ng/kg, tetanospasmin 
(or tetanus neurotoxin; Tent) is one of the most potent toxins known to man (Gill, 1982). 
The actions of TeNT can remain localised if released in small amounts, but if released in 
large quantities it can diffuse into adjacent muscle tissues and can be transported 
throughout the body via retrograde axonal transport to the central nervous system (CNS). 
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Once it reaches the CNS, TeNT blocks inhibitory moterneuron activity resulting in the 
classical clinical manifestations associated with generalised tetanus such as muscle 
stiffness and spasm. Classical features of tetanus disease are shown in Figure 1.3. Early 
onset of the disease usually affects the facial muscles, referred to as ‘Lock-jaw’or Risus 
sardonicus.  This is usually followed by spasms of the back muscles (opisthotonos), and as 
the disease progresses in severity, rigidity of muscles extends throughout the body, first in 
response to stimuli, but later spontaneously in painful spasms. 
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Figure 1.2. Micrograph of Clostridium tetani bacteria. Arrows indicate sub terminal 
endospores giving rise to bacillus with a drumstick appearance. (Picture courtesy of Centre 
for Disease and Control, USA; http://phil.cdc.gov/phil/home.asp). 
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Figure 1.3. Classical symptoms of tetanus disease. a) Patient suffering from tetanus 
spastic paralysis; b) neonate displaying body rigidity and paralysis of the back muscles 
known as opisthotonos; c) patient presented with symptoms of facial tetani including 
contractions of the masseter neck muscles; d) child suffering from a very painful spasms 
with the characteristic posture of raised elbows and full body muscles contracting. (All 
pictures courtesy of Centres for Disease Control and Prevention, USA; 
http://phil.cdc.gov/phil/home.asp) 
 
 
 
 
 
 
a) b) 
c) d) c) 
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Tetanus neurotoxin: structure and function 
Together with 7 serotypes of  botulinum neurotoxins (BoNT / A-G), TeNT belong to the 
family known as Clostridial neurotoxin (CNT), all of which exhibit a high degree of 
sequence and structural homology to one another. Collectively, BoNT and TeNT share 
approximately 30% sequence identity (Lacy and Stevens, 1999) and over 50% structural 
identity (Kurazono et al., 1992).  All members of the CNT are synthesized as single 
inactive 150 kDa polypeptides and are post-translationally modified before being released 
into the extracellular matrix. Following interaction with bacterial or host proteases (Farrar 
et al., 2000), the polypeptide is then cleaved into an active form consisting of two 
disulphide linked polypeptide chains termed the light chain (L-chain) and heavy chain (H-
chain; Figure 1.4). The 100kDa heavy chain can be further sub-divided into two 50kDa 
domains: the N-terminal (HN) and C-terminal (HC) domains. Both BoNT and TeNT have 
similar functions at the molecular level as each cleaves intracellular proteins essential for 
neurotransmitter release. However, whereas BoNT acts locally at the neuromuscular 
junction causing flaccid paralysis (Herreros et al., 1997;Lalli et al., 1999), TeNT 
undergoes axonal retrograde transport until it reaches the soma of the inhibitory motor 
neurones located within the CNS (Lalli et al., 2003). An assay system has been developed 
which allows visualisation of the TeNT fragment HC transportation in motor neurones to 
be followed via fluorescence microscopy (Lalli and Schiavo, 2002). In these neuronal 
cells, fluorescently tagged HC fragment was internalised in carriers which were powered by 
distinct molecular motors such as cytoplasmic dynein and myosin Va (Deinhardt and 
Schiavo, 2005; Lalli et al., 2003). Furthermore, HC retrograde carriers are shared with that 
for the nerve growth factor and the low affinity neuritrophin receptor p75NTR (Lali & 
Schiavo 2002). 
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Following uptake into the nerve axon, TeNT is transported across the synaptic junctions 
until it reaches the CNS where is rapidly attached to receptors at the presynaptic junctions 
of inhibitory motorneurones. A number of in vitro studies have shown that the HC domain, 
particularly the 25 kDa C-terminal domain of HC, is responsible for binding to neuronal 
cell receptors (Goldberg et al., 1981; Halpern and Loftus, 1993; Lalli et al., 1999). 
Although these receptors have yet to be fully characterised, experimental data has 
demonstrated that the HC fragment binds to complex gangliosides, in particular, those that 
belong to the 1b series such as GT1b or GD1b  (Fotinou et al., 2001; Sinha et al., 2000) 
which are present at high densities on neuronal cells. However, polysialogangliosides have 
been shown to bind TeNT with relatively low affinity, which therefore implies that they 
are not the only receptors involved in this initial binding step (Halpern and Neale, 1995). 
Numerous studies have been carried out to identify and characterise this second receptor. 
Early in vitro studies demonstrated that TeNT neuronal cell binding was sensitive to 
proteases thus suggesting that a protein receptor is also involved in the initial binding step. 
(Lazarovici and Yavin, 1986). Furthermore, cross-linking experiments with TeNT show 
the presence of a putative protein receptor that interacts with the neurotoxin (Herreros et 
al., 2000). Despite numerous efforts, the nature of this second putative receptor has yet to 
be fully established and remains a subject of great interest for future investigation.  
  
Following binding to inhibitory motorneurones, TeNT is taken up into endosomal 
compartments before being translocated into the cytosol of inhibitory motorneurones. The 
HN-fragment of TeNT is thought to be responsible for initiating the pH-dependent 
activation and translocation of the L-chain through the neuronal endosomal compartment 
(Montecucco and Schiavo, 1994). Upon release into the cell cytosol the L-chain zinc 
endopeptidase attacks vessel associated membrane proteins (VAMP) such as 
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synaptobrebin II  which are important  components of the molecular machinery responsible 
for controlling exocytosis of inhibitory neurotransmitters such as gamma-aminobutyne 
(GABA) and glycine  (Montecucco and Schiavo, 1994; Schiavo et al., 1992. This results in 
the generation of the characteristic clinical features of tetanus disease, such as unopposed 
muscle contraction and spasm, which can be detected in the infected host. 
 
Vaccination against tetanus disease 
Like many other toxin related diseases, immunity against tetanus is traditionally generated 
through active or passive immunisation. The vaccine responsible for protection against 
tetanus disease consists of tetanus toxoid (TTxd) which is produced by inactivation of 
TeNT through treatment with formaldehyde. The immunogenicity of TTxd can be further 
improved by absorption with aluminium salts. With a failure rate of only 4 in 100 million 
immunocompetent people, vaccination with TTxd is an extremely effective method of 
inducing protection against the development of tetanus disease (Farrar et al., 2000). 
 
Tetanus vaccines are available as a single TTxd component or as part of a combination 
vaccine. In an attempt to reduce the prevalence of neonatal tetanus in under developed 
countries, vaccination with TTxd alone is used for immunisation of pregnant woman and 
those of childbearing age (Demicheli et al., 2005;Maral et al., 2001). In the developed 
world it is more commonly used to prevent the development of tetanus di sease following 
possible exposure to C. tetani or spores through cuts or puncture wounds or as a booster in 
adults if antibody titres are low (Bracebridge et al., 2004). In regions with developed 
immunisation programmes, TTxd is usually administered in combination with diphtheria 
and whole cell pertussis antigenic components as part of the DTwP (diphtheria, tetanus and 
whole cell pertussis) vaccine. Alternatively, TTxd can be combined with a less reactogenic 
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and more immunogenic acellular pertussis component to form the DTaP (diphtheria, 
tetanus and acellular pertussis) vaccine. In an attempt to reduce the number of individual 
vaccination administrated to an individual, a number of antigens have been added to the 
core DTaP vaccine (Pines et al., 1999). Such antigens include hepatitis B (HBV), 
inactivated polio (IPV), H.influenzae type b (Hib) or more recently a six-valent 
combination of all, DTaP-HBV-IPV-Hib, was introduced for paediatric used (Aristegui et 
al., 1997; Aristegui et al., 1998; Aristegui et al., 2003). Although immunisation schedules 
differ from country to country, at least three doses of DTP are offered to infants before the 
age of 1 year. Following the final immunisation, anti-tetanus toxin serum concentrations 
remain above the minimum protective level (0.01IU/ml) for a number of years. However, 
the level of protective antibodies decline over time and therefore booster immunisations 
are required every 10 years to maintain an adequate level of immunity.  
 
Production of the TTxd component is laborious, time consuming and often requires 
handling large quantities of highly concentrated toxic material. Also, as the native TeNT is 
detoxified by treatment with formaldehyde, vigorous safety testing is required to confirm 
batches of vaccine are free of residual and reversible toxicity.  It has recently been argued 
that the diphtheria and pertussis components of the current DTaP vaccine could be 
replaced with genetically modified non-toxic mutants in order to reduce the incidence of 
adverse reactions (Robbins et al., 2005). This argument has also been extended to include 
the tetanus component too, and recent studies have already demonstrated the feasibility of 
a tetanus subunit vaccine candidate when given by the subcutaneous route (Qazi et al., 
2006).  
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Figure 1.4. Schematic illustration of the Clostridial neurotoxins. a) Linear illustration 
of tetanus toxin showing the characteristics of the L, HN and HC domains. b) Crystal 
structure of botulium.neurotoxin, which is highly homologous in sequence to TeNT. Red, 
Catalytic light chain domain; Blue, endosomal translocation HN domain; green, neuronal 
binding HC domain.  
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Tetanus toxin fragment HC as a potential novel vaccine candidate  
The HC domain of tetanus toxin has been proposed as a potential new vaccine candidate 
against tetanus (Fairweather et al., 1987).  Early studies showed that HC fragment  
produced following papain digestion of TeNT could induce the production of TeNT 
neutralising antibodies when administered  subcutaneously into mice or guinea pigs 
(Helting and Nau, 1984). HC fragment was subsequently cloned and expressed as a soluble 
form in Escherichia coli (Fairweather et al., 1986) and later in yeast (Romanos et al., 
1991). Upon testing, these recombinant HC fragments were found to retain the 
immunogenic properties of native HC protein as evident with the production of TeNT 
neutralising antibodies following immunisation of mice (Fairweather et al., 1987).   
 
A number of novel vaccination strategies have been proposed regarding the use of 
recombinant HC as a potential novel tetanus vaccine candidate. For example, a number of 
studies have shown that anti-HC antibodies can be generated following intramuscular 
administration of DNA encoding the gene for fragment HC (Anderson et al., 1997;Stratford 
et al., 2000). Nevertheless, in these studies the immune response generated against the 
tetanus component was relatively weak. This was probably because DNA vaccination 
caused the production of intracellular proteins and therefore a cellular, rather than a 
humoral immune response was generated. This was exemplified by the generation of IgG2a 
antibodies and interferon-gamma (IFN-γ) secretion in splenocytes. 
 
In addition to DNA vaccination, HC fragment has also been expressed in Salmonella 
enterica serovar Typhimurium and Lactococcus for oral immunisation in animal models. 
Results from a number of animals studies have shown that oral immunisation can readily 
induce a neutralising antibody immune response against both HC fragment and the bacterial 
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carrier (Barry et al., 1996; Chatfield et al., 1992; Fairweather et al., 1990; Jackson et al., 
1994; Khan et al., 1994; Roberts et al., 1998;Tacket et al., 2000). Furthermore, attenuated 
Salmonella carriers expressing HC have been successful for oral immunisation against 
tetanus in humans (Khan et al., 2007). The genes encoding HC fragment have also been 
successfully integrated into the chloroplasts of plants (Tregoning et al., 2003;Tregoning et 
al., 2005) giving rise to the possibility of development of a safe plant based vaccine for 
nasal or oral applications. Intranasal delivery of recombinant Bacillus subtilis spores (Duc 
et al., 2003; Isticato et al., 2001) expressing HC have also been shown to elicit protective 
levels of serum tetanus antitoxin antibodies in mouse models. More recently, (Qazi et al., 
2006) have shown that subcutaneous immunisation with recombinant HC fragment induced 
a response almost 1000-fold higher than the level considered minimum for full protection 
in mice. 
 
HC fragment with reduced ganglioside binding capacity: a safer 
alternative vaccine candidate
  
Although fragment HC has no demonstrated toxicity, and is devoid of any active enzymatic 
activity (Morris et al., 1980), it retains the neuronal cell binding and retrograde trafficking 
properties of full-length TeNT (Lalli et al., 2003). As the effects of HC protein trafficking 
to the CNS are still largely unknown, there are potential safety issues surrounding its use in 
vaccination.  Therefore, a HC mutant protein with reduced or negligible ganglioside and 
neuronal cell binding properties would be a more desirable vaccine candidate than native 
fragment HC protein. 
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Ganglioside binding and HC fragment 
Several lines of evidence suggest that gangliosides are involved in TeNT binding to 
neuronal cells. Early studies by (Stoeckel et al., 1977) described how preincubation of 
TeNT with gangliosides prevented neuronal cell binding and subsequent retrograde 
transportation. Separate studies in cell lines showed that cromaffin cells have an increase in 
TeNT sensitivity when treated with exogenous gangliosides (Marxen and Bigalke, 1989). 
Furthermore, the N18RE-105 and NGF-differentiated rat pheochromocytoma (PC12) cell 
lines, which readily express complex carbohydrates such as GT1b have been shown to bind 
TeNT with high affinity (Schiavo et al., 1991;Staub et al., 1986;Walton et al., 1988). The 
role of gangliosides in TeNT binding has also been studied in vivo using knockout mice 
deficient in ganglioside synthesis (Kitamura et al., 1999). Compared to control mice, 
ganglioside knockout mice took longer to succumb to the effects of TeNT infection.  
 
As shown in Figure 1.5 the three-dimensional structure of the HC fragment (residues 865-
1315) contains two domains; an N-terminal lectin-like domain and a C-terminal β-trefoil 
domain linked by a single chain (Emsley et al., 2000; Umland et al., 1997) Both of these 
domains consist largely of β sheets joined by loops which protrude from the molecule. A 
number of studies suggest that it is the C-terminal β-trefoil domain, rather than the N-
terminal lectin-like domain that is involved in ganglioside interaction, and therefore 
neuronal cell binding (Halpern and Loftus, 1993; Sinha et al., 2000). Halpern & Loftus 
(1993) showed that deletion of 263 amino acid residues from the N-terminus region of the 
HC fragment did not inhibit binding to ganglioside or neuronal cells, but removal of 10 
amino acids from the C-terminal abolished ganglioside binding activity. Interestingly, 
Sinha et al (2000) showed that although the C-terminal HC fragment was essential for 
ganglioside binding, removal of the first 10 amino acids only reduced ganglioside binding 
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to 80% of wild-type HC, which implies they are not critical for ganglioside binding. The 
first indication of the location of ganglioside binding sites on HC fragment came from 
cross-linking studies (Shapiro et al., 1997). A photoaffinity reagent based upon the GD1b 
structure was developed to help define the ganglioside-binding domain of TeNT. Results 
indicated that a 34 amino acids belonging to the C-terminal of the HC domain was involved 
in ganglioside binding. Furthermore, mass spectrometry of a photoaffinity labelled 
synthetic polypeptide representing the 34 amino acid domain revealed modification at a 
single residue (His1293). Interestingly, other studies showed that binding of a 15kDa 
glycoprotein is also mediated via the C-terminal β-fold domain (Herreros et al., 2000). 
This implies that the C-terminal of HC fragment may not only be responsible for 
ganglioside binding, but also interaction with a putative second protein-like receptor.  
 
All ganglioside consists of a sialic acid-containing oligosaccharide linked to ceramide and 
have the basic form: Gal(β1-3)GalNAc(β1-4)(NeuAc(α2-3))(Gal(β1-4)Glc(β1-1)Cer to 
which one or more N-acetylneuraminic (sialic) acids are bound. In vitro studies have 
revealed that gangliosides of the series b, such as GT1b or GD1b, have the highest affinity 
for the TeNT HC fragment (Janshoff et al., 1997). Similarly, binding studies have revealed 
that at least two sialic acid residues are required for efficient HC fragment binding to 
gangliosides (Holmgren et al., 1980). It is for this reason that gangliosides containing a 
single sialic residue, such as GM1b, will not permit HC binding (Angstrom et al., 1994; 
Holmgren et al., 1980), whereas gangliosides with more than one sialic acid residue, such 
as GD1b, GT1b and GQ1b, can readily bind HC fragment (MacKenzie et al., 1997). To 
further characterise the ganglioside binding site HC fragment was crystallised together with 
a ganglioside analogues (Emsley et al., 2000; Fotinou et al., 2001).  For initial 
crystallisation studies, component residues of gangliosides were used to identify possible 
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ganglioside binding sites on the HC fragment (Emsley et al. 2000). In total, four sites were 
identified; one site bound lactose and was composed of amino acid residues, Trp1289, His 
1293, His1271, Phe1218 and Tyr1290. The GalNAc sialic acid / N-acetylgalactosamine 
region bound to a second site containg amino acid residues, Arg1226, Asn1216, Asp1147, 
Asp1214 and Gly1215. A third site was shown to bind a second GalNAc molecule, which 
bound near amino acids Tyr 1199, Glu1206, Ile1208 and Lys1197. A fourth site which 
bound galactose was also identified near amino acid Arg1179. Fotinou et al., (2001) 
further analysed the crystal structure of HC protein in complex with a GT1b ganglioside 
analogue. Consistent with previous results the ganglioside molecule was found to induce 
binding at two distinct sites on the HC fragment. One domain binds the Gal4-GalNAc3 
portion of the glycolipid and consisted of a narrow groove formed by the side chains of 
amino acid residues Trp1289 and His1271, withTyr1290 forming the base. The other site 
binds sialic acid (Sia7-Sia6) portion and was found to be made from a shallow pocked 
involving amino acid residues Arg1226, Asn1216, Asp1214, Asp1147 and Tyr1229. 
 
Site-directed mutagenesis (SDM) was been used to investigate the role of amino acids in 
the process of ganglioside binding (Rummel et al., 2003; Sinha et al., 2000; Sutton et al., 
2001). HC deletion mutants were constructed in the Gal4-GalNAc3 site (∆Trp1274-
Pro1279 and ∆His1271-Asp1282) and Sia7-Sia6 binding site (∆Asp1214-Asn1219), and 
all displayed very low ganglioside binding affinities and were also deficient in neuronal 
cell binding and retrograde transportation (Sinha et al., 2000). In a study by (Sutton et al., 
2001b) they showed that substitution of amino acid Tyr1290 with Ala, Ser or Phe in the 
Gal4-GalNAc3 binding site resulted in a severe deficiency in the ganglioside binding 
properties of HC. Other site directed mutagenesis studies showed that Trp1289 and His 
1271 in the Gal4-GalNAc3 binding site or Arg1226 substitution in the Sia7-Sia6 binding 
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site caused decreased binding to ganglioside GT1b and rat brain synaptosomes (Rummel et 
al., 2003).  
 
HCM115: an HC fragment derivative defective in ganglioside binding activity 
In light of the above results, a HC fragment mutant derivative called HCM115 (Figure 1.5) 
was constructed (Qazi et al., 2006a). HCM115 contains two site directed mutations at key 
residues involved in ganglioside binding: residue Trp1289, located in the Gal4-GalNAc3 
site was substituted with Ala, as was Arg1226, located in the Sia7Sia6 site. CD 
spectroscopy analysis revealed that HCM115 had minimal structural differences to HCWT 
but had near negligible ganglioside and neuronal cell binding activity. It has therefore been 
proposed that such a mutant could be used as a potentially safer alternative vaccine 
candidate to the HCWT protein.  Interestingly, when injected into mice via the 
subcutaneous route, mutant derivative HCM115 was not as an effective antigen at 
stimulating the production of protective anti-TeNT antibodies as HCWT or TTxd (Qazi et 
al., 2006). The reason for these differences remains to be determined but it has been 
suggested that the Trp1289 or Arg1226 amino acids might be important epitopes for 
generating an effective protective antibody response (Qazi et al., 2006). It may also 
highlights the importance of considering that if novel vaccine candidates are going to 
replace existing ones, conventional vaccination delivery routes might not be the best for 
mounting optimum protective immune responses.  
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Figure 1.5. Crystal structure of tetanus toxin fragment HC. The 50kDa fragment HC 
protein contains two distinct domains–an amino terminal jelly-like domain and a β-trefoil 
carboxyl terminal domain. The β-trefoil domain contains two ganglioside binding sites, 
termed Gal4-GalNAc3 and Sia7-Sia6 (Fotinou et al., 2001). Mutation of Trp1289 (within 
the Gal4-GalNAc3 site) and Arg1226 (in the Sia7-Sia6 site) to alanine leads to the near 
abolishment of GT1b ganglioside binding activity in the mutant protein HCM115.  
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Needle- free antigen delivery strategies  
With the exception of the Sabin oral polio vaccine (OPV), the majority of vaccinations are 
administered by injection via the parenteral route (intramuscular or subcutaneous). Fear of 
needle penetration (Cohen et al., 2001; Logullo et al., 2008; Schechter et al., 2007) an 
increase in the frequency of adverse reactions and infections associated with unsafe 
injection practices (Alves et al., 2007; Siegrist, 2007) are issues which have threatened to 
hinder the implementation of vaccination programmes. With reference to the latter point, 
the WHO has estimated that up to a third of immunisation injections are unsafe in 4 out of 
6 regions of the world (Miller and Pisani, 1999). A further study has demonstrated that 
over 50% of injections are unsafe because of practices such as using the same needle 
between patients or by use of non-sterile vaccines or vaccine equipment (Sood et al., 
1995).  Furthermore, population based studies have demonstrated a possible link between 
unsafe injection practice and the spread of blood-borne viruses such as Hepatitis B, 
Hepatitis C and the Human Immunodeficiency Virus (HIV) especially in the developing 
world (Kane et al., 1999). It is for these reasons that the development of novel, safer and 
more efficient strategies for vaccine delivery have been made a global priority by the 
WHO (Simonsen et al., 1999). Of particular interest is the development of needle-free/non-
invasive vaccination delivery techniques.  
 
Mucosal immunisation via the oral or intranasal route is a particularly attractive site for 
needle-free immunisation as it targets highly specialised lymphoid tissues located in the 
gastrointestinal tracts (gut-associated lymphoid tissue; GALT), lungs (bronchus-associated 
lymphoid tissue; BALT) and nasal passage (nasal-associated lymphoid tissue; NALT), 
which are the portals of entry for most pathogens. Studies have shown that local 
immunisation at one mucosal site can lead to systemic in addition to mucosal immune 
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responses at secondary sites (Isaka et al., 1999; Isaka et al., 2003; Yasuda et al., 2003)  To 
date, mucosal immunisation via the oral route has been the only successful form of needle-
free antigen delivery. The trivalent live attenuated OPV has become one of the most 
widely used vaccines worldwide since its introduction in 1961. Through the global 
poliomyelitis eradication program, the WHO’s Weekly Epidemiology Record (WER) for 
March 2008 estimated that only 1310 cases of polio were reported in 2007.  
 
Several hurdles need to be overcome for successful mucosal immunisation. For example, 
although immunologically very active, mucosal surfaces are highly tolerant environments 
rich in antigens from food, air and commensal organisms.  In addition, mucosal surfaces in 
the nose are covered in very active innate immune mechanisms such as mucus, which may 
sweep the vaccine antigen away. Similarly, environmental conditions can be very harsh 
particularly in the stomach and intestine where acids and proteolytic enzymes are in 
abundance.  Despite these difficulties, a number of studies have shown that protective 
immunity can be induced against Bordetella pertussis (Cahill et al., 1995; Jones et al., 
1996; Shahin et al., 1992), Chlamydia trachomatis (Whittum-Hudson et al., 2001), 
Salmonella typhimurium (laoui-Attarki et al., 1997) and also against ricin toxin (Kende et 
al., 2002) following oral immunisation in rodent models. Moreover, in primate models, 
oral immunisation with antigen-loaded microparticles have induced immunity against 
challenge with simian immunodeficiency virus (SIV; (Marx et al., 1993) and 
Staphylococcus enterotoxin B (Tseng et al., 1995). Numerous studies including Phase I/II 
clinical trials have been conducted for nasal administration of vaccine candidates using 
outer membrane vesicles (OMV; (Katial et al., 2002), virosomes (Gluck et al., 
1999b;Gluck et al., 1999a), or PLGA (poly(lactic-co-glycolic acid) microspheres (Alpar et 
al., 1994). The Food and Drug Administration (FDA) in the USA has licensed a live cold-
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adapted trivalent influenza vaccine for use in healthy individuals between the age of 5 to 
49 years (Belshe et al., 1998).  Studies found that when administered as a single spray into 
the nostrils, a 93% efficacy rate for protection against cultured confirmed influenza was 
observed (Belshe et al 1998; King, Jr. et al., 1998).  
 
Edible vaccination using genetically modified food products from transgenic plants has 
been another promising technology for successful mucosal immunisation (Walmsley and 
Arntzen, 2000), and a number of plants such as corn (Streatfield et al., 2003), tomatoes and 
bananas (Tacket and Mason, 1999) have been tested as possible host candidates. A recent 
study by Dong et al., (2005) showed that oral immunisation with a group A rotavirus 
nucleocapsid protein (VP6) transfected into the genome of alfalfa leaves elicited a high 
level of serum anti - VP6 IgG  and mucosal IgA antibodies as well as passive protection in 
neonatal mice.  
 
Although mucosal immunisation holds great potential as a practical and economical means 
of needle free immunisation, most studies to date have been limited to small-scale trials in 
animal models, and in comparison, results in human studies have been disappointing 
(Lambert et al., 2001; Tacket et al., 1994). For example, when human volunteers were 
immunised with an oral PLGA vaccine containing ETEC colonisation factor antigen II 
(CFA/II) 70% of subjects developed diarrhoea following challenge (Tacket et al., 1994). 
Similarly, Phase I clinical trials with a potential HIV vaccine candidate failed to show any 
signs of any significant humoral, cellular or mucosal immunity (Lambert et al., 2001). In 
addition, to overcome the innate immune mechanisms the vaccination dose required to 
achieve adequate protection can be a lot higher when given via the mucosal route 
compared to the current vaccines in use. This in turn is undesirable as it will increase 
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production costs and may increase the incidence of adverse reactions. Alternative strategies 
for needle free immunisation have therefore been sought. Transcutaneous immunisation 
(TCI), through the topical application of vaccine antigens onto skin has been implicated as 
a highly efficient and practical method for generating immunity in both animal and human 
studies (Alving et al., 1995;Glenn et al., 1998;Glenn et al., 2000). 
 
Transcutaneous immunisation as a novel method of vaccine delivery  
The skin is an attractive site for non-invasive immunisation because of its abundance and 
ease of access. Furthermore, like mucosal surfaces, the underlying layers of the skin are 
rich in immunologically active cells. TCI involves the application of a vaccine antigen onto 
intact skin and relies upon successful penetration of the antigen to immune cells located in 
the underlying layers (Glenn et al., 1998). TCI holds great promise for increasing the 
safety, compliance with immunisation schedules and decrease in the level of pain and 
adverse reaction at the site of application. Furthermore, a number of studies have been 
carried out in both animal and human subjects which showed that TCI can generate both 
systemic and mucosal protective immune responses against a number of different 
pathogenic entities including viruses, intracellular bacteria and bacterial toxins (El-Ghorr 
et al., 2000; Eyles et al., 2004; Glenn et al., 1999; Mawas et al., 2004; Partidos et al., 
2002). 
 
Skin penetration techniques  
One of the major limitations for successful antigen delivery into the inner layers of the skin 
is overcoming the barrier function of the outer layers. The outer layers of the skin are 
heavily keratinised and thus form a watertight barrier, which protects the underlying tissue 
from the external environment. Until recently, the tough outer most region of the skin were 
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thought to be impermeable to large molecules (Paul et al., 1998). However, many different 
penetration-enhancing strategies have been developed to overcome this problem. 
 
A number of needle-free devices have recently been developed to help TCI by overcoming 
the physical structure of the skin barrier.  Multi/mono-dose injection systems such as jet 
guns have been developed to deliver liquid or powdered vaccines directly into the 
epidermis. However, the major restraint for their widespread use is the high cost of existing 
devices and potential spread of blood borne infections through the use of multi-dose 
devices (Canter et al., 1990).  Other needle-free devices such as microneedles (Widera et 
al., 2006) or microprojections (Matriano et al., 2002) have also been developed to enhance 
penetration and delivery of vaccine antigens into the immunologically active regions of the 
skin. 
 
Studies have shown that alteration of the skin through the means of physical or chemical 
enhancers can also facilitate translocation of topically applied antigen onto skin. 
Electroporation through application of short electrical pulses with an electrode is one such 
method (Prausnitz et al., 1993). Studies by (Misra et al., 1999) demonstrated that delivery 
of a peptide derived from Hepatitis B surface antigen (HBsAg) via skin electroporation 
could elicit a higher antibody response compared to intradermal injection with the same 
antigen in mice. Similarly, the creation of microscopic pores in the outer layers of the skin 
has been accomplished through microporation (Bramson et al., 2003). This technique has 
been shown to enhance the delivery of antigens such as protein or DNA. Although animal 
studies have suggested that this technology is safe and does not cause any lasting damage 
to the skin, the effects on human skin has yet to be determined (Prausnitz et al., 1993b). 
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A further method of modifying the permeability of the outer layer of the skin is to remove 
the stratum corneum by tape stripping with adhesive tape (Godefroy et al., 2005). Studies 
have shown this technique to be effective at eliciting immune responses to a number of 
topically applied antigens such CRM197 protein of diphtheria toxin (Godefroy et al. 2005), 
tumour associated peptides (Seo and Takigawa, 2007), adenovirus expression vectors 
expressing tetanus toxin HC (Shi et al., 2001) and DNA vaccines expressing the matrix 
gene for influenza (Watabe et al., 2001). Furthermore, physical disruption of the 
outerlayers of the skin by tape stripping has also been implicated as a factor responsible for 
releasing immunoregulatory cytokines in the skin such as IL-1 or TNF-α (Nickoloff et al., 
1994). This in turn is expected to have a positive effect on the function and activity of 
other immune cells of the cutaneous system.   
 
Application of chemical enhancers such as oleic acid (OA) or retinoic acid (RA) have also 
been shown to enhance penetration of topically applied antigens by generating pores in the 
outer surface of the epidermis (Touitou et al., 2002) or by activating the underlying 
immune cells to generate a more efficient immune response (Varani et al., 2002). Studies 
have shown that when skin is treated with RA and OA, immune responses generated by an 
influenza whole cell vaccine delivered in a patch are increased (Skountzou et al., 2006). 
 
Transcutaneous immunisation generates both systemic and mucosal immunity  
The first TCI study showed that strong antigen-specific systemic and mucosal immune 
responses could be generated following topical application of the 86 kDa heterodimeric 
cholera toxin (CT) secreted from the bacterium Vibrio cholerae (Glenn et al., 1998) . 
Furthermore, this response proved to be protective in subsequent lethal challenge studies 
(Glenn et al., 1998). Since these initial studies, other ADP-ribosylating exotoxins such 
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Escherichia coli heat-labile enterotoxin (LT) and the Pseudomonas aerginosa exotoxin A 
have been shown to induce similar responses upon topical application in animal models 
(Glenn et al., 1999b). Despite the promising results of initial immunisation studies, many 
antigens when delivered transcutaneously do not generate a robust immune response alone. 
Instead, they need to be co-administered with bacterial toxins such as CT or LT, other 
bacterial products such as CpG-motifs from bacteria DNA, lipopolysaccharide (LPS), or 
cytokines such as IL- 2 and IL-12 (Beignon et al., 2005; Partidos et al., 2004; Scharton-
Kersten et al., 2000) which act as adjuvants. It has also been demonstrated that different 
combinations of adjuvants in conjunction with an antigen can be used to generate the 
production of T-helper cell type 1 (TH1) or T-helper cell type 2 (TH2 ) - specific immune 
responses or a combination of both (Tierney et al., 2003). Recent studies have also 
demonstrated that application of an immunostimulant (IS) patch containing adjuvant can 
enhance the immunogenicity of poorly immunogenic parenteral delivered vaccine 
candidates (Berenzon et al., 2003;Guebre-Xabier et al., 2004). This has been exemplified 
with influenza immunisation in the elderly who often respond poorer to vaccination 
compared to younger individuals. Following application of an LT IS patch at the site of 
injection, significant increases in seroconversion rates were evident (Guebre-Xabier et al., 
2003).  
 
The feasibility of TCI as a vaccine delivery technique has been demonstrated with a wide 
range of different antigens including tetanus and diphtheria toxoids (Tierney et al., 2003); 
(Godefroy et al., 2005), multivalent subunit vaccines such as the conjugated 
polysaccharides of H. influenzae type b (PRP-CRM 197; (Mawas et al., 2004) when 
administrated in combination with adjuvant. Studies in humans have shown that TCI using 
a patch containing LT antigen can induce the generation of robust serum and mucosal anti-
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LT IgG and IgA specific responses which are effective at generating protection against 
enterotoxigenic E. coli (ETEC) infection (Glenn et al., 2007; McKenzie et al., 2007). 
Similarly, Phase-I/II  clinical trials with live attenuated measles vaccine showed that 
following TCI, an increase in the production of measles specific IgA was evident in the 
saliva in addition to an increase frequency of interferon gamma (IFN-γ) secreting T-cells 
(Etchart et al., 2007). 
 
Although adjuvants have been successfully used in animal models, their use in humans is 
limited. In a recent study by Mutsch et al. (2004)  an association between nasal vaccination 
with an attenuated influenza vaccine preparation and Bell’s palsy (a condition that cases 
paralysis of the facial muscles) was found. Further analysis showed that these associations 
were most probably due to the presence of the small amount of LT that was co-
administered with inactivated influenza vaccine as an adjuvant. Further studies showed that 
LT in addition to CT can bind to facial nerve fibres, thus causing neuronal nerve damage 
(van Ginkel et al., 2000). Thus far, no adverse reactions have been described following 
TCI with bacterial adjuvants mainly due to the fact that the skin is not the natural site of 
action. However, in light of the potential serious safety risk surrounding the use of 
bacterial exotoxins in human vaccine formulations, a number of alternative strategies have 
been sought. For example, genetically detoxified mutants of CT or LT have been produced 
and proven effective at generating protective antigen specific serum IgG responses (Pizza 
et al., 2000). In addition, pre-treatment of the skin with low frequency ultrasound has been 
shown to act as an effective adjuvant for TCI (Tezel et al., 2005). It has been hypothesised 
that ultrasound enhances both the penetration of topically applied antigens and activation 
of underlying immune cells. 
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Collectively, these studies show that TCI has realistic potential as a novel technique for 
future delivery of vaccine components in both humans and animals. Nevertheless, to fully 
understand and manipulate the cutaneous immune system for such purposes it is important 
to understand how the immune system responds to the topically applied antigenic 
components. Thus far, few studies have addressed this issue, and the immune mechanisms 
involved in the generation of protective responses against topically applied antigens remain 
to be fully determined.  
 
Mechanisms involved in the induction of immune responses following 
transcutaneous immunisation 
The skin can be divided into three very distinct layers: (i) an epithelial layer called the 
epidermis, (ii) a collagen rich layer the dermis and (iii) the subcutaneous tissue which 
contains appendages such as blood vessels and nerves (Figure 1.6a). A number of 
immunologically active cell types are present in both the dermis and epidermis (Kupper 
and Fuhlbrigge, 2004).  The dermal layer consists primarily of connective tissue produced 
by dermal fibroblasts. However, immune cells such as dermal dendritic cells (DDC), mast 
cells and a small number of cutaneous lymphocyte antigen (CLA) positive memory T-
lymphocytes are also present. In particular, a great deal of interest has surrounded the 
function of DDCs during cutaneous immune responses (Fukunaga et al., 2008; Santegoets 
et al., 2008). It has been suggested that DDCs effectively drive the differentiation of naïve 
B-cells into IgM secreting plasma cells (Ratzinger et al., 2004). Despite the array of 
immune cells present in the skin, it has been suggested that those in the outer layers are 
more immunocompetent than those present in deeper tissues because of their constant 
exposure and interaction with the external environment (Eisenbraun et al., 1993). The 
outermost layer, the epidermis, consists primarily of three different cell types: (i) the 
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epithelial-derived keratinocytes; (ii) the bone marrow-derived Langerhans’ cells (LCs) and 
(iii) the neuro- ectodermal melanocytes (Kollisch et al., 2005). Whereas melanocytes 
produce melanin which contribute to the pigmentation of the skin, keratinocytes and LCs 
are considered to play an important role in generating immune responses following TCI 
(Warger et al., 2007).  
 
The role of keratinocytes in the generation of cutaneous immune responses 
Keratinocytes are by far the most abundant cell type within the epidermis. They are 
arranged as a multilayered (stratified) structure of differentiated cells, which change in 
size, shape and content as they travel from the basal region to the superficial region where 
they are shed (Figure 1.6b). The inner-most layer of the epidermis, the stratum basaie, 
contains actively dividing basal stem cells that are attached to the basement membrane 
(Leary et al., 1992). Stem cells undergo a limited number of cell divisions before detaching 
from the basal membrane and migrating towards the external surface in a process known as 
terminal differentiation (Barrandon and Green, 1987). Although the precise sequences of 
events leading to differentiation are yet to be determined (Fuchs and Raghavan, 2002), 
definite morphological changes to keratinocytes are evident. It appears that differentiation 
requires keratinocytes to pass through three distinct stages. The first stage, the stratum 
spinosum (prickle layer) lies directly above the stratum basaie and contains keratinocytes 
which readily synthesise tonolilaments. These tonolilaments condense, giving rise to 
desomosomes and act by mediating the interconnection of differentiating keratinocytes. 
The stratum granulosum and stratum corneum represent the outermost layer of the 
epidermis, and thus the latter two stages of differentiation. As keratinocytes travel closer 
towards the outer surface, they gradually begin to loose their nuclei and develop thickened 
envelopes. At the outermost layer, the stratum corneum, keratinocytes form a layer of 
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dead, flattened cells that are continually being shed by new cells pushing upwards from the 
layers below. The thickness of this outermost layer differs depending on the anatomical 
location, the thickest being on the palms of the hands and on the soles of the feet. 
Numerous studies suggest that keratinocytes play an important role in the initiation and 
regulation of cutaneous immune responses. For example, in response to challenges with 
microbes or microbial-derived products (Mempel et al., 2003) observed activation of the 
Nuclear Factor Kappa B (NF-КB)-pathway leading to an up-regulation in the production of 
antimicrobial mediators such as inducible nitric oxide (NO). Furthermore, many studies 
have shown that keratinocytes can be induced to express different pattern recognition 
receptors (PRRs) such as Toll-like receptor-2 and 4 (Kollisch et al., 2005;Takeda and 
Akira, 2001) both of which are pivotal to innate immune recognition and the subsequent 
response to microbes. Nevertheless, by far the most impressive and perhaps influential 
function of epidermal keratinocytes during cutaneous immune responses is their ability to 
secrete a surplus of cytokines (IL-1, IL-4, IL-10, IL-12, IL-18 and TNF-α) which not only 
act upon cells within the surrounding vicinity, but also on the immune system at large 
(Barker et al., 1991; Kupper, 1990; Tuzun et al., 2007). Although not regarded as classical 
antigen presenting cells, in vitro experiments have shown that under certain pathologic 
conditions keratinocytes can induce the surface expression of MHC-II molecules (Skov 
and Baadsgaard, 1996;Todd et al., 1992), and act as accessory cells for T-cell activation 
(Nickoloff et al., 1993). Furthermore, this interaction has been demonstrated to require 
close contact between keratinocytes and T-cells as monoclonal antibodies directed against 
co-stimulation molecules or adhesions blocked T-cell stimulation (Leung et al., 1995). 
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Figure 1.6. Cross section of skin. a) The human skin is composed of three distinct layers: the epidermis, dermis and subcutaneous tissue 
(subcutis). It also contains appendages such as sebaceous and sweat glands, hair follicles, blood vessels and muscle. b) Differentiating 
keratinocytes further divide the epidermis into four distinct layers: the stratum basale (SB), stratum spinosum (SP), granulosum (SG) and 
stratum corneum (SC). Figure adapted from Holbrook (1997) 
b a) 
b) 
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Initiation of immune responses: a pivotal role for dendritic cells 
The goal of successful vaccination is to prime the immune system to mount a rapid and 
efficient immune response following infection with the invading pathogen.  Recognition of 
foreign antigens usually occurs in non-lymphoid tissues and relies on specialised antigen 
presenting cells (APC), such as macrophages and dendritic cells (DCs), to process and 
present peptide antigen to T-lymphocytes in the context of MHC class I or II molecules. 
Activation of DCs is of particular importance as these cells has been shown to be solely 
responsible for initiating the activation of naïve T-lymphocytes during primary immune 
responses (Inaba and Steinman, 1987).  
 
DCs can be found in a number of locations throughout the body including the spleen 
(Steinman et al., 1975), lungs (Nelson et al., 1994), intestine (Wilders et al., 1983) and the 
skin (Lappin et al., 1996) and all share a common features in terms of function. Immature 
DCs constantly sample the environment for foreign material such as those derived from 
pathogens such as bacteria or viruses. This is done through specialised PRRs, which 
include Toll-like receptors and Mannose-binding lectin (Sallusto et al., 1995). These 
receptors recognise conserved structures associated with microorganisms called pathogen 
associated molecular patterns (PAMPs). These PAMPs include endotoxin, flagella, viral or 
bacterial nucleic acids.  DCs can be activated directly through activation of PRR or 
indirectly through the exposure to inflammatory signals. Following activation, DCs leave 
peripheral tissues and migrate into regional lymphoid tissues, such as spleens or lymph 
nodes, where they can readily interact with naïve T-lymphocytes.  During this migratory 
process, DCs decrease their protein uptake and processing ability but increase the 
expression of specialised surface molecules that are crucial for interaction with naïve T-
lymphocytes (Cella et al., 1997). These include up-regulation of adhesion molecules such 
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as the intracellular adhesion molecule (ICAM) 1, co-stimulatory molecules CD40, CD80 
and CD86 and MHC molecules, which all provide the necessary signals for T-cell 
activation (Figure 1.7).  
 
Upon activation, effector and memory T-lymphocyte populations develop and are crucial 
for an immediate and rapid responses upon re-exposure to antigen, respectively. Two 
different subsets of T-lymphocytes can be activated and depend on the class of MHC 
molecule presenting the peptide antigen. Peptides in conjunction with Class I MHC 
molecules activate CD8+ cytotoxic T-lymphocytes (TC) which are important for destroying 
intracellular infections or tumour cells (Crowley et al., 1991;Tighe et al., 1987) Crowley. 
In contrast, when peptides are presented to the corresponding naive T-lymphocyte via 
MHC class II molecules, the CD4+ helper T-(TH) lymphocytes are activated (London et al., 
1998;Reiner and Seder, 1995).  This subset of T-lymphocytes cannot kill infected cells 
directly but are crucial for driving the direction of subsequent immune responses by 
instructing other cells such as macrophages, B-cells or DCs. For example, upon activation, 
the TH lymphocytes rapidly divide and secrete cytokines that help direct and instruct the 
other cells belonging to the adaptive immune system. Depending on the cytokines released, 
TH lymphocytes can further differentiate into TH1 or TH2 cells. TH1 lymphocyte responses 
are characterised by their ability to secrete IFN-γ or TNF-β and are responsible for 
directing cell-mediated immune responses, which are required for immunity against 
intracellular pathogens. In contrast, TH2 lymphocyte response are characterised by the 
secretion of IL-4, 5, 6, 10 and 13 and are essential for development of humoral immune 
responses by stimulating naïve B-cell proliferation and antibody subclass switching. The 
important role of TH cells in shaping and generating immune response is evident in 
individuals infected with the Human Immunodeficiency Virus (HIV; (Norris and 
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Rosenberg, 2001;Norris and Rosenberg, 2002). HIV is a virus that specifically targets and 
ultimately depletes the CD4+ T-lymphocyte population and in turn, is responsible for the 
symptomatic stage of infection known as Acquired Immunodeficiency Syndrome (AIDS). 
As protection against tetanus is dependent on the production of neutralising antibodies 
against the toxin, it is of great importance to consider this during vaccine development. 
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Figure 1.7. Activation of T-lymphocytes by antigen presenting cells in vivo. Activation 
of T-lymphocytes occurs through the engagement of both the T-cell receptor (TCR) and 
CD28 on the T-lymphocyte by the MHC-II/peptide complex and B7 family members on 
antigen presenting cells, respectively. Signal-1 is provided by the TCR and MHC/peptide 
complex. Signal-2 is provided by the co-stimulation molecules on antigen presenting cells 
(B7 molecules) which interact with CD28 on T-lymphocytes. Both signals are required for 
production of an effective immune response. In the absence of CD28 co-stimulation, TCR 
signalling alone will result in anergy. 
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Langerhans’ cells: the professional antigen presenting cells of the skin 
Originally, DCs were considered to be cells with purely myeloid origin. Recent studies 
have now demonstrated that DCs can also develop from lymphatic progenitors (Ardavin et 
al., 2001;Ardavin, 2003). Myeloid derived LCs are the professional antigen presenting 
DCs of the epidermis (Streilein and Bergstresser, 1984) and reside in close proximity to the 
external environment between the stratum granulosum and spinosum layers of the 
epidermis. As shown in Figure 1.8, they can be easily identified through their long finger-
like projections which extend between keratinocytes, and the presence of a Birbeck 
granules in the cytoplasm (Steinman et al., 1995). Like other DCs, the functional ability of 
LCs to mount an effective adaptive immune response is solely dependent on efficient 
mobilisation to the regional lymphoid organs. Upon encounter with antigen, LCs are 
stimulated to leave the epidermis and travel to the lymph nodes via the afferent lymphatics 
(Stoitzner et al., 2002; Weinlich et al., 1998). By the time they reach the T-cell paracortal 
region of the lymph nodes they have developed the ability to present antigen to the 
corresponding T-lymphocyte in the context of MHC molecules. 
 
Consistent with other DC subsets, LCs undergo a number of morphological and functional 
changes during migration to lymph nodes. A number of studies have demonstrated that 
MHC molecules, adhesion molecules (ICAM-1) and T-cell co-stimulatory molecules (B7.1 
and B7.2) are upregulated during LC maturation and migration to regional lymphatics 
(Banchereau and Steinman, 1998; Caux et al., 1996). Furthermore, up-regulation of 
chemokines and receptors, such as CCR7, that drive LC migration towards the T-
lymphocyte rich paracortex region of lymph nodes has also been observed (Yanagihara et 
al., 1998). 
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The role for LCs during topical application of substances has been demonstrated in a 
number of studies. Guebre-Xzbier et al., (2003) observed an increase in the number of 
activated LC-like cells in regional lymph nodes following topical application of LT onto 
mouse skin. Similar results were obtained in earlier studies, demonstrated an increase in 
fluorescein isothiocyanate (FITC) bearing cells in regional lymph nodes following topical 
application of FITC onto mouse skin (Macatonia et al., 1986;Macatonia et al., 1987). 
When characterised further, these FITC+ cells were Ia+ and contained Birbeck granules in 
the cytoplasm, both of which are present in LCs.  
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Figure 1.8. Morphology of an epidermal Langerhans’ cell. Electron micrograph 
showing a LC migrating out from a sheet of cultured murine epidermal cells.  
ker, keratinocyte; LC, Langerhans cell.  Picture modified from (Romani et al., 2003). 
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The role of IL-1 and TNF-α in Langerhans’ cell mobilisation   
Initiation of an immune response following TCI is largely mediated by LC activation and 
migration is, in part, mediated by the down-regulation of adhesion molecules such as E-
cadherin between LCs and keratinocytes (Blauvelt et al., 1995). In situ studies have shown 
that exposure to contact allergens or cytokines such as IL-1 or TNF-α has resulted in a 
down-regulation of E-cadherin and an increase in LC migration out of the epidermis 
(Borkowski et al., 1994;Schwarzenberger and Udey, 1996). Although the exact 
mechanisms responsible for initial LC activation and mobilisation have yet to be 
determined, there is substantial evidence to suggest that it is, in part, due to the production 
of cytokines such as IL-1-β and TNF-α which are constitutively secreted or inducible in 
epidermal cells (Cumberbatch and Kimber, 1992a). 
  
Studies in rodent models have shown that when recombinant TNF-α was injected 
intradermally into the pinnane of the ear, LCs were lost from the epidermis and an increase 
in the number of LCs was evident in the regional lymph (Cumberbatch and Kimber, 1992b 
Cumberbatch et al., 1994). The effects of TNF-α were rapid, as a measurable loss of LCs 
was evident within 30 minutes of injection whereas a measurable increase in LC number 
was evident in lymph nodes within 2 hours. Further evidence for the role of TNF-α in LC 
mobilisation was shown in separate studies using TNF receptor knock-out mice (Wang et 
al., 1996). They suggested that, in mice, two distinct membrane receptors were responsible 
for TNF-α activity; the TNF receptor I (TNF-R1) and TNF receptor II (TNF-R2). When 
FITC solution was applied onto the skin of TNF-R1 deficient mice, a normal number of 
FITC+/Ia+ cells were found in the draining lymph nodes. This suggests that TNF-R1 is not 
crucial for TNF-α signalling. However, when the activity of TNF-R2 was blocked LC 
mobilisation and accumulation in draining lymph nodes was significantly inhibited. These 
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results therefore suggest that TNF-α signalling through TNF-R2 is important for LC 
mobilisation from epidermis to regional lymph nodes. The role of TNF-α in LC 
mobilisation has not been limited to murine models. Intradermal injection of recombinant 
TNF-α into human subjects showed a reduction of Ia+ cells in the epidermis (Cumberbatch 
et al., 1999a; Groves et al., 1995).  
 
Although the role of TNF-α has been demonstrated in rodent models and in human it 
appears that a further cytokine, IL-1β, is also important for providing a second signal for 
activation and mobilisation of LCs from the epidermis. IL-1β is constitutively produced in 
the murine epidermis and has been shown to be exclusively produced from LCs (Enk and 
Katz, 1992; Matsue et al., 1992; Schreiber et al., 1992). As with TNF-α, injection of 
recombinant IL-1β into the ear of mice caused a decrease in LC density within the 
epidermis but an increase in LC number in the draining lymph nodes (Cumberbatch et al., 
1997a). Interestingly, the kinetics of LC migration following IL-1β injection was much 
slower compared to that caused by TNF-α administration. For example, LC migration out 
of the epidermis was evident after 2 hours and accumulation of LCs in draining lymph 
nodes was evident after 4 hours. Furthermore, separate studies showed that keratinocyte 
TNF-α mRNA expression was increased following intradermal injection of IL-1β thus 
suggesting that IL-1β may be responsible for stimulating keratinocyte production of TNF-α 
which in turn initiates LC mobilisation and migration (Enk et al., 1993). Cumberbatch et 
al., (1997) tested this hypothesis using murine models and showed that mobilisation of 
LCs by intradermal injection of IL-1β  was prevented when mice were systemically pre-
treated with TNF-α neutralising antibodies prior to skin sensitisation with contact 
allergens. Similarly, administering anti-IL-1β neutralising antibodies inhibited TNF-α 
induced LC mobilisation and migration to lymph nodes.   
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Based upon this data it has been proposed that induction of LC activation and migration 
requires two independent signals; one provided by TNF-α and the other by IL-1β (Figure 
1.9). This model proposes that following stimulation of LC, IL-1β is produces and acts in 
an autocrine fashion via the IL-1 receptor (IL-1RI) providing Signal 1 (Cumberbatch et al., 
1998; Cumberbatch et al., 1999b). In addition, IL-1β also acts in a paracrine fashion, 
activating neighbouring keratinocytes via the IL-1RI and stimulating the production of 
TNF-α. This in turn is delivered exclusively to LCs via the TNF-R2 (Wang et al.,1996), 
where it acts as Signal 2 for mobilisation.  Evidence for the interplay between IL-1β and 
TNF-α comes from earlier studies by Enk et al., (1993) who showed that upon application 
of a contact sensitizer, an increase in IL-1β mRNA is initially observed and this is quickly 
followed by an increase in TNF-α mRNA expression. From these observations, the authors 
suggest that IL-1β may be acting as a master molecule that controls the initiation of a 
cytokine cascade, which results in the initiation of LC translocation into the local draining 
lymph nodes. 
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Figure 1.9.  Regulation of Langerhans’ cell mobilisation from epidermis by cytokines. 
The stimulation of LC migration by exposure to local stimuli is dependent on the receipt 
by LC of at least two independent cytokine signals. One signal is provided by LC-derived 
IL-1β that acts in a autocrine fashion via the IL-1R1 expressed on LCs. IL-1β also acts in a 
paracrine fashion on adjacent keratinocytes to stimulate the production of TNF-α. This 
keratinocyte produced TNF-α delivers a second signal for LC immobilisation via TNF-R2. 
Together, both signals stimulate LC mobilisation and migration to local secondary 
lymphoid organs. 
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Aims of this project 
Induction of systemic and mucosal immune responses following TCI has been 
demonstrated using a number of soluble antigens in both human and animal models. 
However, the underlying cutaneous immune mechanisms responsible for the generation of 
protective responses are not well defined. It has been hypothesised that following topical 
application of antigens, their interactions with keratinocytes and LCs play an important 
role in the induction of immune responses following transcutaneous immunisation. 
 
The specific aims of this project were: 
 
(1) to evaluate the immunogenicity in mice of recombinant antigens (HCWT and 
HCM115) of tetanus toxin following transcutaneous immunisation, in comparison 
with tetanus toxoid, the conventional tetanus vaccine antigen. 
(2) to use these proteins as models for studying the mechanisms of interaction of 
antigens with keratinocytes and LCs using both in vivo and in vitro systems. 
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Preparation and characterisation of recombinant HC proteins 
Bacterial strains and growth conditions 
Escherichia coli strain BL21 F-, dcm, ompT, hsd SB, rB-, mB-, gal, (λDE3) was used for 
all HCWT and HCM115 protein expression. The DNA sequence encoding the TeNT 
fragment HC was previously cloned  in pET28a (Figure 2.1) between the Bam HI and Nde I 
restriction endonucease cleavage sites to form plasmid pKS1  (Sinha et al., 2000) (Figure 
2.2). Plasmid pKS1-M115, which is derived from pKS1 and contains two amino acid 
substitutions within the ganglioside binding site, Trp1289Ala and Arg1226Ala, and was 
kindly provided by Dr Omar Qazi, Division of Cell and Molecular Biology, Imperial 
College, London. Prior to use, bacteria were stored at –70oC in Luria-Bertani (LB) broth 
containing 16% (w/v) glycerol. Resuscitation of cultures from storage was carried out by 
streaking a small quantity of the frozen stock onto LB agar plates and incubating overnight 
at 37oC. The surface of the agar was examined for growth and any signs of contamination.  
Overnight cultures were prepared by inoculating LB-broth with single bacterial colonies 
and incubating at 37˚C with shaking.  For plasmid selection, 50µg/ml of kanamycin (Km) 
was added to the growth medium.   
 
Overnight cultures of E. coli BL21 λ (DE3) carrying the appropriate plasmid were used to 
inoculate LB-broth containing 50µg/ml of Km. The culture was incubated at 37˚C with 
shaking at 250rpm until the OD650 reached 0.8 to 1.0. At this point, expression of HCWT or 
HCM115 protein was induced by the addition of isopropyl-β-D-thiogalactopyranoside 
(IPTG) (final concentration, 1 mM) and incubation was continued for a further 3.5 hours. 
The cultures were harvested by centrifugation for 15 minutes at 6000rpm (4oC). The 
supernatant was discarded and the resulting bacterial pellet stored at -20˚C. Samples of 
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culture were taken prior to and after IPTG induction and centrifuged for 2 minutes at 
13000rpm. Supernatants were discarded and pellets were collected and stored at -20oC.  
 
Protein production by fermentation 
Colonies of E. coli BL21 (λ DE3) carrying the appropriate plasmid were grown in LB-
broth supplemented with 50µg/ml of Km. Following incubation for 2 hours at 37˚C (with 
shaking at 250rpm), 300ml of fresh LB culture medium containing 50µg/ml Km was 
inoculated with 5ml of bacterial culture and allowed to grow overnight at 37oC as pre-
culture. This pre-culture was used to inoculate 15-litres of sterilised LB/Km broth in a 20 
litres Biobench fermentor (Applikon). The fermentor was operated by a Biobench 
Biocontroller (Applikon) and OD650nm readings taken manually every 30 minutes until it 
reached 0.8 to 1.0. At this point, expression of HCWT or HCM115 protein was induced by 
the addition of 1mM IPTG. Incubation was continued for a further 3.5 hours and cells were 
harvested by continuous centrifugation for 15 minutes at 12000rpm. At this point, the 
OD650nm was between 2 to 3. Supernatants were discarded and the resulting bacterial 
pellet was weighed before being stored at -20˚C until further use.  Approximately, 36g wet 
weight of cells was obtained from 15-litres of culture. 
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Figure 2.1. The pET–28a (+) plasmid vector used for cloning tetanus HC fragments. 
Circular vector map: HCWT is cloned between the BamHI and Nde I endonuclease 
restriction sites. pET28a (+) is 5369bp in size (6695bp with HCWT insertion) and contains 
a kanamycin (Km) resistance gene for selection purposes. In addition, the gene for the lac 
repressor, lac I, is present. lac I prevents the expression of HCWT until induced by IPTG.  
Image reproduced from Novagen manufacturers instructions. 
HCWT DNA 
Lac repressor 
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Figure 2.2. Multiple cloning sites in the pET – 28a (+) plasmid vector. Red arrows indicate the location of HCWT DNA. Images 
reproduced from Novagen manufacturers instrucitions.
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Affinity purification of recombinant proteins  
An overview of the methods used for purification of recombinant HCWT and HCM115 are 
shown in Figure 2.3.  Bacterial pellets were defrosted and kept on ice at all times. Pellets 
were resuspended in 10ml of sonication/lysis buffer (50mM sodium phosphate buffer, 300 
mM NaCl, 10 mM imidazole, pH 7.8) and sonicated for 12 minutes in total using a Sonics 
Vibra-Cell Ultrasonic Processor connected to a flat tip sonication probe. Pulses of 30 
seconds sonication ‘on’ were followed by 30 seconds ‘off’. The lysed cells were 
centrifuged for 20 minutes at 12000rpm (4˚C), and the supernatants containing the soluble 
protein removed.  
 
Affinity chromatography purification was carried out by use of nickel nitrilotriacetic acid 
(Ni2+-NTA) agarose (Qiagen). Two-millilitres of resuspended Ni2+-NTA agarose was 
added to a 20ml universal tube and washed with 5ml of lysis buffer. The tube was 
centrifuged for 5 minutes at 2000rpm and the buffer was removed (leaving approximately 
1ml of resin). The supernatant from the bacterial lysates was added and the tubes rotated 
overnight at 4˚C to bind the protein to the column. The resin was centrifuged for 5 minutes 
at 2000rpm and the supernatant discarded. The resin was washed twice with wash buffer 
(50mM sodium phosphate buffer, 300mM NaCl, 25mM imidazole, pH 7.8) and retrieved 
again by centrifugation. The resin was resuspended in 10ml of wash buffer and added to a 
disposable Bio-Rad chromatography column. Bound protein was eluted with elution buffer 
(50mM sodium phosphate buffer, 300 mM NaCl, 200mM imidazole, pH 7.8) and collected 
in 0.5ml fractions. A rough measurement of protein concentration was carried out by 
measuring the absorbance of at 280nm (A280nm). Samples with A280nm ≥ 0.5 were pooled 
and immediately subjected to FPLC-SEC purification. 
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Figure 2.3. Overview of HCWT and HCM115 protein purification and 
characterisation. See text for details. 
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Purification of recombinant HC proteins by Fast Protein Liquid Chromatography 
Size exclusion chromatography (FPLC-SEC) 
Fast Protein Liquid Chromatography Size exclusion chromatography (FPLC-SEC) was 
carried out using a Hiload 16/60 Superdex 200 preparatory grade chromatography column 
(Amersham Biosciences, 10 to 600kDa separation range for globular proteins) connected 
to an ACTA fast performance liquid chromatography (FPLC) system with fraction 
collector (Amersham). All solutions and samples were stored at 4˚C, and the FPLC system 
and fraction collector are enclosed in a refrigerator maintained at 4˚C. The running buffer 
used was PBS (pH 7.4) made from PBS tablets (Sigma). All HC protein samples were 
centrifuged for 2 minutes at 13000rpm prior to loading, in order to remove any 
particulates. SEC column was first equilibrated with 2 column volumes (CVs) of running 
buffer at a flow rate of 0.4ml/minute. Between 1 to 2ml of protein was loaded into a 2ml 
loop and injected into the SEC column after a 0.2CV equilibration.  The protein was eluted 
with 2CVs at a flow rate of 0.4ml/minute. The fraction collector was set to collect 1ml 
peak fractions when the absorbance (A280nm) was recorded to be above baseline levels. To 
determine the molecular weights of eluted fractions, the column was calibrated prior to this 
project using low and high molecular weight calibration kits (Amersham Bioscience). 
Selected eluted protein fractions were pooled and stored at -80˚C until further use. 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated by SDS-PAGE under reducing conditions using 12% acrylamide 
resolving gels. The resolving gel was prepared by adding together 2.5ml of 1.5M Tris-HCl, 
pH 8.8, 100µl of 10% SDS, 100µl of 10% ammonium persulphate, 4µl of N, N, N′, N′-
tetramethylethylenediamine (TEMED) and 4.0ml of 30% acrylamide/bis-acrylamide 
(Sigma). The volume was made up to10ml with dH2O. The acrylamide mixture was poured 
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(3 to 4 ml/gel) into a SDS-PAGE gel cast (Bio-Rad), and overlaid with approximately  
500µl of methanol to polymerise. The stacking gel was made by mixing the following 
reagents: 1.25ml of 1M Tris (pH, 6.8), 100µl of 10% (w/v) SDS, 100µl of 10%  (w/v) 
ammonium persulphate, 10µl of TEMED, 1.7ml of 30% (w/v) acrylamide/bis-acrylamide 
and 6.8ml of dH2O. The methanol was removed from the resolving gel and the stacking gel 
added. The comb, which forms the wells in the gel, was inserted and the stacking gel was 
left to polymerise.  
 
Protein samples were diluted in sample buffer containing 0.125M Tris-HCl, pH 6.8, 0.8% 
bromophenol blue, 10% (w/v) SDS, 50% (w/v) glycerol and 10% (w/v) β-mercaptoethanol. 
The samples were boiled for 5 minutes and centrifuged for 2 minutes at 13000rpm before 
loading on the gel. Pre-stained, broad range SDS-PAGE molecular weight markers (Bio-
Rad #161-018) were also loaded to help confirm measurements. The SDS-PAGE gel was 
immersed in buffer consisting of 0.025M Tris, 0.19M glycine and 0.0035M SDS and a 
constant voltage of 140V applied until the required separation was achieved. The stacking 
gel was cut away and the resolving gels stained for at least 2 hours in a solution containing 
0.5g of Coomasie blue R-250 (Sigma) in a solution of 200ml of methanol, 50ml of glacial 
acetic acid and 250ml of dH2O. The gels were de-stained by soaking in a solution 
consisting of 200ml of methanol, 50ml of glacial acetic acid and 250ml of dH2O, until the 
background staining was sufficiently diminished. Gels were then scanned and dried 
between two sheets of gel drying film (Promega). 
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Determination of protein concentration 
Protein concentrations were determined using the Pierce BCA assay in accordance to the 
manufactures guidelines. This method is based on the detection of Cu+ ions by BCA when 
Cu2+ is reduced by protein in the presence of an alkaline solution. Briefly, a series of seven 
doubling dilution of protein standard (BSA; bovine serum albumin), starting at 1mg/ml 
was prepared, and 20µl of each standard solution was added to a 96 well microtitre plate in 
triplicate. Test proteins were diluted (1:1, 1:5, 1:10 or 1:20) in PBS and 20µl of each 
sample was added to the plate in duplicate. Pierce working reagent (WR) was made up at a 
50:1 ratio of BCA reagent A to reagent B, and 180µl was added to each sample well and 
the plate was then incubated for 30 minutes at 37˚C.  The absorbance was read on a Bio-
Rad benchmark ELISA plate reader at 595nm (A595nm). Test sample concentrations were 
calculated in relation to the standard curve generated by the BSA standard. 
 
GT1b ganglioside binding assay 
The ganglioside binding activity of HC proteins was assessed by their ability to bind to 
bovine GT1b (Sigma) as previously described (Sinha et al., 2000). Fifty-microlitre 
volumes of GT1b (10µg/ml in methanol) was added to Nunc Maxisorp microtitre plates. 
Plates were left overnight at room temperature where the methanol evaporated leaving the 
ganglioside bound to the plate. Plates were washed with PBS/0.05% (w/v) Tween-20 
(PBS/T) and blocked by incubating plates for 1 hour at 37˚C with 100µl volumes of PBS/ 
3 % (w/v)  BSA. Following a further three washes with PBS/T, test proteins were diluted 
to a concentration of 2µg/ml. Doubling dilutions were then made in PBS/3% (w/v) 
BSA/0.05% (w/v) Tween on separate microtitre plates and 50µl of each dilution was added 
to the appropriate well on microtitre plates containing ganglioside. The last column on 
each plate contained blocking buffer as a negative control. The plates were incubated at 
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37˚C for an hour and washed 3 times as before. Polyclonal rabbit α-HC antibodies were 
diluted (1 in 10000 in PBS/3% (w/v) BSA/0.05% (w/v) Tween) and 50µl volumes were 
added to the microtitre plates for an hour at 37˚C. The plates were washed and goat α-
rabbit horseradish peroxidase (HRP)-conjugated antibodies (DAKO) (50µl; diluted 1 in 
1000) were added in volumes of 50µl prior to an hour incubation at 37˚C. The plates were 
washed as before and the substrate (o-phenylenediamine dihydro-chloride (OPD, Sigma-
Aldrich) was prepared by dissolving a single 20mg tablet in a solution containing 5ml of 
0.1M citric acid, 5ml of 0.2M Na2HPO4, 10ml of H2O and 8µl of H2O2), and 50µl was 
added to each well. The reaction was stopped after 20 minutes of colour development by 
the addition of 15µl/well of H2SO4. ELISA plates were read at an absorbance of 490 nm 
(A490nm) on a Bio-Rad Benchmark ELISA plate reader. 
 
Limulus amoebocyte lysate (LAL) gelation test 
The LAL gelation assay is a semi-quantitative test used to detect and quantify endotoxin, a 
fever-producing product of Gram-negative bacteria. This assay was carried out by Gill 
Tarrant, Department of Biotherapeutics, NIBSC. The basis of the assay is that endotoxin 
causes gelation of Limulus amoebocyte lysate (LAL), an aqueous extract of blood cells 
(amoebocytes) from the horseshoe crab Limulus polyphemus.  Proteins were diluted (1:5) 
in pyrogen free water (Baxter) to a final volume of 500µl. Ten-microlitres of diluted 
protein and 10µl of LAL reagent (Pyrotell, Associates of Cape Cod (ACC)) were mixed 
together on a sterile petri dish and incubated at 37˚C for 1 hour in a humidified 
atmosphere. The mixture was tested for the formation of a gel-clot by the addition of a 
small drop (approximately 1µl) of dye in alcohol (0.2% New Methylene Blue in 70% 
alcohol). If a gel-clot has formed (positive result), the dye does not mix with it, and 
remains as a blue ‘star’  or centralised blue spot, on top of the clot. However, a negative 
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result is indicated by the absence of a firm gel-clot due to the loss of surface tension when 
the dye is added. This results in a uniformly blue solution. Examples of positive and 
negative results are shown in Figure 2.4. The lowest dilution of each sample producing a 
clot was noted and the endotoxin concentration calculated by comparison to an endotoxin 
standard (International standard for endotoxin, 2000IU/ml) which had been diluted in 
pyrogen-free water to cover a range of lysate sensitivities (100IU/ml to 0.008IU/ml). PBS 
acted as a negative control and was included with each batch of samples tested.  
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Figure 2.4. Limulus amoebocyte lysate (LAL) gelation test. Examples of a negative 
(left) and a positive (right) result. Picture from Gill Tarrant, Department of 
Biotherapeutics, NIBSC. 
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Immunological studies  
Transcutaneous immunisation of mice 
Groups of 6-8 week old female Balb/c mice (5-7 animals per group; Harlan Olac, UK) 
were used throughout these studies. Mice were anaesthetized for approximately 1 hour by 
intra-peritoneal (i.p) injection with 0.15ml of a mixture of ketamine (Vetalar, Pharmacia 
100mg/ml), xylazine (Rompun, Bayer 2%) plus sodium chloride (BP 0.9 % w/v, Phoenix 
Pharma Ltd). A restricted area of the abdomen (1 to 2cm2) was carefully shaved with 
clippers without breaking the skin. With exception of Experiment 1, a small amount of 
depilatory cream (Nair) was applied onto the shaved skin for 2 to 3 minutes and was 
removed with a damp cloth followed by 70% ethanol. The skin was hydrated for 5 minutes 
with dH2O and blotted dry prior to topical applications of 50µl volumes of PBS containing 
different concentrations of TTxd (NIBSC, 02/126; 12.5mg/ml), HCWT, HCM115. All 
negative control groups were given PBS. Unless otherwise stated, all animals were 
immunised on day 0, 28 and 56 with the same dose and formulation of antigen, and 
terminal bleeds were collected 14 days after the final boost. Serum samples were collected 
and stored at -20˚C until further use. 
 
ELISA assay for measuring IgG specific antibodies  
Anti-TTxd or anti-HCWT IgG responses were determined by an in-house ELISA assay for 
individual immune sera. Nunc Maxisorp 96 well microtitre plates were coated with 100µl 
of TTxd (1µg/ml) or HCWT (1µg/ml) in 0.05M carbonate buffer (pH 9.6) and incubated 
overnight at 4oC. After washing the plates with wash buffer (PBS/0.05% (w/v) Tween-20), 
sera samples were diluted 1:100 in assay diluent (PBS/0.05%(w/v)Tween-20/2.5% (w/v) 
Marvel), and titrated across the plate to a final volume of 100µl /well. To account for plate-
to-plate variation, each individual sera sample was tested in tandem on two different 
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microtitre plates. Detection of mouse IgG was carried out using 50µl/well of goat anti-
mouse- IgG HRP-conjugate (Sigma, 1:2000 dilution), followed by 100 µl ELISA substrate 
(2, 2’-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid, Sigma).  Absorbance was measured 
at 405nm (A405nm) by a Multiscan ELISA plate reader (ThermoLifeSciences). An in-
house anti-TTxd mouse reference serum (1.68IU/ml) was titrated in duplicate on each plate 
and was used to calculate the relative antibody concentration in test samples. Data derived 
from all ELISAs were analysed by use of the principles of parallel-line analyses. Briefly, 
only the results within the linear-dose range of the titration curves for both reference and 
test sample were used in the calculations. Analysis of variance was used to test the 
significance of departure of the log dose log response relationships from linearity or 
parallelism. Titres of individual samples were statistical analysed by analysis of variance 
(ANOVA).  A P≤0.05 value was considered statistically significant. Cut-off limits for the 
assay were calculated as twice the A405nm value of sera obtained from the negative control 
(PBS) group. For the purpose of statistical analysis, negative sera were assigned a value of 
0.01IU/ml. Where possible, all ELISA data was presented from individual animals, 
geometric mean concentrations and 95% confidence intervals.  
 
For the detection of IgG1, 2a, 2b, 3, IgA and IgM subclasses, individual mouse sera were 
used at a single sub-saturating dilution in a similar ELISA. Bound antibodies were detected 
using isotype-specific HRP-conjugated monclonal antibodies (Serotec). The relative 
concentration of the antibody isotype was calculated from the standard curves of serially 
diluted mouse myeloma proteins of the various immunoglobulin subclasses. A similar 
ELISA protocol was used to generated standard curves, with the exception that wells were 
initially coated with goat anti-mouse IgG + M + A (BD Pharmingen) instead of TTxd. 
Results for IgG subclasses were expressed as a percentage of total anti-TTxd IgG antibody. 
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Measurement of antibody avidity 
The avidity of anti-tetanus antibodies was measured by a modified ELISA as described 
previously (Tierney et al., 2003). Individual sera samples at a sub-saturating dilution were 
added to the appropriate wells of Nunc Maxisorp 96 well microtitre plates pre-coated with 
TTxd or HCWT and incubated at 37 oC for 2 hours. Plates were washed with PBS-Tween-
20, and 100µl ammonium thiocyanate (ATC) at different concentrations (0 to 10M) diluted 
in PBS-Tween-20/2.5% (w/v) Marvel was added to each well and plates were allowed to 
stand for 15 minutes at room temperature. Plates were washed with PBS-Tween-20 and the 
remaining bound antibody was detected by the addition of HRP-conjugated rabbit anti-
mouse IgG (Sigma) as previously described. The percentage antibody binding in the 
presence of ATC was determined by comparing the absorbance value (A405nm) in the 
presence of ATC treatment to that in the absence of ATC treatment. Avidity was expressed 
as avidity index, which corresponds to the concentration of ATC required to induce a 
reduction of antibody binding to coating antigen by 50%. 
 
Tetanus toxin neutralisation assay 
Tetanus toxin neutralisation assays were performed using pooled sera from mice 
immunised with TTxd, HCWT or HCM115. A series of dilutions (5 to 7, between 0.006 to 
0.001IU/ml) of pooled sera samples (as determined by ELISA) and of a reference standard 
(International Standard for anti-TeNT, Human IgG TE-3) were made in 2.5% Gelatine - 
PBS, in the presence of a fixed pre-determined concentration of TeNT (50 PD50). All 
mixtures were allowed to stand for 30 minutes at room temperature before being injected 
subcutaneously into groups of 4 NIH mice (0.5ml/mouse). The mice were observed for 96 
hours for signs of paralysis. The protective capacity of test samples was compared against 
the paralytic effect of 50 PD50 of TeNT with the reference standard required to give the 
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same 50% protection. Therefore, protective concentration was expressed in IU/ml, with 
upper and lower limits calculated from the ED50 dose-response curves. 
 
Spleen proliferation assay 
To measure the cellular response in spleen cells from immunised animals, spleens were 
removed and single cell suspensions were prepared in PBS/5% Foetal calf serum (FCS).  
Cell suspensions were washed for 10 minutes at 1200rpm and supernatant discarded. Red 
blood cells were lysed by resuspending cell pellets in approximately 1ml sterile distilled 
water for 1 to 2 seconds. Ten millilitres of PBS/5% FCS was added to the cells before 
washing for 10 minutes at 1200rpm. Cells were re suspended to a final concentration of    
4x106/ml in complete culture medium (RPMI-1640 culture medium supplemented with 
10% FCS, 1% penicillin/streptomycin (Sigma) and 10-5 M of 2-mercaptoethanol (Gibco)).  
Unless otherwise stated, aliquots of spleen cells were added to the appropriate wells of 96-
flat bottom plates (Falcon, Becton Dickinson, UK) and cultured for 5 days at 37oC/5% CO2 
in the presence of 10µg/ml of tetanus proteins in a final volume of 200 µl.  Spleen cells 
were also cultured with 1µg/ml concanavalin A (Sigma) as a positive control or with 
complete culture medium alone as a negative control.  On day 5, cells were pulsed with 
0.25µCi/well of 3H-Thymidine (Amershan, UK) and plates incubated for a further 6 hours. 
Cells were harvested onto glass fibre filters using an automated cell harvesting apparatus 
(Micro96 Harvester, Molecular Devices). Bulk cultures were set up in parallel for cytokine 
analysis and levels of interleukin (IL)-5, IL-6 in the supernatants of stimulated cells were 
measured by standard sandwich ELISA.  3H-Thymidine incorporation was measured in a 
β-scintillation counter. Results were expressed as a stimulation index (SI) of the mean 
counts per minute obtained from triplicate cultures in the presence of specific antigen 
(HCWT, HCM115 or TTxd) divided by the mean counts per minute of triplicate cultures 
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incubated in culture medium only. Alternatively, results were expressed as counts per 
minute (cpm for cells cultured with tetanus antigens–cpm for cells cultured in complete 
culture medium alone). Data was expressed as the mean stimulation ± SEMs from three 
separate spleen cultures. Statistical analysis was carried out by the 2-tailed Student's t test. 
P≤0.05 was considered statistically significant. 
 
Cytokine analysis by ELISA 
Determination of cytokine levels (IL-5, IL-6 and IFN-γ) in spleen cell culture supernatants 
was carried out using standard sandwich ELISA following the manufacturers instructions. 
Briefly, plates were coated with 100µl/well of cytokine-specific capture antibodies in 0.1 
M carbonate buffer (pH, 9.5). Non-specific binding sites were blocked with 200µl/well of 
PBS/10% FCS. Following 1 hour incubation at room temperature, plates were washed, cell 
culture supernatants were added (100µl/well) and incubation was continued for a further 2 
hours at room temperature. Cytokine specific binding was detected with biotin labelled 
antibodies and streptavidin-HRP, followed by tetramethylbenzidine (TMB) substrate and 
hydrogen peroxide. Absorbance was measured at A450nm and values for cytokine 
concentrations were expressed by reference to a standard curve constructed by assaying 
serial dilutions of the respective mouse cytokine. 
 
Interaction keratinocytes and dendritic cells with tetanus proteins in vitro 
To study the interaction of tetanus proteins with skin cells, keratinocytes (HaCaT) cells and 
dendritic cells (mouse bone marrow derived) were co-cultured with tetanus proteins and 
the level of activation was assessed. 
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Interaction of HaCaT cells with tetanus proteins 
HaCaT cells are non-tumorgenic human keratinocyte that have been derived from adult 
trunk skin (Boukamp et al., 1988). Although immortalised and genetically abnormal, they 
share many features of differentiation with normal human kerationcytes and are therefore a 
widely used model for studies on human skin kerationcytes (Schoop et al., 1999). HaCaT 
cells (provided by Dr. N Fusening, German Cancer Research Centre, Heidelberg, 
Germany) were grown in 75cm2 flasks (Costar, Cambridge, MA USA) and maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10%FCS, 1% L-
glutamine, 1% penicillin/streptomycin, at 37oC, 5% CO2 ,and were passaged at confluence 
(every 3 to 4 days). At approximately 80% confluent, monolayers of HaCaT cells were 
incubated with TTxd, HCWT or HCM115 protein (5µg/ml) at 37oC, 5% CO2 for 48 hour. 
To assess if HaCaT cells were activated by tetanus proteins, the expression level of 
selected cell surface activation markers (CD54; ICAM-1, CD80; B7.1 and MHC-II) was 
determined by indirect immunofluorescence staining. Culture supernatants were also 
collected and stored at -20oC for cytokine analysis by ELISA (R & D Systems) as 
previously described. 
 
Interaction of dendritic cells with tetanus proteins 
Preparation and enrichment of dendritic cells from bone marrow precursors 
Dendritic cells were generated from mouse bone marrow precursors using a modification 
of the methods previously described by (Inaba et al., 1992a). Tibiae and femurs were 
removed from the rear legs of 6 to 12 weeks old Balb/c mice, and placed in  RPMI-1640 
culture medium supplemented with 10% heat inactivated FCS. Bones were then sterilized 
for 1 minute in 70% ethanol followed by a wash in culture medium. 
Bone marrow was ejected by removing both ends of the bone and flushing cold culture 
medium into the bone shafts using a 25-gauge needle. Single cell suspensions were 
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obtained by gentle pipetting and cells were washed twice in complete culture medium by 
centrifugation for 10 minutes at 1300rpm. Cells were resuspended in culture medium and 
cell viability was determined using trypan blue stain. Cell concentration was adjusted to 
1x106cells/ml in culture media supplemented with 20ng/ml of granulocyte-macrophage 
colony stimulating factor (GM-CSF; NIBSC, 91/658) and 20ng/ml of IL-4 (NIBSC, 
91/656).Cells were cultured in 6-well tissue culture plates in a final volume of 4ml per well 
and incubated at 37o C in a humidified environment in the presence of 5% CO2. Cultures 
were fed on days 3 and 5 by removing (without disturbing the cells) 50% of the culture 
medium and adding back fresh GM-CSF- and IL-4-supplemented culture medium. 
Cultures were maintained for a total period of 7 to 11 days.  
 
To enrich for dendritic cells at the end of the culture period, bone marrow derived cells 
were harvested by gentle pipetting and centrifugation for 10 minutes at 1000rpm. The cell 
pellet was then washed three times in Hanks’ Balanced Salt Solution (HBSS; Sigma) by 
centrifugation for 5 minutes at 1000rpm. Pellets were resuspended in 3 ml of HBSS and 
cell viability was determined. Dendritic-like cells were then enriched using OptiPrep 
density gradient (Axis-Shield; 60% (w/v) solution of iodixanol in water; ρ=1.32g/ml) as 
follows: 3ml of cell suspension containing dendritic cells was mixed gently with 1ml of 
OptiPrep stock (giving a 15% (w/v) iodixanol solution; ρ = 1.085 g/ml). Five millilitre of 
an 11.5% (w/v) iodixanol solution (ρ=1.065g/ml) was carefully overlaid on top of the cell 
suspension and this was carefully overlayed with 3 ml of HBSS. Following centrifugation 
for 20 minutes at 1000rpm, the rotor was allowed to decelerate without the break and 
dendritic cells were visible as a band at the interphase between the 11.5% iodixanol and 
HBSS (Figure 2.5). Cells at the interphase were harvested and washed twice in culture 
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media to remove iodixanol. Determination of the level of enrichment for dendritic cells 
was performed by staining the cells for CD11c and MHC-II expression. 
 
Co-culture of tetanus proteins with dendritic cells 
To study the interaction of dendritic cells with tetanus proteins, cells enriched for dendritic 
cells as described above. Cell concentration was adjusted to 1 x 106 cells/ml and dendritic 
cells were incubated for 24 to 48 hours at 37oC/5% CO2 in culture medium supplemented 
with 10% heat inactivated FCS in the presence of varying concentrations of TTxd, HCWT, 
HCM115 or with LPS (1000ng/ml) as a control. Surface expression of activation molecules 
was assessed by single staining for ICAM-1, B7.1, B7.2 and MHC-II molecules (BD 
Pharmingen). Analysis of cytokine secretion in culture medium supernatant was assessed 
by ELISA, as previously described. 
 
Immunofluorescent staining and flow cytometry analysis 
HaCaT and dendritic cells were adjusted to 1x106 cells/ml in FACS buffer (PBS, 4% BSA 
and 0.01% sodium azide). One-hundred microlitres of cells (1x105 cells) were incubated 
with 2µl of the appropriate FITC-labelled monoclonal antibody (direct staining of dendritic 
cells) or with unconjugated mouse anti-human monoclonal antibody (indirect staining of 
HaCaT cells). Control cells were incubated with isotype specific Ig. Cell suspensions were 
incubated for 1 hour on ice and washed three times with FACS buffer by centrifugation for 
10 minutes at 1000rpm. Dendritic cells were then fixed with 500µl formaldehyde (1% in 
FACS solution).  For indirect staining HaCaT cells were further incubated (after washing) 
for 1 hour on ice with 5µl FITC- labelled goat anti-mouse Ig (BD Pharmingen).Cells were 
washed three times and fixed in formaldehyde, as previously described for dendritic cells. 
All cells were stored overnight at 4oC prior to analysis using a Becton Dickinson flow 
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cytometer. Between, 0.5 to 1x104 cells were acquired for analysis. All flow cytometry data 
were analysed using WinMDI software. Data were presented as percent (%) positive cells 
and changes in mean fluorescence intensity (MFI). 
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Figure 2.5. Purification of dendritic cells by flotation through a density gradient. 
Dendritic-like cell suspension was mixed gently with OptiPrep stock (giving a 15%  
iodixanol solution. An 11.5% iodixanol solution was carefully overlaid on top of the cell 
suspension and this was carefully overlayed with HBSS.  Following centrifugation the 
rotor was allowed to decelerate without the brake and dendritic cells were visible as a band 
at the interphase between the 11.5% iodixanol and HBSS.  See text for further details. 
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Activation of skin cells with tetanus proteins in vivo 
To study the effects of tetanus protein on the skin tissue, IL-1-α, IL-1β and Tumor 
Necrosis Factor (TNF)-α gene expression was measured using real-time PCR after TCI. 
RNA from an LPS (0.5µg/ml) activated mouse macrophage cell line (RAW264.7) was 
used as a positive control. 
 
Total RNA extraction from murine skin samples 
Balb/c mice were immunised with a single dose (30µg/ml) of HCWT or TTxd and an area 
of skin (approximately 1 to 2cm2) was excised from the immunisation site, snap-frozen in 
liquid nitrogen and immediately stored at –80oC until further use. For RNA extraction, 
between 10 to 30mg of tissue was placed in 300µl of guanidine-isothiocyanate containing 
lysis buffer (Buffer RTL) and homogenised using a mortar and pestle. Homogenates were 
collected and 10µl of Proteinase K solution (Qiagen) and 590µl double distilled water was 
added prior to incubation for 10 minutes at 55oC . Debris was pelleted by centrifugation for 
3 minutes at 10,000 rpm and supernatant was collected and transferred to a new eppendorff 
tube. Approximately 450µl of ethanol (96 to 100%) was added to the cleared lysates in 
50µl volumes. Lysates were transferred to RNeasy mini columns and the RNA allowed 
binding to silica gel membranes. Membranes were washed with 350µl buffer RW1 by 
centrifugation for 15 seconds at 10 000rpm, and the flow through was discarded. Columns 
were transferred to new 2 ml collection tubes and silica-gel membranes were washed with 
buffer RPE by centrifugation for 2 minutes at 10 000rpm. To elute RNA, columns were 
transferred to a new 1.5ml collection tube and 50µl RNeasy-free water was added directly 
onto the silica-gel membrane prior to centrifugation for 1 minute at 10 000rpm. 
Immediately after RNA extraction, contaminating DNA was removed using a DNA-free 
kit (Ambion) according to the manufacturer’s instructions. RNA was quantified using a 
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Nanodrop spectrophotometer, taking A260 of 1.0= 40µg/ml RNA. RNA purity was assessed 
by calculation of the A260/A280, where values above 1.6 were considered sufficiently pure. 
DNase-treated RNA was either used immediately for reverse transcription or stored at  -
70oC until further use.  
 
Total RNA extraction from RAW264.7 cells 
The mouse macrophage cell line, RAW264.7, was maintained in Dulbecco’s Modified 
Eagles Medium (DMEM) supplemented with 10% FCS. Cells were passaged (1: 4 passage 
ratio) every 2 to 3 days into a new 75cm2 tissue culture flask and incubated at 
37oC/5%CO2. RAW264.7 cells were stimulated with 0.5 µg/ml LPS and incubated for a 
further 24 hours at 37oC/5% CO2. RNA was extracted using the Qiagen RNeasy mini-kit 
according to the manufacturer’s instructions. Cell lysates were homogenised using QIA 
shredders (Qiagen) and RNA was eluted into 30µl of RNase free water. 
 
Reverse transcription PCR (RT-PCR) 
All reagents used for reverse transcription were purchased from Invitrogen and Promega 
unless otherwise stated. Approximately 4µg of total RNA was combined with 1µg of 
oligodeoxyribothimidine (oligo (dT) 15) (25ng/ml) in a sterile 0.2ml PCR tube. The 
volume was made up to 24µl with sterile dH2O. Each tube was incubated for 10 minutes at 
70oC using a T1 Thermocycler PCR machine (Biometra) and chilled on ice. To this 
reaction, the following components were added: 10mM dithiotheritol (DTT), 8µl of first 
strand buffer (50mM Tris-HCl, 75mM KCl, 3mM MgCl2), and 500µM of each dNTP. 
Following incubation for 10 minutes at 42oC in a PCR machine, 10U/ml of Superscript II 
reverse transcriptase (RTase) was added and the reaction was incubated for 50 minutes at 
42oC. The reverse transcription reaction was stopped by incubation for 10 minutes at 70oC. 
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The concentration of the resulting cDNA was calculated using a Nanodrop 
spectrophotometer. 
 
Real-time reverse-transcription PCR (Real-time RT-PCR) 
To measure cytokine gene expression in cDNA preparations, reverse transcription RT-PCR 
was used. This method of PCR requires a pair of PCR primers as regular PCR does, and 
additional fluorogenic probe, which is an oligonucleotide attached with both a reporter 
fluorescent dye and a quencher dye (Figure 2.6). RNA was extracted and cDNA produced 
using RT-PCR as described above. All real time RT-PCR reactions were carried out in 
Optical-384 96-well microwell plates (Applied Biosystems). To each well, 4µl of nuclease-
free H2O, 10µl 2x PCR mixture (Applied Biosystems), 1µl 20x primer/probe mixture (900 
nm primer; 250nm probe) and 5µl cDNA (diluted to 15µg/ml from stock in nuclease-free 
H2O). All reactions were carried out in triplicate and run under the following cycle 
conditions using a 7500 Fast sequence detection system (Applied Biosystems): 40 cycles 
of 2 minutes, 50oC; 10 minutes, 95oC; 15 seconds, 95oC and 1 minute, 60oC. 
 
After the reactions were complete, the parameters for the SDS 1.3.1 software (Applied 
Biosystems) were set so that for each gene studied, product quantity was measured during 
the exponential phase of amplification. Data analysis was performed using the comparative 
Cycle threshold (Ct) method as recommended in Applied Biosystems’ User Bulletin #2. 
Briefly, raw data from real time RT-PCR analysis are plotted as the increase in 
fluorescence (target amplification) per cycle. The Ct, which is the cycle number at which 
amplification crosses a threshold, was used for analysis. The threshold is set as the lowest 
point where all the samples are in the exponential amplification phase of the reaction. 
 
  
Chapter 2: Materials and methods 
 71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Real-time RT-PCR TaqMan chemistry. a) An oligonucleotide probe (green) 
is constructed containing a reporter fluorescent dye on its 5’ end and a quencher dye on its 
3’end. If the target sequence is present, the probe anneals downstream from the primer 
binding site. b) As the primer (red) is extended, the 5’nuclease activity of Taq DNA 
polymerase cleaves probe. c) Cleavage of the probe results in the separation of the reporter 
dye from the quencher dye, thus increasing the reporter dye signal, and d) removes the 
probe from the target strand, allowing primer extension to continue to the end of the 
template strand. Adapted from Applied Biosystems manufacturers instructions.  
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Localisation of tetanus proteins in vivo  
To study the fate of HCWT and TTxd protein after TCI, tissue biopsies were taken from the 
immunisation site. The presence of proteins was detected using immunohistochemistry 
with purified rabbit anti-HC antibodies. 
 
Rabbit anti-HCWT IgG purification 
The IgG fraction of serum from rabbits previously immunised with HCWT protein was 
purified on a Protein A column (GE Healthcare). Briefly, the Protein A column was 
equilibrated by washing with 10 column volumes (CVs) of binding buffer (20mM sodium 
phosphate solution, 0.5M sodium chloride, pH7.0). Rabbit serum diluted 1 in 4 in binding 
buffer was loaded onto the Protein A column and washed with a further 10CVs of binding 
buffer. Fractions (0.5ml) containing rabbit IgG were then eluted using elution buffer (0.1M 
glycine and 0.5M sodium chloride, pH2.7) and immediately adjusted to physiological pH 
by adding 200µl of neutralisation buffer (1M Tris-HCl, pH9.0). Purified IgG content was 
monitored by measuring the A280 nm readings. Fractions with A280 nm readings of ≥ 0.1 
were pooled and dialysed overnight at 4oC against PBS. Prior to immunohistochemistry 
staining, the specificity of purified antibody for HCWT and TTxd was confirmed by an 
anti-TTxd and anti-HCWT ELISA and the protein concentration was confirmed by the 
BCA assay as previously described. 
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To compare the up take and localisation of tetanus proteins within the skin layers following 
TCI, Balb/c mice were immunised with tetanus proteins and skin samples were taken at 
different time points. Following hydration with dH20, 100µg of HCWT or TTxd were 
applied onto the skin, as previously described. Skin samples (1 to 2 cm2) were excised at 
various time intervals and fixed for 24 hours in 10% formalin solution. 
 
All fixed tissues were processed in paraffin wax using an automated tissue processor 
(Leica ASP200 Tissue Processor, Global Medical Instramentation) and 5µm skin sections 
were prepared using a microtome. Sections were sealed to Superfrost Plus slides (VWR 
International) by overnight incubation at 60oC and stored at room temperature until 
stained.  
 
Preparation of tissue and immunohistochemistry staining  
Before staining, paraffin was removed from slides and sections were rehydrated by a series 
of washes in Xylene and decreased concentrations of ethanol solutions. To suppress 
endogenous peroxidise activity, slides were washed three times with 0.5M Tris-HCl 
buffered saline (pH7.0) and incubated for 30 minutes at room temperature in a solution of 
0.5% H2O2 . Following a further three washes, non-specific binding sites were blocked by 
incubation with goat serum (1 in 5 dilution) for 30 minutes at room temperature.  To detect 
the presence of tetanus protein within the skin layers, slides were incubated with rabbit 
anti-HCWT IgG primary antibodies (1 in 100 dilution) followed by biotinylated goat anti-
rabbit IgG (1 in 200 dilution; BD Pharminogen). Slides were then washed thoroughly in 
Tris-HCl and 0.5ml of streptavidin-HRP conjugated solution (BD Pharminogen) was 
added for a further 30 minutes at room temperature. The extensive washing step was 
repeated and bound antibodies visualised by incubating slides with diaminobenzidine 
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(DAB) substrate solution (BD Pharminogen) until the development of adequate colour.  
Following a further three washes, slides were counterstained with haematoxylin for 2 
minutes, dehydrated in decreased concentrations of ethanol and mounted in organic 
mounting media. Slides were examined using a light microscope at x400 magnification. 
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Introduction 
The aim of this initial study was to obtain sufficient quantities of highly purified wild type 
and Trp1289Ala/Arg1226Ala (HCM115) HC proteins to use as model antigens for TCI. 
Mutant HCM115, containing alanine substitutions within ganglioside binding sites, was 
previously constructed by Dr Omar Qazi. Both HCWT and HCM115 proteins were 
expressed in E. coli strain BL21 (λDE3) containing the appropriate plasmid and purified by 
affinity chromatography. An additional purification step, FPLC-SEC, was introduced to 
reduced the presence of contaminants, such as endotoxin, in the final protein preparations.  
 
Following purification, it was important to characterise batches to ensure that only high 
quality preparations were used for future immunological studies. To test the functional 
activity of recombinant proteins an ELISA based ganglioside binding assay was used. 
Furthermore, the extent of purity and endotoxin concentrations of protein batches were 
tested by SDS-PAGE and the Limulus amoebocyte (LAL) assay respectively. Final protein 
concentrations were determined by use of the BCA assay. 
 
Bacterial growth and protein production 
The HC proteins were expressed in E. coli strain BL21 (λDE3) containing pKS1 (for 
HCWT protein expression) or pKS115 (for HCM115 protein expression)  using a protocol 
which was previously optimised by Sinha et al., (2000). Briefly, 250ml cultures of E. coli 
BL21 (λDE3) harbouring the appropriate plasmid were grown in LB broth to an Optical 
density of 650nm (OD650nm) between 0.8 to 1.0. Protein expression was induced by the 
addition of IPTG (1mM) and growth was continued for a further 3.5 hours. Each bacterial 
culture grew well and was largely unaffected by the addition of IPTG (Figure 3.1.). 
Cultures were then harvested, resuspended in phosphate buffer and lysed on ice by 
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sonication. Supernatants containing whole cell lysates, including the soluble HC protein, 
were collected and fractionated by Ni2+ agarose affinity chromatography. This method 
takes advantage of the high binding affinity between the Ni2+ ions contained within the 
agarose gel matrices, and the 6-histidine tag at the N-terminal of the protein. HCWT or 
HCM115 proteins were easily eluted from gel matrices by the addition of elution buffer 
containing a high concentration of imizadole (200mM). Being structurally related to 
histidine, imidazole competes for binding sites to the Ni2+ ions within the resin. The 
histidine-tagged HC proteins dissociate and are eluted from the column. Protein 
concentration was estimated by absorbance readings at 280 nm (A280 nm). Protein elutions 
with an A280 nm value equal to or greater than 0.5 were collected and run on 10% SDS-
PAGE gels to check both their purity and integrity. High quality protein elutions were 
pooled and the final protein concentrations were calculated by use of the Pierce BCA 
assay. On average, between 1 to 2mg of HCWT or HCM115 protein was purified from each 
250ml culture of E.coli BL21. 
 
To carry out all the necessary immunological experiments, larger quantities of high quality 
HCWT or HCM115 protein was required. To address this issue, a 15-litre fermentation run 
was carried out using E. coli strain BL21 (pKS1) expressing HCWT protein, or strain BL21 
(pKS115) expressing HCM115 protein. As previously described, protein production was 
induced by addition of 1mM IPTG when OD650 nm values were between 0.8 to 1.0. As for 
laboratory-scale production, both cultures grew well under fermentation conditions, and 
growth was unaffected by the addition of IPTG (Figure 3.2). Collectively, 38g of E. coli 
BL21 (pKS1) and 42g E. coli BL21 (pKS115) were harvested and further divided into 
pellets of approximately 6g for easier handling. Following cell lysis and purification of the  
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HC proteins by Ni2+-NTA chromatography and FPLC-SEC, the final protein concentration 
were measured using the BCA assay. The yields from one 6g pellet of bacterial culture 
were as follows: from BL21 (pKS1), expressing HCWT, 37mg was obtained; and from 
BL21 (pKS115), expressing HCM115, 35mg was obtained. Therefore, if using these values 
as a guideline, it should be possible to purify a total of 230 to 240mg of HCWT or HCM115 
protein from a 15-litre fermentation run. 
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Figure 3.1. Growth curves of E. coli BL21 (pKS1) and BL21 (pKS115). Two-hundred 
and fifty millilitres of bacterial culture was grown in LB broth containing 50µg/ml 
kanamycin. Expression of HCWT or HCM115 proteins was induced at OD650nm 0.8 to 1.0 
by the addition of IPTG (1mM). 
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Figure 3.2. Growth curves of E. coli BL21 (pKS1) and BL21 (pKS115) in a 15 litre 
fermentor. Overnight bacterial culture (300ml) was added to LB broth containing 50 
µg/ml kanamycin. Expression of HCWT or HCM115 proteins was induced at OD650nm 0.8 
to 1.0 by the addition of IPTG (1 mM).  
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FPLC–SEC purification of HC proteins 
A size exclusion chromatography step was introduced to reduce endotoxin contamination 
in all recombinant protein batches. Previous studies have shown that HC proteins can exist 
in various oligomeric states which can be separated by SEC (Qazi et al., 2007). 
Polydispersed (not separated by SEC) HCWT or HCM115 protein was loaded onto a pre-
calibrated Superdex 200 SEC column. Figure 3.3 shows the typical gel filtration profiles of 
three preparations of HCWT and three preparations of HCM115. For each individual HCWT 
or HCM115 trace, three distinct peaks were evident, with the proportions remaining 
relatively consistent between batches of protein. With reference to the calibration curve 
(not shown), the three peaks roughly correspond in size to monomer, putative dimer and 
putative trimer protein. Peak 1 had an estimated molecular weight of 178.5kDa, which 
could correspond to trimer of HC (161.7kDa). The molecular weight of peak 2 was 
calculated to be 110kDa, which is a similar value to the molecular weight of an HC dimer 
(107.8kDa). The monomer peak (peak 3) corresponds to a molecular weight of 43kDa with 
is slightly lower than the expected value of 53kDa.  
 
Monomeric HCWT or HCM115 protein fractions were pooled to form individual batches of 
purified protein. Each batch of HCWT or HCM115 protein was assigned a batch number 
(e.g. 1, 2, etc.) according to the order of production. In total, five batches of HCWT and 
five batches of HCM115 were prepared (Table 3.1).  
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Characterisation of purified HC proteins 
Purity and integrity  
It was crucial to check that a high level of purity was attained for all batches of HCWT and 
HCM115 proteins and that the HC proteins had not been modified or partially degraded 
though the purification process. Examples of highly purified of HCWT and HCM115 
proteins are shown in Lane 4 of Figure 3.4 and 3.5, respectively. Consistent with the 
predicted molecular weight of 53.9kDa, a band of approximately 50kDa was evident in 
each culture induced with IPTG (Figure 3.4 and 3.5, Lane 2). These proteins were purified 
to homogeneity by Ni2+ affinity chromatography and FPLC-SEC, to yield a preparation 
containing predominantly a single protein (Figure 3.4 and Figure 3.5, Lane 4). 
Furthermore, no obvious protein contaminants or protein degradation was evident. 
 
Functional activity  
Previous studies have indicated that TeNT HC protein binds with highest affinity to 
gangliosides belonging to the GT1b family (Holmgren et al., 1980). Figure 3.6 gives an 
example of typical HCWT and HCM115 protein binding profiles to ganglioside GT1b. 
Overall, data showed that HCWT protein bound to GT1b at concentrations as low as 0.03 
to 0.06 mg/ml. Although the binding of the HCWT protein did not achieve saturation, the 
results show that the HCWT had the expected GT1b binding activity. In contrast, HCM115 
protein had near negligible GT1b binding activity, even at concentrations as high as 2.0 
mg/ml. This is consistent with the two mutations, Trp1289Ala and Arg1226Ala, which are 
located in the ganglioside binding sites of the protein. 
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Figure 3.4. Purification of HCWT protein. Samples were taken during an experiment to 
purify HCWT protein, and analysed by 10% SDS PAGE and visualised with coomasie 
blue. Lane 1, protein marker; lane 2, E. coli BL21 (pKS1) lysate (non-induced); lane 3, 
E.coli BL21 (pKS1) lysate (induced); lanes 4, HCWT protein after Ni2+ affinity purification 
and FPLC-SEC purification (2.5µg).   
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Figure 3.5. Purification of HCM115 protein. Samples were taken during an experiment 
to purify HCM115 protein, and analysed by 10% SDS PAGE and visualised with coomasie 
blue. Lane 1, protein marker; lane 2, E. coli BL21 (pKSM115) lysate (non-induced); lane 
3, E. coli BL21 (pKS1M115) lysate (induced); lanes 4, HCM115 protein after Ni2+ affinity 
purification and FPLC-SEC purification (2.5µg).   
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Figure 3.6. GT1b ganglioside binding activity of HCWT and HCM115 proteins. 
Microtitre plates were coated with GT1b ganglioside serial dilutions of purified HCWT 
(▲) and HCM115 (■) proteins were added to the plate and their ability to bind ganglioside 
determined by addition of anti-HC antibody. The graph is a typical binding curve obtained 
for HCWT or HCM115 proteins.  
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Measurement of endotoxin 
Endotoxin (lipolysacharide, LPS) is an integral component of Gram-negative bacteria, 
providing structural organisation and stability for the outer membrane. Mammalian 
exposure to such molecules can cause the induction of the inflammatory responses 
(Kronborg., 1995). Therefore, because of the immunological nature of future experiments, 
endotoxin levels in protein batches had to be minimal. 
 
Endotoxin levels of the purified proteins were determined using the LAL assay (Table 3.1). 
Comparison of endotoxin levels of the Ni2+ affinity purified HCWT protein (3000 to 
6000IU/mg) and of HCWT and HCM115 proteins after an additional FPLC-SEC 
purification step (3 to 558 and 6 to 203IU/mg, respectively) shows a significant reduction 
in the endotoxin concentrations for both proteins after FPLC-SEC. Although endotoxin 
levels were observed to vary between batches, all values were below 550IU/mg. These 
were regarded negligible, particularly for subsequent transcutaneous immunisation studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Purification and characterisation of HC proteins 
 88 
Table 3.1. Characterisation of HC proteins used in this study 
Protein Purification 
Technique b 
Ganglioside 
binding activity c 
(%) 
Endotoxin level 
(IU/mg) d 
HCWT-Batch 0 a AC 100 3000-6000 
HCWT-Batch 1 AC & SEC 100 23-46 
HCWT-Batch 2 AC & SEC 100 185-370 
HCWT-Batch 3 AC & SEC 100 279-558 
HCWT-Batch 4 AC & SEC 100 60-120 
HCWT-Batch 5 * AC & SEC 100 3-6 
HCM115-Batch 1 AC & SEC < 1 87-174 
HCM115-Batch 2 AC & SEC < 1 101-203 
HCM115-Batch 3 AC & SEC < 1 6.9-13 
HCM115-Batch 4 AC & SEC < 1 12-60 
HCM115-Batch 5 * AC & SEC < 1 6-12 
 
a
 produced by Dr Omar Qazi for endotoxin comparison only 
b AC, Ni 2+ affinity chromatograph, SEC, size exclusion chromatography 
c determined using ELISA and expressed as the binding of each protein to GT1b 
gangliosides relative to the binding of HCWT protein 
d determined using the LAL assay and expressed in IU/mg protein. 
* Protein produced by fermentation 
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Discussion 
Fragment HC of TeNT has previously been used as a model antigen for studying a number 
of different novel vaccination strategies (Chatfield et al., 1993;Douce et al., 1995;Stratford 
et al., 2001). Recent studies have shown that alanine substitutions of Trp1289 in the Gal4-
GalNAc3 and Arg1226 in the Sia7-Sia6 ganglioside binding sites results in an HC protein, 
HCM115, which has near negligible ganglioside binding, neuronal cell binding and 
retrograde transport activities (Qazi et al., 2006). The aim of this initial study was to 
produce sufficient quantities of highly purified recombinant TeNT HCWT and HCM115 
proteins for use in future TCI studies.  
 
Initially, a small-scale laboratory-based culture system was used to purify HCWT and 
HCM115 proteins. However, it was decided that for the purpose of this project, a more 
efficient method of protein production was necessary to cater for the amount of protein 
required for future immunological experiments. Protein production by fermentation has the 
distinct advantage of allowing bacterial growth parameters such as pH and oxygen levels 
in culture medium to be closely monitored. This in turn should maximize the growth of the 
culture, producing high yields of cells and therefore of protein to be purified. The data 
obtained showed that the final yield of both HCWT and HCM115 protein was significantly 
increased by fermentation. Scaling up the production therefore holds great potential as 
being a more efficient method for future HC protein production. 
 
Recombinant proteins expressed in Gram-negative bacteria such as E. coli, are normally 
contaminated with endotoxin, which is an integral component of the bacterial cell 
membrane. Endotoxin can readily induce inflammatory responses by a number of cells of 
the immune system (Erridge et al., 2002). Therefore, for the purpose of use in future 
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immunological experiments it was crucial to remove excess endotoxin from purified 
batches of HCWT and HCM115 proteins. FPLC-SEC has been used successfully by others 
to reduce the endotoxin concentration from protein vaccine preparations (Fiske et al., 
2001). Endotoxin measured by the  LAL assay showed that levels in HCWT or HCM115 
protein preparations subjected to just one run of FPLC-SEC was approximately 400-fold 
lower compared to HCWT purified only by  Ni2+ affinity chromatography. Although 
endotoxin was not completely removed, no adverse reactions at the application site or 
systemically were observed in mice immunised transcutaneously with the different batches 
of HC proteins (see Chapter 4). 
 
Following the purification processes, all batches of recombinant HC proteins were checked 
to ensure they retained the desired functional activity of TeNT native protein, and that they 
were of the highest level of purity. Functional activity analysed by use of an ELISA based 
assay which assessed the binding activity of purified HCWT and HCM115 proteins to GT1b 
ganglioside. All batches of HCWT protein were able to bind GT1b ganglioside even at very 
low concentrations (0.02mg/ml). In contrast, all batches of HCM115 protein had near 
negligible binding activity. These results were consistent with data obtained from previous 
studies (Qazi et al., 2006). Finally, to ensure that protein samples had not become modified 
or partially degraded by the purification process samples from each batch of HCWT and 
HCM115 were assessed by SDS-PAGE. For all batches of HC protein, a single band with  
the predicted molecular weight for HC (approximately 50kDa) was evident with no visible 
signs of degration or unfolding.  
 
Collectively, all batches of purified HCWT and HCM115 proteins retained the 
characteristics of native proteins and indeed had a much lower endotoxin levels in 
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comparison to the affinity purified protein only. All batches of HCWT and HCM115 were 
therefore deemed acceptable for use in future in studies to assess their immunogenicity via 
the transcutaneous route. 
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Introduction  
Potential safety concerns and the need for extensive testing to monitor freedom from 
toxicity with retention of adequate immunogenicity has prompted the development of 
novel stratagies to replaceTTxd with more defined recombinant non-toxic molecules. The 
HC fragment and mutant derivatives of tetanus toxin have been proposed as potential novel 
vaccine candidates (Helting and Nau, 1984a); Makoff et al., 1989; Qazi et al., 2006). 
However, recent studies have shown that when administered by the subcutaneous route HC 
fragments elicit a protective antibody response that was considerably lower to that of TTxd 
(Qazi et al., 2006). Such results have therefore prompted exploration into novel and more 
relevant delivery routes for successful immunisation with recombinant sub-unit fragments. 
The aim of this study was to explore the immunogenicity of HC proteins by TCI delivery. 
Groups of mice were immunised transcutaneously with highly purified recombinant HCWT 
or HCM115 proteins and the humoral and cellular immunogenicity were measured and 
compared to that of conventional tetanus toxoid vaccine. Furthermore, TeNT neutralisation 
potencies of immune sera were assessed in vivo using passive protection studies.  
 
Optimisation of transcutaneous immunisation delivery conditions                           
Preliminary experiments were carried out to optimise TCI skin pre-treatment conditions 
and antigen concentration. To demonstrate if the pre-treatment of skin had an effect on the 
antigen specific response, various concentrations of HCWT, HCM115 or TTxd were 
applied onto shaved or shaved with depilatory cream (Nair) treated abdominal skin, on 
days 0, 28 and 56 (Table 4.1; Experiment 1 and 2, respectively). Mouse sera was collected 
on day 70 and tested for the presence of anti-TTxd or anti-HCWT antibodies.  
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In the first experiment tetanus proteins were applied onto hydrated shaved BALB/c mouse 
skin. Only 2 out of 50 mice had a measurable IgG antibody response when measured 
against TTxd (0.3 and 0.9IU / ml, respectively; Figure 4.1a) or against HCWT protein (0.4 
and 0.6 IU/ml, respectively; Figure 4.1b) by ELISA. Sera from all other mice (n=47) did 
not generate a response greater to that of the saline control group.  
 
In an attempt to improve the immunogenicity of tetanus proteins following TCI, the 
residual hair following shaving was removed by application of a hair depilatory cream 
(Nair). Compared to shaving alone, application of Nair for 2 to 3 minutes resulted in the 
complete removal of all hair from the treated area of the abdomen (Figure 4.2). 
Furthermore, no noticeable inflammation was recorded post-application. A second TCI 
experiment (Experiment 2) was then carried out on shaved and depilatory cream pre-
treated skin (as described in Table 4.1). Three doses of 80µg, 30µg or 10µg of tetanus 
proteins were applied to shaved and depilatory cream pre-treated skin. Sera was collected 
on day 70 and the anti-TTxd and anti-HCWT responses were analysed by ELISA. Results 
showed that all tetanus proteins were immunogenic at concentrations of 30µg/ml and 
80µg/ml as indicated by the generation of measurable antibody responses against HCWT or 
TTxd protein (Table 4.2 and Figure 4.3). In contrast, when mice were immunised with the 
lower dose (10µg/ml) of tetanus proteins, serum antibody responses were somewhat lower. 
Only two out of five mice immunised with 10 µg/ml of TTxd generated a measurable anti-
TTxd or anti-HCWT IgG response, whereas none of the mice immunised with 10µg/ml 
HCM115 generated a measurable anti-TTxd or HCWT IgG response. All mice immunised 
with 10µg/ml HCWT induce a measurable anti-TTxd IgG response of 0.09 which is well 
above the level considered minimal for protection (0.01IU/ml). 
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 Collectively, the results from Experiment 2 showed that total anti-TTxd and anti-HCWT 
results showed that the optimum dose for TCI with TTxd was ≥80µg. However, 
immunisation with only 30µg was required for both HCWT and HCM115 proteins as there 
was no significant difference (P >0.05) between the antibody response of mice immunised 
with 30 or 80µg. When comparing the anti-TTxd IgG titres from mice immunised with 3 x 
30µg in experiment 2, results showed that mice immunised with HCWT (1.05IU/ml) was 
considerably higher than those values obtained when immunising with TTxd (0.16IU/ml). 
This difference, however, was not statistically significant (P>0.05). A similar trend was 
found when the antibody responses were measured on HCWT coated ELISA plates. Data 
showed that the geometric mean ant-HCWT IgG titre from mice immunised with 3 x 30µg 
of HCWT (20.6IU/ml) was significantly higher (P<0.05) than those from mice immunised 
with TTxd at the same dose (0.05IU/ml). Immunisation with 3 x 30µg HCM115 showed 
that the anti-HCWT IgG titres were comparable to those obtained for immunisation with 
HCWT. Furthermore, anti-HCWT IgG levels were significantly higher (P<0.05) for mice 
immunised with 3 x 30µg HCM115 (17.8IU/ml) when compared to titres of mice 
immunised with 3 x 30µg TTxd (0.05IU/ml). All mice immunised with PBS failed to 
induce any measurable anti-HCWT or TTxd IgG response. 
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Table 4.1. Summary of the HCWT and TTxd proteins used for the transcutaneous 
immunisation experiments 
 
Experiment 
Number 
Method of 
hair removal 
Immunising 
Antigen 
Dose ** 
(µg/50µl) 
Protein batch No. 
used for TCI *** 
 
1 
 
 
Shaving 
 
TTxd 
HCWT 
HCM115 
200 / 100 / 30   
30 / 10 / 5 
30 / 10 / 5 
NIBSC, 02 / 126 
HCWT Batch-1 
HCM115 Batch-1 
 
2 * 
 
Shaving/Nair 
 
TTxd 
HCWT 
HCM115 
80 / 30 / 10 
80 / 30 / 10 
80 / 30 / 10 
NIBSC, 02 / 126 
HCWT Batch-3 
HCM115 Batch-3 
 
3  
 
Shaving/Nair 
TTxd 
HCWT 
HCM115 
30 
30 
30 
NIBSC, 02 / 126 
HCWT Batch-4 
HCM115 Batch-4 
 
4 
 
Shaving/Nair 
TTxd 
HCWT 
HCM115 
30 
30 
30 
NIBSC, 02 / 126 
HCWT Batch-2/3 
HCM115Batch-2/3 
 
5 
 
Shaving/Nair 
TTxd 
HCWT 
HCM115 
30 
30 
30 
NIBSC, 02 / 126 
HCWT Batch-4 
HCM115 Batch-4 
 
*In Experiment 2, because of the low starting antigen concentrations, 2 x 50µl were 
applied per mouse on day 0, 28 and 56 
**Mice were immunised with a single dose on day 0, 28 and 56. 
*** See Table 3.2 for more details. 
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Figure 4.1. Experiment 1: total IgG response following topical application of various 
concentrations of TTxd, HCWT or HCM115 onto shaved mouse skin. Individual sera 
samples from groups of mice (n = 5) in Experiment 1 were collected 14 days after the third 
immunisation. Individual sera were tested for a) anti-TTxd and b) anti-HCWT IgG 
ntibodies by ELISA. Data are presented for individual mice (∆).
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Figure 4.2. Skin pre-treatment prior to topical application of tetanus proteins. Before topical application of tetanus proteins onto 
abdominal skin, hair was removed by a) shaving or b) by application of a depilatory cream (Nair) for 2 to 3 minutes prior to removal by a 
dampcloth.
a) b) 
1 cm 1 cm 
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Tables 4.2. Experiment 2: Anti-IgG responses following TCI of shaven / depilatory 
cream mice 
a) Geometric mean anti-TTxd IgG response (95% CI)  
PBS                             N/A                  < 0.01   
 
b) Geometric mean anti-HCWT IgG response (95% CI) 
 
PBS                            N/A                    <0.01   
 
Antibody levels were detected in individual mouse sera by ELISA against TTxd or HCWT protein. Data are 
the calculated geometric mean antibody levels from 5 different animals expressed as IU/ml against an in-
house reference serum (1.68 IU/ml). For analysis, mice with antibody levels below twice the level obtained 
for the saline control groups were assigned the value of 0.01 IU / ml. CI, confidence intervals were assigned 
to groups where > 40% of mice responded. *P < 0.05 compared to TTxd. N/A, not applicable.  
Antigen Dose 
(µg) 
Anti-TTxd IgG, IU/ml 
(95% CI) 
3 x 80 5.30 (1.40 - 19.4) 
3 x 30 0.16 (0.01 – 1.29) 
 
TTxd 
3 x 10 0.02 (0.01 – 0.15) 
3 x 80 1.04 (0.20 – 5.20) 
3 x 30 1.05 (0.28 – 3.80) 
 
HCWT 
3 x 10 0.09 (0.02 – 0.34) 
3 x 80 0.40 (0.02 – 6.01) 
3 x 30 0.85 (0.02 – 4.69) 
 
HCM115 
3 x 10 < 0.01 
Antigen Dose 
(µg) 
Anti- HCWT  IgG, IU/ml 
(95% CI) 
3 x 80 3.37 (0.3 - 35.70) 
3 x 30 0.05 (0.02 - 1.43) 
 
TTxd 
3 x 10 < 0.01 
3 x 80 7.95 (0.79 - 79.6) 
3 x 30 * 20.6 (8.60 - 49.1) 
 
HCWT 
3 x 10 7.80 (3.87 - 15.7) 
3 x 80 23.9 (7.0 - 81.7) 
3 x 30 * 17.8 (6.29 - 50.6) 
 
HCM115 
3 x 10 0.15 (0.01 – 16.5) 
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Figure 4.3. Experiment 2: Total IgG response following topical application of various 
concentrations of TTxd, HCWT or HCM115 onto hydrated depilatory cream treated 
mice skin. Individual sera samples from groups of mice (n = 5) were collected 14 days 
after the third immunisation. Individual sera were tested for a) anti-TTxd and b) anti-
HCWT IgG antibodies by ELISA. Data are presented for individual mice (∆) in addition to 
the geometric mean titre (GMT; (-)) expressed as IU / ml.  * P < 0.05 vs. TTxd. 
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Kinetics of antibody and neutralising antibody response following TCI 
with tetanus antigens 
To compare the immunogenicity of HCWT, HCM115 and TTxd following TCI, the kinetics 
of the anti-TTxd and anti-HCWT IgG and TeNT neutralising antibody responses were 
followed by measuring serum antibody levels 4 weeks after both the primary immunisation 
(day 28) and the first boost (day 56), and 2 weeks after second boost (day 70). (Experiment 
3; see Table 4.1). Results from initial optimisation experiments showed that 30µg was the 
optimal dose for TCI with HC fragments. Therefore, for the purpose of the kinetics and 
neutralisation studies, groups of mice were immunised with 30µg of all tetanus proteins. 
Separate groups of mice were immunised for each time point and control group of mice 
were given PBS alone.  
 
Kinetics of anti-TTxd or anti-HCWT antibody response 
Mice given a single immunisation of tetanus proteins did not induce a significant anti-
TTxd IgG response to any antigen on day 28 (P>0.05; Figure 4.4a). However, after a 
second immunisation the antibody levels, as determined on day 56, revealed a substantial 
anti-TTxd IgG response in groups that received HCWT or TTxd, but not in those that 
received HCM115. After a third dose of antigen, and when analysed on day 70, an antibody 
response was seen in groups of mice immunised with HCM115, and an increased response 
in groups immunised with HCWT.  Nevertheless, no significant difference between the 
responses of the three proteins was evident after the third immunisation as determined on 
day 70 (P>0.05). When the anti-IgG response to HCWT protein was measured, the kinetics 
was slightly different (Figure 4.4b). A primary anti-HCWT IgG response was detected in 
mice immunised with HCWT only. A steady increase in IgG titre was observed following a 
second and a third dose for all proteins, with the response of mice immunised with HCWT 
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remaining significantly higher than either HCM115 or TTxd at all measured time points 
(P<0.05). All mice given PBS alone remained negative at all time points, when tested for 
anti TTxd or anti-HCWT responses. 
 
Kinetics of antibody tetanus toxin neutralising potency 
To confirm the anti-TTxd and anti-HC ELISA results, sera samples were pooled and used 
in an in vivo mouse TeNT neutralisation assay using a pre-determined concentration of 
TeNT (50 PD50). The TeNT neutralising kinetics was followed by measuring the 
neutralising potency of serum antibodies 4 weeks after both the primary immunisation and 
the first boost, and 2 weeks after second boost concluding the study on day 70.  Results 
showed that in contrast to anti-HC ELISA following primary immunisations, the TeNT 
neutralising potencies were below the level of detection (<0.05IU/ml) for all of the sera 
samples (Figure 4.5). However, after one booster (and as measured on day 56), the level of 
neutralising antibodies increased in both the HCWT and TTxd groups between 0.5 to 
0.6IU/ml, but remained below the level of detection in the group of mice immunised with 
HCM115 protein. Interestingly, results showed that the kinetics of the protective antibody 
responses following TCI with HCWT and TTxd were different. A continuing increase in 
protective antibody response was only observed for HCWT (<0.05, 0.6 and 1.9IU/ml at 28, 
56 and 70 days respectively) whereas the response to TTxd did not appear to improve over 
the same period and following second booster     (<0.05, 0.5 and 0.2IU/ml). However, 
different sets of animals were used in the kinetic study for each time point, and some 
variability between groups can be expected.  
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Figure 4.4. Kinetics of the IgG antibody responses following transcutaneous 
immunisation of mice with HC fragments or TTxd. Mice (n = 5) were immunised with 
30µg of HCWT, HCM115 or TTxd on days 0, 28 and 56. Sera samples were collected on 
days 28, 56 and 70 and tested for a) anti-TTxd and b) anti-HCWT antibodies. Results are 
expressed as geometric mean titre (GMT) with only upper standard error of the mean 
(SEM) values showing. *, P ≤ 0.05 when compared to TTxd or HCM115. Arrows indicate 
immunisation time points, post bleeds. (♦) HCWT; (▲), HCM115; (■), TTxd and (●), PBS. 
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Figure 4.5. Kinetics of tetanus toxin neutralisation antibody response following TCI 
with HC proteins and TTxd. Neutralisation potency was determined on pooled mouse 
sera samples from each group (5 mice per group) taken on days 28, 56 and 70 after TCI 
with 30µg TTxd (black), HCWT (white) or HCM115 (grey). The neutralising potencies 
were determined in a mouse passive protection model using a pre-determined 
concentration of TeNT (50 PD50) taking WHO International Standard for Tetanus 
Antitoxin (TE-3 at 120IU/ampule) as reference. Results are expressed in International 
Units per millilitre (IU/ml).  
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Antibody responses following transcutaneous immumisation with tetanus 
proteins 
To study the magnitude of antigen-specific antibody responses following TCI, an in-depth 
analysis of the anti-TTxd and anti-HCWT IgG response following 3 immunisations with 
30µg of HCWT, HCM115 or TTxd, was carried out. A total of 4 independent experiments 
were performed and all experiment numbers are comparable to those reported in Tables 4.1 
 
As shown in Table 4.3 and Figures 4.5 and 4.6, on day 70 (i.e. 2 weeks after the third 
dose), all proteins induced measurable antibody responses above background levels with 
the exception of HCM115 in Experiment 2 where no measurable response was detected  
any of the 5 mice (<0.01IU/ml). Furthermore, in all experiments, mice immunised with 
HCWT consistently induced higher antibody responses as determined by ELISA. However, 
the magnitude of responses for each of the proteins was dependent on the coating antigen 
used in the ELISA. For example, when TTxd was used as a coating antigen, the response 
of sera from mice immunised with HCWT was 2 to 12 fold higher than the response 
induced when mice were immunised with TTxd (Table 4.3, part a; Figure 4.6). This 
difference was not statistically significant (P>0.05). However, in all 4 experiments, when 
HCWT protein was used as a coating antigen (Table 4.3, part b; Figure 4.7), the responses 
of mice immunised with HCWT were significantly higher (100 to 340 fold; P<0.05) than 
responses induced from the sera of mice immunised with TTxd. In contrast to mice 
immunised with HCWT, the antibody response following TCI with HCM115 was highly 
variable between experiments, ranging from no response (Experiment 2) to an appreciably 
high response (Experiment 5). However, they were always lower than responses to the 
HCWT fragment, regardless of the coating antigen used for ELISA (Table 4.3, parts a and 
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b; Figure 4.6 & 4.7) and this difference was significant (P<0.05) in experiment 3 (Table 
4.3, part a; Figure 4.6c).   Interestingly, HCM115 induced a significantly higher anti-HCWT 
response (P<0.05) compared to mice immunised with TTxd in 2 of the 4 experiments 
(Table 4.3, part b; Figure 4.7). All control mice treated with PBS alone remained negative 
for anti-tetanus antibodies (i.e below detection limit of 0.01IU/ml). 
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Table 4.3. Anti-TTxd and anti-HC responses following transcutaneous immunisation 
with TTxd or HC fragments 
 
a) Geometric mean anti-TTxd IgG response (95% CI) 
 
   Immunising agent  
 
Experiment 
No 
 
No. Mice 
 
TTxd 
 
HCWT 
 
HCM115 
 
PBS 
2 
3 
4 
5 
5 
5 
5 
7 
0.3 (0.04-1.9) 
0.1 (0.01-1.3) 
0.8 (0.1-5.1) 
0.8 (0.2-2.8) 
1.7 (0.4-7.05) 
1.1 (0.3-3.8) 
2.5 (1.3-5.0) 
1.3 (0.7-2.7) 
< 0.01 
0.4 (0.03-4.7) 
0.2 (0.05-0.8) a 
1.1 (0.4-2.8) 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
 
 
 b) Geometric mean anti-HCWT IgG response (95% CI) 
 
Animals were immunised on days 0, 28 and 56 with 30 µg of TTxd, HCWT or HCM115 protein and 
anti-IgG antibody responses against a) TTxd and b) HCWT were measured by ELISA on day 70.  a 
P < 0.05, when compared to IgG response for mice immunised with HCWT.  b P < 0.05, when 
compared to IgG response for mice immunised with TTxd. Experiment numbers are comparable to 
those in Table 4.1. 
 
 
 
 
   Immunising agent  
 
Experiment 
No 
 
No. Mice 
 
TTxd  
 
HCWT 
 
HCM115 
 
PBS 
2 
3 
4 
5 
5 
5 
5 
7 
0.1 (0.01-1.9) 
0.1 (0.02-1.4) 
0.4 (0.01-10.6) 
2.1 (0.6-7.7) 
10.8 (0.9-129.4) b 
20.6 (8.6-49.2) b 
25.3 (12.0-53.8) b 
20.8 (9.5-45.9) b 
< 0.01 
4.0 (0.06-270.6) b 
0.6 (0.02-16.5) 
16.2 (9.1-28.4) b 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
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Figure 4.6. Total IgG anti-TTxd response following topical application of HCWT, 
HCM115 or TTxd onto hydrated depilatory cream treated mouse skin. Individual sera 
samples from groups of mice (n=5 to 7) were collected 14 days after the third 
immunisation. Sera were tested for anti-TTxd IgG antibodies by ELISA. Data are 
presented for individual mice (∆) in addition to the geometric mean concentration (GMC; 
(-)) expressed as IU/ml. Results from a) Experiment 2; b) Experiment 3;c) Experiment 4; 
and d) Experiment 5. Experiment numbers are comparable to those in Table 4.1 and 4.3 
 
 
 
 
 
a) Experiment 2 b) Experiment 3 
c) Experiment 4 
* 
d) Experiment 5 
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Figure 4.7. Total IgG anti-HCWT response following topical application of HCWT, 
HCM115 or TTxd onto hydrated depilatory cream treated mouse skin. Individual sera 
samples from groups of mice (n= 5 to 7) were collected 14 days after the third 
immunisation. Sera were tested for anti-TTxd IgG antibodies by ELISA. Data are 
presented for individual mice (∆) in addition to the geometric mean concentration (GMC; 
(-)) expressed as IU/ml. Results from a) Experiment 2; b) Experiment 3; c) Experiment 4; 
and d) Experiment 5. Experiment numbers are comparable to those in Table 4.1 and 4.3.
c) Experiment 4 d) Experiment 5 
* 
* 
* 
* * 
* 
a) Experiment 2 b) Experiment 3 
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Neutralising potency of tetanus antibodies following TCI 
To further study the neutralising potency of tetanus antibodies after TCI, a total of 4 
independent neutralisation experiments were performed using the same sera samples 
(collected on day 70) as in ELISA studies. Experiment numbers are comparable to those 
reported in Table 4.1. Collectively, results showed that sera from mice immunised with 
HCWT exhibited the highest neutralising potency in all 4 of the independent experiments 
(Table 4.4). The geometric mean neutralisation potency of sera from mice immunised with 
HCWT (1.6IU/ml) was significantly higher (P<0.05) compared to the mean neutralisation 
potency of sera from TTxd immunised mice (0.3IU/ml) or HCM115 immunised mice 
(0.3IU/ml). 
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Table 4.4. In vivo neutralisation activity of sera from mice immunised with TTxd and 
HC fragments 
 
Neutralisation potency was determined on pooled mouse sera samples from each group (5-7 mice 
per group) taken on day 70, 14 days after the third transcutaneous immunisation with tetanus 
proteins. The neutralising potencies were determined in a mouse passive protection model taking 
WHO International Standard for Tetanus Antitoxin (TE-3 at 120 IU/ampule) as reference. Results 
are expressed in International Units (IU)/ml of serum. N/D, not determined as antibody response 
below detection limit. *, Geometric mean calculated from Experiment 3 to 5.  
 
 
 
 
 
 
 
 
 
 
 
 Immunising agent 
 
Experiment No 
 
TTxd 
 
HCWT 
 
HCM115 
 
2 
3 
4 
5 
< 0.5 
0.1 (< 0.1 - 0.13)  
0.2 (0.2 - 0.3) 
0.9 (0.8 - 1.1) 
2.3 (2.0 - 2.5) 
0.8 (0.7 - 0.9) 
1.9 (1.6 - 2.3) 
2.9 (1.8 - 8.8) 
N/D 
0.3 (0.2 - 0.3) 
< 0.1 
0.6 (0.4 - 1.1) 
Geometric  
mean antitoxin 
potency (IU/ml)* 
 
0.3 (n=3) 
 
1.6 (n=3) 
 
0.3 (n=2) 
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Antibody subclass distribution profile and avidity 
In addition to the generation of robust protective antibody response following TCI, 
antibody subclass distribution and avidity are also important factors to consider in the 
prevention of tetanus. In this study, the subclass distribution and avidity was investigated 
following TCI with tetanus proteins. Analysis of the relative concentrations of anti-TTxd 
IgG subclasses showed that immunisation with HCWT, HCM115 or TTxd induced mainly 
the IgG1 subclass (over 94 % of total IgG) with less than 5% of the total IgG belonging to 
IgG2a, IgG2b or IgG3 subclasses. This is indicative of a TH-2 type immune response. No 
measurable serum IgA or IgM was detected in any of the immunisation groups. 
 
A chelating agent (ammonium thiocyanate; ATC) was used to measure the antibody 
avidity in an ELISA assay as previously described (Chapter 2). Preliminary experiments 
were carried out to determine if solid-phase antigens could be affected by ATC treatment. 
Various concentrations of ATC (1 to 9M) were added to HCWT or TTxd coated ELISA 
plates before the addition of a NIBSC in-house mouse reference sera (Biken DTaP, 
1.68IU/ml). Results showed that ATC had very little effect on the binding of TTxd 
(1µg/ml) to ELISA plates (Figure 4.8). As concentrations of ATC reached 9M, over 80% 
of the reference sera remained bound to TTxd coated ELISA plates. However, when 
HCWT protein was used as a coating antigen, the concentration of bound reference sera 
decreased in a dose-dependent manner as the ATC concentration increased (Figure 4.8). 
When the ATC concentration reached 8M, only 20% of the reference sera remained bound 
to ELISA plates. For future antibody avidity ELISAs, TTxd was used as the coating 
antigen as high concentrations of ATC appeared to affect the binding of HCWT protein to 
ELISA plates.  
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The antibody avidity kinetics were studied by measuring serum antibodies 28 days after 
both the primary immunisation and the first boost, and 14 days after the second boost (sera 
from Experiment 3). Over the course of the immunisation schedule, affinity maturation of 
immune sera was evident for all mice immunised with HCWT, HCM115 or TTxd (Figure 
4.9). Results showed that following primary immunisation, the avidities of anti-TTxd 
antibodies from groups of mice immunised with HCWT or TTxd were very low (avidity 
index= 1.5 and 1, respectively). Mice immunised with 30µg of HCM115 did not give a 
measurable anti-TTxd IgG as determined by ELISA (Table 4.4, part a), therefore, the 
antibody avidity was not determined. Following a second immunisation, the avidity indices 
were significantly increased in all groups (P<0.05). The avidity index for sera from mice 
immunised with TTxd (avidity index= 5) was higher than that of HCWT (avidity index= 3) 
and HCM115 (avidity index=3.4). Further increases in avidity indices were evident in 
groups immunised with HCWT, HCM115 and TTxd after a third immunisation. However, 
this increase was not significant for mice immunised with HCWT or HCM115 (P>0.05), but 
was for groups of mice immunised with TTxd (P<0.05). 
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Figure 4.8. The inhibitory effect of ammonium thiocyanate (ATC) on IgG binding to 
solid-phase antigens.   TTxd) or HCWT (1µg/ml) coated ELISA plates were incubated 
with various concentrations of ATC before the addition of anti-TTxd reference sera 
(1/100).  The antibody content in control wells (without ATC) was considered to represent 
the total concentration of anti-TTxd or HCWT antibody, and antibody content in wells with 
added ATC was expressed as a proportion of this total. Results are the mean of 5 replicates 
± SEM. (■) HCWT or (♦) TTxd coated ELISA plate. 
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Figure 4.9. Relative avidity maturation of anti-TTxd antibodies from mice immunised 
with HC protein or TTxd. Sera samples were collected on days 28, 56 and 70 following 
immunisation with 30µg a) TTxd b) HCWT or c) HCM115 and antibody avidity was tested 
using ATC displacement ELISA. Avidity was expressed as avidity index, which 
corresponds to the concentration of ATC required to induce a reduction of antibody 
binding to coating antigen (TTxd) by 50%. Results are expressed as the mean of 5 animals 
± SEM. 
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Cellular immune response following transcutaneous immunisation with 
tetanus proteins                                                                                               
In this study, the cellular immune response following TCI with HC proteins or TTxd was 
investigated on day 70, 14 days after the third immunisation. Once initial assay conditions 
were optimised, the degree of antigen-specific T-cell responses was measured by spleen 
cell proliferation upon in vitro re-stimulation with tetanus proteins, and by examining the 
cytokine profiles of culture supernatant. 
 
Optimisation of spleen proliferation assay 
To optimise spleen cell proliferation assay conditions spleen cells were collected from 
immunised animals on day 70 and incubated in vitro with the corresponding immunising 
antigen at a concentration of 10µg/ml. The kinetics of spleen cell proliferation was 
measured on days 3, 5 and 7 by incorporation of 3H-thymidine into cells. Results were 
expressed as counts per minute (cpm) relative to cells cultured in the absence of protein. 
As shown in Figure 4.9, no measurable proliferative response to recall antigens was 
detected for any groups on day 1. However, a significant increase in proliferation was 
evident for all groups of mice by day 3 (P<0.05), with the response in mice immunised 
with HCWT protein being over 2-fold higher than those of groups immunised with 
HCM115 or TTxd. By day 5, a further significant increase in the cellular response was 
observed for all groups of mice (P<0.05). Once again, the proliferative response of groups 
of mice immunised with HCWT was over 2-fold higher when compared to groups 
immunised with HCM115 or TTxd.  A significant decrease was evident on day 7 in groups 
of mice immunised with HCWT or TTxd (P<0.05) but not for mice immunised with 
HCM115 where the proliferative responses remained consistent to that of day 5. However, 
the cellular immune response to recall antigens for mice immunised with HCWT was still 
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higher than that of groups immunised with HCM115 or TTxd on days 5 and 7. These 
results were significant for responses on day 5 only (P<0.05). Overall, results demonstrated 
that the optimal end-point for the spleen proliferation assay was day 5. 
 
To optimise the concentration of recall antigens for use in spleen cell proliferation assays, 
spleens were taken from immunised animals and cells were incubated with 0.4, 5, 10 and 
50µg of the corresponding immunising antigen. Levels of 3H-thymidine incorporation were 
measured on day 5 as determined by the end-point optimisation assay. A clear dose 
response relationship (a higher response with higher antigen concentration) was observed 
for groups of mice immunised with HCM115 or TTxd (Figure 4.11).  However, the 
proliferation was relatively weak for mice immunised with HCM115 when concentrations 
of recall antigens were below 10µg.  Cells taken from mice immunised with HCWT 
showed the highest proliferative response to recall antigens at all doses except 50µg. 
Counts remained above 7000cpm when protein concentrations were between 0.4 to 10µg 
but dropped to 3000cpm when treated with a protein concentration of 50µg (P<0.05).  
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Figure 4.10. Optimisation of spleen proliferation assay time point. Mice were 
immunised with 3 x 30µg of HCWT, HCM115 or TTxd and spleens were collected on day 
70. Approximately, 4 x 106 spleen cells were incubated in vitro with 10µg/ml of the 
corresponding immunising antigen. On days 3, 5 or 7 spleen cells were pulsed with 
0.25µCi 3H-Thymidine for 8 hours prior to harvesting onto filter mats. 3H-Thymidine 
incorporation was read using a Nucrobeta reader. Results are expressed as counts per 
minute (cpm). Each data point is the mean cpm of 3 animals ± SEM. Spleen cells from a), 
TTxd b) HCWT and c) HCM115 immunised mice. 
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Figure 4.11. Optimisation of protein concentration for spleen proliferation assay time 
point. Approximately, 4 x 106 spleen cells were incubated in vitro with 0.4, 5, 10 or 
50µg/ml of the corresponding immunising antigen. On days 3, 5 or 7 spleen cells were 
pulsed with 0.25µCi 3H-Thymidine for 8 hours prior to harvesting onto filter mats. 3H-
Thymidine was read using a Nucrobeta reader. Results are expressed as counts per minute 
(cpm). Each data point is the mean cpm of 3 animals ± SEM. Spleen cells from a), TTxd; 
b) HCWT and c) HCM115 immunised mice.  
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Analysis of spleen cell proliferation and cytokine secretion following TCI with tetanus 
proteins 
To analyse the spleen cell proliferative responses following TCI with tetanus antigens 
spleens were collected on day 70, 2 weeks after the third immunisation, and antigen-
specific T-cell responses were measuring by the degree of spleen cell proliferation on 
exvivo re-stimulation with tetanus antigens, and by analysis of the cytokine profiles 
production in the culture supernatant from the same experiment.  Results showed that 
spleen cells from mice immunised trascutaneously with TTxd, HCWT or HCM115 proteins 
exhibited a strong proliferative response to all antigens, which was significantly higher 
(P<0.05) compared to control groups (Figure 4.12).  Immune spleen cells taken from mice 
immunised transcutaneously with HCWT protein exhibited the highest proliferative 
response to all antigens, with a stimulation index (SI) of  3.5, 7.4 and 5.7 in responses to 
TTxd, HCWT or HCM115, respectively. All of these responses were significantly higher   
(P<0.01 or P<0.001) when compared to the equivalent proliferative responses of spleen 
cells taken from mice immunised with TTxd. In addition, the proliferative responses in 
mice immunised with HCWT were higher in comparison to cells taken from mice 
immunised with HCM115, and this response was significantly higher (P<0.05) when re-
stimulated with HCWT.  
 
Cytokine secretion from the same ex vivo re-stimulated spleen cells collected from the 
immunised animals on day 70 was also measured. Compared to PBS controls, low but 
detectable levels of IL-5 and IL-6 were present in all supernatants of spleen cells in the 
presence of the immunising tetanus proteins (Figure 4.13). 
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Figure 4.12. Proliferation of spleen cells from mice following transcutaneous 
immunisation with HC fragments or TTxd. Spleen cells from individual mice (3 per 
group) were isolated 14 days following the third immunisation with 30µg HcWT, HcM115 
or TTxd. Cells were cultured with 10µg/ml of HC or TTxd proteins for 5 days and 
proliferation was determined by 3H-thymidine incorporation into cells. Results are 
expressed as mean stimulation index (SI) with upper SEM showing. * P <0.01 and ** 
P<0.001 when compared to mice immunised with TTxd.  # P<0.05 when compared to mice 
immunised with HCM115. 
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Figure 4.13. Cytokine secretion by immune cells from mice transcutaneously 
immunised with HC fragments or TTxd. Spleen cells from individual mice (3 per group) 
were isolated 14 days following the third immunisation with 30µg TTxd, HCWT or 
HCM115 and were cultured for 48 hours in the presence of the immunising antigens. 
Supernatants were harvested and assayed for a) IL-5 and b) IL-6 by ELISA. Results are 
expressed as mean concentration (pg/ml) with upper SEM limit showing. Detection limits 
of the assays are shown by the broken line (---). 
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Discussion  
Like other toxin-related diseases such as diphtheria, protection against tetanus is directly 
co-related to the level of neutralizing antibodies in the serum (MCCOMB, 1964). 
Protection against tetanus is entirely dependent on vaccination to induce protective 
antibodies, and periodic booster doses are required to maintain immunity. Conventional 
tetanus vaccines consist of TTxd, prepared by the treatment of the toxin with 
formaldehyde, and it is recognised that the ability of such proteins to induce specific toxin 
neutralising responses could be improved (Robbins et al., 2005b). Potential safety concerns  
and the need for extensive testing to monitor freedom from toxicity with retention of 
adequate immunogenicity has prompted investigations into replacing TTxd with more 
defined recombinant non-toxic molecules (Robbins et al., 2005). Highly purified vaccine 
antigens have provided an opportunity to explore new and more relevant delivery routes 
for immunisation, including oral (Tacket et al., 2000b) and intranasal routes (McNeela et 
al., 2004a). TCI is a promising method for vaccine delivery which has been successful in 
animal models (Glenn et al., 1998; Beignon et al., 2001) and shown to be safe and 
effective in clinical trials with an E.coli derived vaccine antigen (Etchart et al., 2007) 
including bacterial toxins (Glenn et al.,1998; Guerena-Burgueno et al., 2002; Glenn et 
al.,2007; McKenzie et al., 2007). In the present study, the immunogenicity and antigen-
specific TeNT neutralising antibody responses of HCWT, HCM115 or TTxd in mice 
following TCI was investigated in the absence of any mucosal adjuvants.  
 
Preliminary experiments were carried out to optimise TCI skin pre-treatment conditions 
and antigen dose. The results from these studies showed that all tetanus proteins were 
poorly immunogenic when applied directly onto hydrated shaved skin. This is consistent 
with the results from previous studies where simple topical application of antigens in the 
Chapter 4: Immunogenicity of tetanus antigens following TCI in mice 
 124 
absence of adjuvant onto hydrated shaved skin did not induce effective immune responses 
(Glenn et al., 1998). The majority of TCI studies reported to date have relied on powerful 
mucosal adjuvants for induction of effective and protective immune response against 
traditional and emerging infectious diseases and for cancer immunotheraphy (Beignon et 
al., 2001; Glenn et al., 1998; Glenn et al., 1999; Ghose, et al., 2007; Pitcovski et al., 
2006). In the present study, measurable serum antibody responses were generated only 
when shaved skin was also treated with the depilatory cream prior to antigen application. 
The application of the depilatory cream appeared to remove the residual hair that was left 
behind after shaving. There was no sign of any adverse reactions such as inflammation or 
irritation following application of the cream. It is possible that removal of residual hair by 
the application of depilatory cream allows the topically applied antigens to gain better 
access to the underlying skin layers. On the other hand, it is possible that some of the 
depilatory cream remains in the epidermis and acts as an adjuvant by stimulating the 
underlying immune cells. Results from theses initial studies  also demonstrated that the 
optimal does for TCI was considerably lower for HC proteins compared to that for TTxd. 
Data showed that in groups of mice immunised with HCWT or HCM115, no significant 
difference (P > 0.05) in antibody response was observed between TCI with 30µg/ml or 
80µg/ml. In contrast, the optimum dose for TCI with TTxd was ≥80µg/ml, as when the 
concentration of TTxd was increased from 30µg/ml to 80µg/ml, a significant increase 
(P<0.05) in antigen specific IgG antibodies was evident in serum samples.    
 
Results from the kinetic studies showed a continuing increase in total and functional 
antibodies induced by HCWT, from below the level of detection after primary 
immunisation to 0.5 IU/ml and 1.9 IU/ml after a second and third dose, respectively. This 
was opposed to the kinetics induced following immunisation with TTxd where no further 
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increase in antibody or functional antibodies was evident after the second immunisation. 
Furthermore, measurable protective antibody responses were evident in groups immunised 
with HCM115 following the third dose only. When the humoral response was further 
analysed on day 70, results from 4 independent experiments showed that TCI with HCWT 
was consistently more potent than TTxd in inducing antigen-specific TeNT neutralising 
antibodies. Overall, results showed that mice immunised transcutaneously with HCWT 
protein induced antibodies that had > 6-fold higher TeNT neutralisation activity than those 
immunised with TTxd. Characterisation of the antibody response showed that the majority 
of IgG antibodies formed following booster vaccinations with tetanus proteins were 
predominately IgG1 subclass. This is in line with the fact that immunization with proteins 
antigens, such as tetanus proteins, induces a T-cell-dependent immune response which 
consists mainly of IgG1 (Seppala et al., 1984). After repeat vaccination with HCWT, 
HCM115 and TTxd the affinity of antibodies also increased. Affinity maturation is a 
consequence of mutation of the immunoglobulin genes followed by selection of B-cell 
clones. Such a production of memory B-cells, which occur primarily in T-cell dependent 
antibody responses, confer a long lasting ability to respond to subsequent encounters with 
the same antigen (Kroon et al., 1999). 
 
The result presented in this study are in contrast to previous immunisation studies using the 
subcutaneous route, where the recombinant HCWT protein was at least 100-times less 
potent/dose compared to TTxd (Qazi et al., 2006). A possible reason for this is that that 
there is a more efficient uptake of the HC protein through the skin due to its small size 
compared to TTxd. In addition, due to formaldehyde treatment, TTxd is heavily cross-
linked which not only increases its size, but also could increase its stability in the 
circulation. The stability of TTxd could be important for its ability to induce antibodies 
Chapter 4: Immunogenicity of tetanus antigens following TCI in mice 
 126 
after subcutaneous immunisation but could be less important for TCI, where antigen may 
be taken up directly by local immune cells. Toxoiding of proteins with formaldehyde is 
known to alter the immunogenicity of proteins in a variety of ways. Treatment with low 
concentrations of formaldehyde has been shown to increase stability and immunogenicity 
of some recombinant toxin antigens (McNeela et al., 2004b;Nencioni et al., 1991a) when 
delivered subcutaneously or orally, but excessive treatment can also result in a drastic 
reduction of protective antibodies upon immunisation (Nencioni et al., 1991b;Robbins et 
al., 2005c).   
 
As mentioned, the data presented in this study showed that high and sustained levels of 
protective antibody responses could be generated following TCI with HCWT in the absence 
of adjuvant. Furthermore, only 4 to 5 fold higher antigen doses were required to induce 
comparable protective tetanus antibody response with HCWT protein delivered by TCI 
compared to the dose used for the subcutaneous delivery route as shown by Qazi et al., 
(2006) using identical proteins. Only one previous study reported the delivery of HCWT 
protein (also termed TetC) by TCI, which in the absence of CT adjuvant, failed to induce 
appreciable protection (Glenn et al., 1999). This study also showed that in the absence of 
adjuvant, low anti-tetanus antibody responses were observed after 4 doses of 100µg 
HCWT, with only 2 out of 5 mice showing protection upon challenge with TeNT. Whereas 
it is difficult to directly compare the results from the present study with that of previous 
work, a high neutralising antibody response, approximately 200-times above the minimum 
protection level (0.01IU/ml), was obtained after 3 doses of 30µg of HCWT. Furthermore, 
neutralizing anti-TeNT potency in this study with HCWT was comparable or superior to 
those induced with TTxd by TCI in the presence of LTR72 or LTK63, respectively 
(Tierney et al., 2003). Interestingly, the results presented in this study are in agreement to 
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another TCI study using diphtheria antigens. These results demonstrated that the native 
CRM197 of diptheria toxin was sufficiently stable and immunogenic for TCI delivery as it 
was able to significantly boost pre-existing immunity to diphtheria, and neutralising 
antibody levels were comparable between groups boosted subcutaneously with diphtheria 
vaccine or via TCI using native CRM197 in the absence of adjuvant (Stickings et al., 2008). 
Furthermore, a recent study using TTxd has also confirmed that effective TCI in the 
absence of adjuvant is also possible. By prolonging the period of time that TTxd was in 
contact with the skin by up to 16 hours generated protective levels of anti-TeNT antibodies 
(Naito et al., 2007b).  Nevertheless, co-administration of CT did, however, significantly 
increase protective antibody responses.  
 
Results presented in this study, showed that the HCM115 mutant was consistently a poorer 
and more variable immunogen by the TCI route than the HCWT protein despite differing in 
only two amino acid residues. This is in agreement with previous subcutaneous studies, 
where HCM115 was up to 100-fold less immunogenic than HCWT (Qazi et al., 2006). 
However, the reason for the lower immunogenicity of HCM115 is unknown.  HCM115 
contains two point mutations that disrupt binding of the protein to the sialic acid and Gal4-
GalNAc3 moieties of the ganglioside receptor The most obvious explanation would be that 
introducing point mutations into the Gal4-GalNAc3 and/or sialic acid binding sites of 
HCM115 protein destroys epitopes that are essential for generating proper protective 
immune response. In addition, it is also possible that because of the introduced mutations 
the HCM115 protein is not as stable as HCWT protein and may therefore be susceptible to 
faster degradation. Previous studies using circular dichroism (CD) analysis showed no 
significant difference in the spectra when HCWT was compared to HCM115 suggesting that 
the mutations introduced caused no gross effect on the secondary structure of HCM115 
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protein (Qazi et al., 2006). It has been postulated that the amino acids at the site of the 
point mutations could be essential for generation of protective epitopes (Qazi et al., 2006). 
It is also possible that loss of ganglioside binding could directly affect immunogenicity by 
altering interactions with immune cells. In this regard, the potent adjuvant CT also has 
ganglioside binding activity (to GM1 as opposed to GT1b or GD1b) and its adjuvant 
activity in TCI has been shown to depend on the ganglioside binding domains, although 
the binding activity per se was not shown to be essential (Godefroy et al., 2005b). 
 
In agreement with previous studies, this study has confirmed that in addition to induction 
of functional and protective antibody response, TCI can also elicit an antigen-specific 
cellular response. Data obtained from a memory recall assay confirmed the strongest 
proliferative response of spleen cells from animals immunised with HCWT protein 
confirming that the cellular immune response induced by HCWT was significantly higher 
than that induced by TTxd (P<0.05). Although a direct comparison between groups could 
not be carried out, cytokine data shows that cells from immunised animals secreted IL-5 
and IL-6 upon restimulation with the immunising antigen which is indicative of a TH-2 
type response and are in agreement with the functional and protective anti-TeNT antibody 
data.  
 
Collectively, the results presented in this thesis have, thus far, provide new information 
regarding use of purified, recombinant sub-unit toxins for effective delivery by TCI and 
may provide a basis for improved vaccines against many infectious diseases that currently 
rely on formaldehyde inactivation of toxins.  
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Introduction 
To understand the molecular mechanisms involved in the induction of an immune 
response following TCI  using tetanus proteins as model antigens, and to explore possible 
reasons for the difference in the magnitude  and the neutralising potency of the antibody 
response induced by HcWT and TTxd, (as shown in Chapter 4), the interaction and 
translocation of tetanus proteins with skin cells in vitro and in vivo was investigated. For 
the in vitro studies, a keratinocyte cell line, HaCaT, and primary cultures of murine bone 
marrow-derived dendritic cells were used. Cells were cultured in the presence of TTxd 
and HC proteins and cell activation was assessed by measuring: (i) cytokine secretion (IL-
1 and TNF-α) and (ii) the levels of expression of some activation markers (ICAM-1, B7 
and MHC-II molecules. For the in vivo studies, the interaction of HC proteins and TTxd 
with skin was indirectly assessed by measuring the levels of IL-1 and TNF-α mRNAs in 
samples taken from the site of topical application using real time RT-PCR. Furthermore, 
the translocation and localisation of HC protein and TTxd following TCI was also 
investigated using immunohistochemistry. 
 
Culture optimisation and characterisation of bone marrow cells 
Bone marrow derived DCs were prepared from murine bone marrow cells as described in 
Chapter 2. Following 3 to 4 days culture in the presence of GM-CSF and IL-4, large 
clusters of adherent cells began to appear on the bottom of culture dishes. By day 5 to 7 
these clustering adherent cells began to dislodge and an increased abundance of semi-
adherent, as well as non-adherent, cells was apparent in the culture medium.  Non-
adherent, or loosely attached, cells were harvested on day 7 by gentle resuspension via 
pipetting. Cell counts, viability and the proportion of cells expressing DC-like markers 
(CD11c and MHC-II) were determined. Results from 3 independent experiments showed 
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that on day 7 of culture, approximately 2 x 107 bone marrow cells were obtainable with a 
viability of 70% per mouse (data not shown).  Phenotype analysis of these cells showed 
that approximately 20% were CD11c+ and 65% were MHC-II+ (Figure 5.1). Enrichment 
for DC by density gradient separation showed that although cell recovery was low, with 
approximately 3 x 106 bone marrow cells per mouse being harvested from the interphase 
between HBSS and the 11.5% OptiPrep density gradient, cell viability increased from 70 
to 95% (data not shown). Furthermore, the proportion of cells expressing DC like markers 
increased significantly from 20 to 50% following density gradient separation (Figure 5.1). 
Similarly, 80% of cells expressed MHC-II molecules compared to only 65% before 
enrichment (Figure 5.1). 
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Figure 5.1. Isolation and characterisation of bone marrow cells. Bone marrow cells 
were collected from female Balb/c mice and cultured in the presence of GM-CSF 
(20ng/ml) and IL-4 (20ng/ml).  Non-adherent cells were harvested on day 7 and stained 
with monoclonal antibodies specific to CD11c or MHC-II molecules and analysed by 
immunofluorescent staining and flow cytometry before (white) or after (grey) density 
gradient separation. Data are expressed as the mean ± SEM of 3 independent experiments. 
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To further optimise bone marrow DC isolation, an experiment was carried out to assess 
cell recovery, viability and phenotype at different time points in culture. As shown in 
Figure 5.2, cell recovery between day 5 and 7 was between 6 to 7 x 106 cells/mouse and 
by day 9 the number of cells recovered dropped to 2 x 106 cells/mouse and continued to 
decrease on day 11 (0.5 x 106 cells/mouse). However, despite a reduction in cell recovery 
with time, a high cell viability (>90%) was maintained during the culture period with the 
exception of day 11 when viability level dropped to 85% (Figure 5.2). Phenotype analysis 
of these cells over time showed that following 5 days in culture, approximately 40% of 
cells were CD11c+ and that this proportion of CD11c+ cells was optimal on day 7 with 
approximately 50% of cells expressing the marker (Figure 5.3a).  Between days 9 to 11, 
the proportion of CD11c+ cells in culture decreased in comparison to day 7, with levels 
returning to that observed on day 5. A similar trend was observed for the expression of 
MHC-II molecules (Figure 5.3b). On day 5, 80% of cells were positive for MHC-II 
expression and this increased to over 90% by day 7. A reduction in the proportion of 
MHC-II+ cells was observed between day 9 and 11 when no more than 65% of cells were 
positive for surface expression. 
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Figure 5.2. Recovery and viability of bone marrow cells following enrichment by 
density gradient separation. Bone marrow cells were cultured in the presence of GM-
CSF (20ng/ml) and IL-4 (20ng/ml) over a period of 11 days. The total cell recovery and 
viability following enrichment for DCs by density gradient separation were determined at 
the indicated time points by trypan blue exclusion assay. Data is expressed as the number 
of cells obtained/mouse and the proportion (%) of viable cells. 
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 Figure 5.3. Kinetics of dendritic cell production. Bone marrow cells were cultured in 
the presence of GM-CSF (20ng/ml) and IL-4 (20ng/ml) over a period of 11 days. At the 
indicated time points the proportion of a) CD11c+ and b) MHC-II+ cells were assessed by 
immunofluorescent staining and flow cytometry following density gradient separation. 
Data is expressed as the proportion (%) of positive cells in the total cell population. 
a) 
b) 
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These data indicate that the proportion of viable, CD11c+ and MHC-II+ cells is highest 
following 7 days of culture with GM-CSF and IL-4. Therefore, to study the effects of 
tetanus proteins on DC activation, murine bone marrow cells were cultured in the 
presence of GM-CSF and IL-4 as described above in all studies. 
 
Effect of tetanus proteins on bone marrow derived dendritic cell 
activation 
Bone marrow derived DCs were incubated for 48 hours with  0.5, 5 or 10µg/ml of HCWT, 
HCM115 or TTxd. Immunofluorescence staining and flow cytometry analysis showed that 
between 88 to 92% of untreated bone marrow DCs expressed ICAM-1 with a MFI of 34 
to 60 (Figure 5.4a). No marked changes in the proportion of cells expressing ICAM-1 or 
in the levels of expression of ICAM-1 molecules were evident when DC cells were 
incubated with a low dose (0.5µg/ml) of any of the tetanus proteins (Figure 5.4a). In 
contrast, following incubation with 5µg/ml HCWT, HCM115 or TTxd almost all cells 
(97%) expressed ICAM-1 compared to 88% of untreated cells. A 32% increase in MFI 
was also observed in cell populations incubated with 5µg/ml of HCWT, HCM115 or TTxd 
(MFI=53, 51 & 53, respectively) when compared to untreated cells (MFI=34). Similar 
results were obtained with a higher concentration (10µg/ml) of tetanus proteins. For all 
experiments, no marked differences in the proportion of cells expressing ICAM-1 or in the 
level of ICAM-1 expression were observed between HC proteins or TTxd. 
 
Analysis of MHC-II expression in these cells showed that the majority of untreated DCs 
(94 to 98%) expressed MHC-II molecules (MFI=360 to 390) as shown in Figure 5.4b. No 
noticeable change in the proportion of cells expressing MHC-II was evident when 
incubated with any of the tetanus proteins at all tested concentrations. A small decrease in 
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MHC-II expression was evident when cells were incubated with 5µg/ml (but not at other 
concentrations) of HCWT or HCM115 (MFI= 292 and 302 respectively) when compared to 
that of untreated bone marrow derived DCs (363). 
 
Analysis of B7 molecule expression in untreated cells showed that between 60 to 89% of 
untreated DC-like cells expressed B7 molecules (MFI=23 to 54). Nevertheless, no marked 
changes in the proportion of cells expressing or on the level of expression of B7.1 (Figure 
5.5a) or B7.2 (Figure 5.5b) was evident in the presence of HC proteins or TTxd at all 
concentrations compared to untreated cells.  In all experiments, incubation of DCs with 
LPS increased the proportion of cells and the level of expression of CD54, MHC-II or B7 
molecules compared to that of untreated cells. 
 
In addition to activation marker expression, IL-1β and TNF-α secretion were measured 
following 48 hour incubation with 0.5, 5 or 10µg/ml HC proteins or TTxd. No measurable 
levels of IL-1β or TNF-α could be detected by ELISA at any of the concentrations used 
(data not shown). 
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Figure 5.4. Surface expression of ICAM-1 and MHC-II molecules on bone marrow 
derived dendritic cells following incubation with tetanus proteins. Bone marrow 
derived cells (106 cells/ml) were cultured with 0.5, 5 or 10µg/ml of HCWT, HCM115 or 
TTxd. Control cultures were treated with culture medium alone or LPS (0.5ng/ml). 
Surface expression of a) ICAM-1 or b) MHC-II was analysed by immunofluorescent 
staining and flow cytometry and data was analysed using WinMDI software. Red filled 
histograms, negative control; open histograms, cells incubated with culture medium alone 
(black), LPS (green), TTxd (dark blue), HCWT (purple) and HCM115 (light blue). MFI, 
mean fluorescence intensity. 
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Figure 5.5. Surface expression of B7 molecules on bone marrow derived dendritic 
cells following incubation with tetanus proteins. DCs were cultured with 0.5, 5 or 
10µg/ml of HCWT, HCM115 or TTxd. Control cells were treated with LPS (0.5ng/ml) or 
with culture medium alone. Surface expression of a) B7.1 or b) B7.2 was analysed by 
Immunofluorescent staining and flow cytometry and data was analysed using WinMDI 
software. Red filled histograms, negative control; open histograms, cells incubated with 
culture medium alone (black), LPS (green), TTxd (dark blue), HCWT (purple) or HCM115 
(light blue). MFI, mean fluorescence intensity. 
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Effect of tetanus proteins on keratinocyte activation 
The immortalised keratinocyte cell line, HaCaT cells were incubated for 24 or 48 hours 
with 10µg/ml of HCWT, HCM115 or TTxd. As shown in Figure 5.6a, a small proportion 
of untreated HaCaT cells (28%) expressed low levels of ICAM-1 molecules (MFI=10) 
following 24 hour in culture medium. However, following 24-hour culture no marked 
change in the proportion of cells expressing ICAM-1, or in the level of ICAM-1 
expression was evident with any of the proteins. Similarly, a very small proportion of 
untreated HaCaT cells (5%) expressed MHC-II molecules (MFI=13) and incubation with 
tetanus proteins did not increase expression or proportion of cells expressing MHC-II 
(Figure 5.6b).  
 
Extending the culture period in the presence of tetanus proteins to 48 hours did not cause 
any change in the proportion of cells expressing or level of ICAM-1 molecule  (Figure 
5.7a) or MHC-II (Figure 5.7b) expression above that of the culture medium control. 
Furthermore, the same cell populations were capable of upregulating the expression of 
ICAM-1 and MHC-II molecules in the presence of IFN-γ. 
 
In addition to measuring the surface expression of activation markers ICAM-1 and MHC-
II on HaCaT cells following 24 to 48 hour incubation with HC proteins or TTxd, cytokine 
secretion (IL-1β and TNF-α) was also determined. No measurable levels of IL-1β or TNF-
α could be detected following 24 or 48 hours incubation with 10µg/ml of HCWT, HCM115 
or TTxd when measured by ELISA (data not shown). 
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Figure 5.6. Surface expression of ICAM-1 and MHC-II molecules on HaCaT cells 
following 24-hour incubation with HC proteins or TTxd. HaCaT cells were cultured in 
the presence of 10µg/ml of HCWT, HCM115 or TTxd for 24 hours. Control cells were 
cultured with IFN-γ (10ng/ml) or culture medium alone. Surface expression of a) ICAM-1 
or b) MHC-II was analysed by immunofluorescent staining and flow cytometry and data 
was analysed using WinMDI software. Red histograms, negative control; open 
histograms, ICAM-1 or MHC-II staining following incubation with culture medium alone 
(purple), IFN-γ (light blue), TTxd (black), HCWT (green) or HCM115 (dark blue). MFI, 
mean fluorescence intensity 
 
 
 
 
 
 
 
 
 (%) 
Positive 
MFI 
Untreated 28 10 
IFN-gamma 99 60 
TTxd 19 9 
HCWT 25 10 
HCM115 30 10 
 (%) 
Positive 
MFI 
Untreated 5 13 
IFN-gamma 99 336 
TTxd 2 12 
HCWT 2 13 
HCM115 3 13 
 ICAM-1                  
 MHC-II 
b) 
a) 
Fluorescence intensity 
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Figure 5.7. Surface expression of ICAM-1 and MHC-II molecules on HaCaT cells 
following 48-hour incubation with HC proteins or TTxd. HaCaT cells were cultured in 
the presence of 10µg/ml of HCWT, HCM115 or TTxd for 48 hours. Control cells were 
treated with culture medium alone or IFN-γ (10ng/ml). Surface expression of a) ICAM-1 
or b) MHC-II was analysed by immunofluorescent staining and flow cytometry and data 
was analysed using WinMDI software. Red histograms, control staining; open histograms, 
ICAM-1 or MHC-II staining following incubation with culture medium alone (purple), 
IFN-γ (light blue), TTxd (black), HCWT (green) or HCM115 (dark blue). MFI, mean 
fluorescence intensity. 
 
 
 
 
 
 (%) 
Positive 
MFI 
Untreated 9 9 
IFN-gamma 99 80 
TTxd 10 10 
HCWT 10 10 
HCM115 10 10 
 (%) 
Positive 
MFI 
Untreated 2 11 
IFN-gamma 66 223 
TTxd 4 10 
HCWT 5 12 
HCM115 4 4 
 ICAM-1                  
 MHC-II 
Fluorescence intensity 
b) 
a) 
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Expression of TNF-α and IL-1 mRNA in skin tissue  
Induction of immune responses following TCI requires adequate penetration of topically 
applied antigens into the epidermis for presentation by LCs (Ghose et al., 2007), and the 
secretion of pro-inflammatory cytokines such as IL-1 and TNF-α to promote LC 
migration from skin to regional lymph nodes (Partidos et al., 2003; Belyakov et al., 2004; 
Rechtsteiner et al., 2005). In the present study, data from in vitro interaction experiments 
provided evidence of DC, but not HaCaT cell, activation by tetanus proteins as shown by 
the up regulation of ICAM-1 molecules. However, no sign of IL-1 or TNF-α secretion by 
DC or HaCaT cells was evident. It was therefore decided to investigate the effect of 
tetanus proteins the local on IL-1 and TNF-α production in vivo using a more sensitive 
approach of real-time RT-PCR. Skin samples from the immunisation site were removed 
from groups of mice at various time points following topical application of 30µg HCWT, 
HCM115 or TTxd and real-time RT-PCR was used to quantify the level of IL-1 and TNF-
α mRNA expression.  Results were calculated relative to cytokine gene expression in 
normal unshaved mouse skin. As shown in Figure 5.8, the expression of IL-1α, IL-1β and 
TNF-α mRNA in normal unshaved mouse skin was consistently low as expected (Ct 
values of 34, 35 and 35, respectively), when compared to that for the  positive control, 
LPS stimulated macrophage cell line  RAW264.7 cells (Ct values of 25, 22 and 20, 
respectively). 
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Figure 5.8. Expression of IL-1 and TNF-α in normal, untreated mouse skin samples. 
Real-time RT-PCR was used to measure the expression of a) IL-1α, b) IL-1β and c) TNF-
α  mRNA in normal unshaved mice. All cytokine levels were normalised to β-actin 
mRNA expression using the comparative Ct method. RAW267.4 cDNA was used as a 
positive control. 
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In vivo expression of TNF-α and IL-1 following TCI with tetanus proteins 
Real-time RT-PCR results showed evidence of low levels of TNF-α gene expression in 
the skin of normal mice. However, a substantial increase in TNF-α gene expression was 
evident at all time points following topical application of 30µg tetanus proteins or PBS 
(Figure 5.9 and 5.10). When compared to that of normal mice, a 2 to 3-fold increase in 
TNF-α gene expression was evident 10 minutes post- application with HCWT or TTxd. 
However, when HCM115 was applied the increase in TNF-α gene expression (0.5-fold 
increase) was significantly lower compared to that of TTxd (P<0.05) and considerably 
lower when compared to that of HCWT or PBS. Further increases (4 to 8-fold) in relative 
TNF-α gene expression was evident 30 minutes post-application in all groups treated with 
tetanus proteins or PBS. Nevertheless, a steady decrease in relative TNF-α gene 
expression was evident in all groups starting at 2 hours post-application with levels 
returning roughly to that of initial recordings by 4 hours. As shown in Figure 5.10, no 
significant differences between skin samples treated with the different tetanus proteins 
was evident for TNF-α gene expression between 2 to 4 hours, with the exception of 
HCWT and HCM115 at 2 hours where a significantly higher TNF-α expression was 
evident in HCM115 treated groups (P<0.05; Figure 5.10c). However, induction of TNF-α 
gene expression was not dependent on application of tetanus proteins as expression levels 
found in the PBS control were similar or even higher than that of levels in skin samples 
following application of tetanus proteins.  
 
When IL-1 expression was measured in skin samples, no significant change in expression 
of IL-1α (Figure 5.11a; Table 5.1) or IL-1β (Figure 5.11b;Table 5.1) compared to that of 
normal mouse skin was evident at any time point post-immunisation with any of the 
tetanus proteins. 
a) 
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b) 
 
Figure 5.9. TNF-α mRNA expression over time in skin samples following topical 
application of tetanus proteins onto shaved or Nair treated skin. Real-time RT-PCR 
was used to measure TNF-α expression following hair removal by shaving with Nair and 
application of 30µg HC protein or TTxd. TNF-α expression was normalised to β-actin 
expression using the comparative Ct method. a) Expression is shown relative to untreated 
cells (broken line). Data are expressed as mean ± SEM of three individual mice. b) Table 
showing data for each individual mouse 
 
Time 
Group 10 min 30 min 2h 4h 
TTxd 
    
Mouse 1 3.0 5.7 2.7 1.2 
Mouse 2 3.6 1.8 3.8 1.3 
Mouse 3 3.1 7.2 3.0 2.2 
HCWT     
Mouse 1 2.1 1.8 1.7 0.9 
Mouse 2 1.4 6.1 1.8 1.0 
Mouse 3 4.1 4.8 3.0 2.6 
HCM115     
Mouse 1 2.8 4.2 3.5 2.4 
Mouse 2 0.6 3.6 3.6 1.5 
Mouse 3 0.7 8.5 3.4 1.6 
PBS 
    
Mouse 1 1.9 5.3 3.8 2.0 
Mouse 2 2.2 9.7 4.9 2.2 
Mouse 3 6.3 13.8 3.5 2.6 
TTxd (□) PBS (○) 
 
HCWT (◊)  HCM115 (∆) 
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Figure 5.10. TNF-α mRNA expression in skin samples following topical application 
of tetanus proteins onto shaved or Nair treated skin. Real-time RT-PCR was used to 
measure TNF-α expression following hair removal by shaving with Nair and application 
of 30 µg HC protein or TTxd. TNF-α expression was normalised to β-actin expression 
using the comparative Ct method. Expression is shown relative to untreated cells  Data are 
expressed as mean of three mice ± SEM following a) 10 minutes; b) 30 minutes; c) 2 
hours; or d) 4 hours post-application. 
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Figure 5.11. Time course of IL-1 mRNA expression in skin samples following topical 
application of tetanus proteins onto shaved or Nair treated skin. Real-time RT-PCR 
was used to measure IL-1α expression following hair removal by shaving with Nair cream 
and application of 30µg HC protein or TTxd. IL-1α expression was normalised to β-actin 
expression using the comparative Ct method. Expression is shown relative to untreated 
cells (broken line). Data are expressed as the mean of three mice ± SEM. TTxd (□); 
HCWT (◊); HCM115 (∆); PBS (○). 
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Table 5.1. Time course of IL-1beta mRNA expression in murine skin samples 
following application of tetanus proteins on shaved and Nair treated skin 
 
a) IL-1 alpha 
 
 
 
 
 
 
 
 
 
 
 
b) IL-1 beta 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time 
Group 10 min 30 min 2h 4h 
TTxd 
    
Mouse 1 0.5 0.2 0.3 0.2 
Mouse 2 0.8 0.3 0.3 0.5 
Mouse 3 0.5 0.4 0.4 0.4 
HCWT     
Mouse 1 0.2 0.2 0.2 0.4 
Mouse 2 0.2 0.4 0.2 2.8 
Mouse 3 0.1 0.3 0.3 0.03 
HCM115     
Mouse 1 0.4 0.6 0.2 0.3 
Mouse 2 0.7 0.2 0.3 0.2 
Mouse 3 0.7 0.3 0.2 0.4 
PBS 
    
Mouse 1 0.1 0.2 0.2 0.9 
Mouse 2 0.2 0.2 0.3 0.4 
Mouse 3 0.4 0.3 0.4 0.1 
 
Time 
Group 10 min 30 min 2h 4h 
TTxd 
    
Mouse 1 0.9 1.1 0.4 0.3 
Mouse 2 0.6 0.5 0.4 0.8 
Mouse 3 0.9 0.7 0.4 0.9 
HCWT     
Mouse 1 0.7 0.8 0.3 0.9 
Mouse 2 0.6 0.9 0.1 0.7 
Mouse 3 1.2 1.1 0.2 0.8 
HCM115     
Mouse 1 1.6 0.3 0.5 0.6 
Mouse 2 0.5 0.4 0.5 0.3 
Mouse 3 0.6 1.9 0.6 0.3 
PBS 
    
Mouse 1 0.6 1.2 0.07 0.6 
Mouse 2 0.5 0.5 0.2 0.7 
Mouse 3 1.5 0.6 0.6 0.6 
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Effect of skin pre-treatment on the local activation of IL-1 and TNF-alpha  
The increased TNF-α gene expression following application of tetanus proteins or PBS 
onto shaved and depilatory cream treated skin suggests that some physical activity during 
the TCI process may be responsible for this effect. We therefore investigated whether skin 
pre-treatment (shaving alone or shaving following application of depilatory cream) had an 
effect on the local induction of cytokine gene expression. As shown in Figure 5.12, TNF-α 
gene expression was increased by both treatments. At 10 minutes post-treatment, a 2-fold 
increase in the relative TNF-α gene expression was evident in both groups (Figure 5.12). 
A further increase in the relative TNF-α gene expression was evident 30 minutes post-
treatment in both groups. Following shaving and treatment with depilatory cream, a 4-fold 
increase in the relative TNF-α gene expression was evident whereas shaving alone caused 
an 8-fold increase in TNF-α gene expression. However, variability between animals in the 
shaved group was high, therefore differences were not significant compared to the group 
that were shaved and treated with depilatory cream (P>0.05). A gradual decline in TNF-α 
was evident following 2 to 4 hours post-treatment, with relative gene expression levels in 
both groups decreasing to levels similar to that of initial readings at 10 minutes (Figure 
5.12). 
 
The level of IL-1 gene expression was also investigated in the same skin samples. No 
noticeable change in the relative expression of IL-1α (Figure 5.13a; Table 5.2) or IL-1β 
(Figure 5.13b; Table 5.2) was evident when compared to that of normal mouse skin. A 
slight increase in IL-1β was evident 2 hours post-treatment in shaved mice. However, 
variation between animals in this group was high, and differences were therefore not 
significant (P>0.05). 
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b) 
 Time 
Treatment   
Shaved 10 min 30 min 2 h 4 h 
Mouse 1 1.7 5.1 4.0 2.2 
Mouse 2 2.2 12.0 4.8 2.8 
Mouse 3 5.2 9.1 3.4 2.1 
Shaved and cream 
    
Mouse 1 2.3 3.3 2.5 1.2 
Mouse 2 3.8 7.6 3.2 1.4 
Mouse 3 1.6 4.1 1.9 1.5 
 
 
Figure 5.12. Expression of TNF-α mRNA in pre-treated skin samples over time.  
Real-time RT-PCR was used to measure TNF-α expression following hair removal by 
shaving (black) or shaving together with Nair cream (red). TNF-α expression was 
normalised to β-actin expression using the comparative Ct method. a) Expression is 
shown relative to untreated cells (broken line). Data are shown as mean ± SEM from three 
individual mice. b) Table showing data for each individual mouse 
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Figure 5.13.  Expression of IL-1 mRNA in pre-treated skin samples over time. Real-
time RT-PCR was used to measure a) IL-1β and b) IL-1α expression following hair 
removal by shaving (black) or shaving followed with Nair cream (red). IL-1 expression 
was normalised to β-actin expression using the comparative Ct method. Expression is 
shown relative to untreated cells (broken line). Data are shown as mean ± SEM of three 
different animals. 
b) 
a)  Shaved 
Shaved with cream 
 Shaved 
Shaved with cream 
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Table 5.2. IL-1 mRNA expression in pre-treated skin samples 
a) IL-1 alpha 
 
 
 
 
    
 
 
 Time 
Treatment   
Shaved 10 min 30 min 2 h 4 h 
Mouse 1 0.5 0.1 0.5 0.5 
Mouse 2 0.6 1.7 0.9 0.9 
Mouse 3 0.3 0.7 0.1 0.1 
Shaved and cream 
    
Mouse 1 0.6 1.1 0.07 0.6 
Mouse 2 0.5 0.4 0.2 0.7 
Mouse 3 1.4 0.5 0.6 0.6 
 
 
b) IL-1 beta 
 
 Time 
Treatment   
Shaved 10 min 30 min 2 h 4 h 
Mouse 1 0.3 0.5 0.2 0.4 
Mouse 2 0.1 0.4 0.2 0.5 
Mouse 3 0.2 0.5 0.0 0.6 
Shaved and cream 
    
Mouse 1 0.4 0.2 0.4 0.1 
Mouse 2 0.3 0.1 0.5 0.1 
Mouse 3 0.3 0.2 0.5 0.2 
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Translocation of tetanus proteins through murine skin  
Successful induction of a systemic immune response following TCI requires antigens to 
overcome the skin physical barrier and translocate into the epidermal layers in order to be 
presented by the skin antigen presenting cells (LCs). Skin pre-treatment, the nature of 
antigen and their size are considered major parameters that determine the rate and speed 
of uptake through the skin layers.  To study the kinetics of translocation of tetanus 
proteins through the skin layers and the effect of skin pre-treatment, animals were 
topically immunised with 100µg of HCWT or TTxd after skin shaving or shaving together 
with the use of depilatory cream treatment. Tetanus proteins were localised in skin 
sections by immunohistochemistry at various time points using polyclonal anti-HCWT 
IgG. 
 
Immunohistochemistry staining of mouse skin sections taken at time intervals up to 2 
hours post-application of HCWT onto shaved and depilatory cream treated skin showed a 
steady translocation of protein from the external layers into the dermis (Figure 5.14a). Ten 
minutes post-application, HCWT protein was present primarily in the external layers of the 
epidermis with evidence of light positive staining in the outer regions of the epidermal 
layers. By 30 minutes after treatment, the majority of HCWT protein appeared to have 
translocated into the epidermis and very little was evident externally. By 2 hours, there 
was a very noticeable amount of positive staining in the epidermis and evidence of 
staining in the dermis around the basal membrane area (Figure 5.14a). When skin samples 
were taken from mice subjected to shaving only, an additional external layer (possibly the 
stratum corneum) in skin samples was evident (Figure 5.14b). Immunohistochemistry 
staining revealed that following topical application of HCWT protein the majority of 
positive staining was evident in this external layer rather than in the epidermis at all time 
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points tested (Figure 5.14b). In contrast to skin samples taken from animals treated with 
depilatory cream, no significant staining above that of the negative control samples was 
evident in the epidermis or dermis for at any of the time points tested. This suggests that 
the translocation of the HCWT protein appeared to be enhanced by the application of 
depilatory cream. 
 
In this study, it was not possible to directly compare the translocation of HCWT with that 
of TTxd following topical application onto mouse skin. In contrast to HCWT protein 
translocation, staining of skin sections taken from animals immunised with TTxd showed 
weak staining at all time points which, in some cases, were similar to that of the negative 
control sections (Figure 5.15). This suggests that either the TTxd was not taken up as 
effectively as HCWT, or that the rabbit anti-HCWT IgG used for detection was not the 
optimal antibody for TTxd detection by immunohistochemistry.   
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Figure 5.14. Immunohistochemical localisation of HCWT  proteins following pre-treatment of mouse skin. Skin samples were collected 
10, 30 minutes and 2 hours post-application of 100µg HCWT onto mouse skin that has been a) shaved and treated with depilatory cream or b) 
shaved only. Anti-rabbit HC antibody was used to detect HCWT protein and skin sections were counterstained with haematoxylin. Animals 
treated with PBS alone are used as negative controls. All pictures are taken at x 400 magnification. D, dermis; E, epidermis. Arrows indicate 
dermal staining.
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Figure 5.15. Immunohistochemical localisation of TTxd following topical application 
onto mouse skin. Skin samples were collected 10 minutes 30 minutes or 2 hours post-
application of 100µg TTxd onto mouse skin that had been shaved and treated with 
depilatory cream. Anti-rabbit HC antibody was used to detect TTxd and skin sections were 
counterstained with haematoxylin. Animals treated with PBS alone were used as a control. 
All pictures are taken at x 400 magnification. D, dermis; E, epidermis.  
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E 
D 
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Discussion 
One of the key events responsible for successful TCI is the translocation of antigens across 
the stratum corneum and into the immunologically active underlying layers of the skin. 
Keratinocytes and LCs are two important immunologically active cells, which are located 
within the epidermis. Previous studies have demonstrated that LCs are involved in the 
uptake, processing and transportation of topically applied substances to the T-lymphocyte 
regions of the local draining lymph nodes (Banchereau and Steinman, 1998) . In addition, 
it is well documented that keratinocytes can secrete a surplus of cytokines, some of which 
have immunomodulatory effects on other cells of the cutaneous immune system (Grone, 
2002;Kono et al., 1994;Uchi et al., 2000). In this thesis, a number of in vitro and in vivo 
studies have been performed to investigate the interactions of tetanus proteins with skin 
cells using the human keratinocyte cell line HaCaT and mouse bone marrow derived DCs.  
Methods for isolation and enrichment for skin DCs (the LCs) directly from epidermal cell 
suspensions have been previously documented (Pena-Cruz et al., 2001;Richters et al., 
1994). However, these techniques are often cumbersome, result in cell suspensions that 
yield a low percentage of LCs and are often contaminated with keratinocytes (Mazanec et 
al., 1992).  In the present study, a large number of DCs were required and therefore the 
direct isolation of LCs from epidermal sheets was not deemed practical. A number of in 
vitro methods using different combinations of cytokines have been used for the expansion 
of DCs from progenitor cells obtained from blood, cord blood or bone marrow (Bender et 
al., 1996; Caux et al., 1992; Inaba et al., 1992; Lenz et al., 1993; Romani et al., 1994); 
Sallusto and Lanzavecchia, 1994). Previous studies showed that culturing murine bone 
marrow cells in the presence of GM-CSF stimulates the growth of DCs from precursor 
cells and that the addition of IL-4 significantly enhances DC differentiation (Inaba et al., 
1992). Furthermore, DC generated by such  methods have been extensively  used by others 
Chapter 5: Interaction of tetanus proteins with skin cells 
 159 
to characterise the molecular mechanisms of LC function (Mahnke et al., 2000;Olasz et al., 
2002; Pierre et al., 1997). In the present study, bone marrow cells were isolated from the 
femur and tibia of mice and cultured in the presence of GM-CSF and IL-4 following 3 to 4 
days in culture, a number of round adherent clusters started to appear on the bottom of the 
culture vessel. Although these adherent cells were not phenotyped in the present study, 
observations from Inaba et al., (1992) suggest that these visible clusters may be 
granulocyte contaminants from bone marrow cells as they also respond to GM-CSF in 
vitro. In addition to granulocytes, many other cells contaminants such as B-lymphocytes, 
T-lymphocytes and macrophages can also be found in bone marrow populations when 
cultured in vitro (Lutz et al., 1999).  A number of techniques using monoclonal antibodies 
with flow cytometry cell sorting, magnetic bead separation, panning or cytotoxic 
elimination with complement have been developed to enrich DCs from bone marrow cell 
cultures. However, these methods are based on the principles of negative or positive 
selection of DC subsets and may therefore interfere with subsequent DC function and 
activity. In the present study, enrichment for DCs by density gradient separation was 
effective as shown by a 60% and 23% increase in CD11c+ and MHC-II+ cells, respectively. 
In addition, density gradient separation also served as a filter to remove dead cells from the 
bone marrow cell preparations as ≥ 95% of cells were viable compared to 70% before the 
treatment (enrichment). 
 
Kinetics studies showed that the optimum day for harvesting DCs (as determined by 
CD11c / MHC-II expression) was on day 7 of culture, which is in line with previous 
studies (Inaba et al., 1992; Lutz et al., 1999).  Our results demonstrated that seeding bone 
marrow cells below 106 cells/ml decreased cell yields and increased the number of dead 
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cells in culture medium, suggesting that bone marrow precursor cells may require a certain 
degree of cell-to-cell contact for optimal growth and differentiation.  
 
The results in the present study demonstrated that tetanus proteins were capable of 
activating bone marrow derived DCs in vitro to a limited extent as shown by the up-
regulation of the level of surface expression of ICAM-1 molecules when cultured in the 
presence of HCWT, HCM115 and TTxd.  This increase in ICAM-1 molecule expression 
was unlikely to be due to the presence of endotoxin in the recombinant HC protein samples 
as the extent of up regulation of ICAM-1 expression on the DCs was the same whether the 
cells were incubated with HC protein or with TTxd, which contains an undetectable 
concentration of endotoxin. An increase in ICAM-1 expression on antigen presenting cells 
(APC) has been previously associated with APC maturation and increased ability to 
activate naïve T-lymphocytes (Dubey et al., 1995). Expression of ICAM-1 has been shown 
to play an important role during the early events of naïve T-lymphocyte priming and 
differentiation. In vitro studies have shown that binding of ICAM-1 on APC to the T-
lymphocyte receptor LFA-1 results in a series of events which leads to increased adhesion 
at the immunological synapse between the two cell types (Bachmann et al., 1997;Porter et 
al., 2002). Furthermore, the lack of ICAM-1 molecule expression on  APCs has been 
shown to lead to poor activation and proliferation of naïve T-lymphocytes (Parameswaran 
et al., 2005).  
 
In contrast to ICAM-1, no major changes in the level of expression of MHC-II molecules 
was evident on DCs following incubation with tetanus proteins, with the exception of a 
small decrease when cells were incubated in the presence of 5µg/ml of HCWT or HCM115, 
which is unlikely to be significant as it was not observed with other doses. 
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Immunofluorescence staining and flow cytometry analysis also showed that no changes to 
the surface expression of B7.1 or B7.2 molecules were evident when DCs were incubated 
with tetanus proteins.  On the other hand, when  DCs were incubated with LPS, an 
increased expression of ICAM-1, MHC-II, B7.1 and B7.2 surface molecules, most likely 
through its interaction with the PRR Toll-like receptor 4 (TLR-4; Currie et al., 2001), was 
evident. Therefore, this suggests that the DCs were capable of being activated to express 
higher level of MHC-II and B7molecules under the appropriate stimuli.  
 
In addition to up regulation in the surface expression of molecules involved in immune cell 
activation, production of cytokines by DCs is another indicator of cell activation. Previous  
studies have demonstrated a role for both IL-1β and TNF-α in activation, maturation  and  
migration of LCs from the epidermis to regional lymph nodes (Cumberbatch et al., 1997b; 
Cumberbatch et al., 1999c; Cumberbatch et al., 2000 ;Cumberbatch et al., 2003). Thus, in 
the present study in addition to surface marker expression, IL-1β and TNF-α cytokine 
secretion was used as an indicator of in vitro DC activation by tetanus proteins.  Results 
showed that no measurable IL-1β or TNF-α was present in the culture supernatant of  DCs 
following incubation with tetanus proteins despite reports of such cytokines being 
expressed constitutively by these cells (Cumberbatch and Kimber, 1992; Matsue et al., 
1992). Surprisingly, no measurable cytokine levels were detected in the positive control 
DC cultures incubated with LPS despite previous reports that this was possible (Sun et al., 
2003).  It is likely that this lack of detection is due to the insufficient sensitivity of the 
ELISA based microtitre assay used to detect these cytokines in the culture medium as the 
cut off levels are between 10 to 15pg/ml. Alternatively, it is possible that cytokines may 
have been produced, and instead of being secreted, have remained intracellular. Further 
studies, using a more sensitive technique such as intracellular staining and flow cytometry, 
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PCR based assay or Western blotting could be used to investigate the production of IL-1 
and TNF-α by DCs following culture with tetanus proteins.  
 
Collectively, the results presented in this thesis suggest that tetanus proteins are not potent 
activators of DCs under in vitro culture conditions. These results are in contrast to previous 
studies using powerful mucosal adjuvants such as CT or LT.  It has been reported, for 
example, that CT and LT can activate DCs in vitro as defined by an increase in the surface 
expression of activation markers such as CD80 and CD86 (Bagley et al., 2002). In 
addition, other studies have demonstrated the ability of CT or LT to induce the secretion of 
TH-2 type cytokines following in vitro incubation with DCs (Braun et al., 1999); Gagliardi 
et al., 2000). Although the mechanisms of adjuvant activity have yet to be fully established 
it is thought that both LT and CT cause an increase in cyclic AMP (cAMP) through 
receptor binding to gangliosides located on cell surfaces (Spangler, 1992). This in turn may 
trigger a cascade of events which leads to immune cell activation. As tetanus proteins are 
functionally similar to CT and LT in ganglioside binding properties, it is plausible that they 
may act in a similar manner by activating immune cells directly through ganglioside or 
other receptor mediated binding mechanisms. However, results from this study showed 
that tetanus proteins cannot directly activate immune cells such as DCs in vitro suggesting 
that HCWT, HCM115 and TTxd have very limited adjuvant activity in comparison to other 
bacterial toxins such as CT or LT. 
 
Keratinocytes are one of the most abundant cells of the epidermis, and along with LCs,  
play an important role during TCI (Beignon et al., 2005a). In the present study, the 
immortalised human keratinocyte cell line HaCaT was used as a model to investigate the 
interaction with tetanus proteins. The results from this study showed that none of the 
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tetanus proteins used induced any measurable changes in the level of ICAM-1 or MHC-II 
surface expression on HaCaT cells.  On the other hand, when HaCaT cells were incubated 
with IFN-γ a considerable increase in the expression of both ICAM-1 and MHC-II 
molecules was evident which is consistent with published literature (Basham et al., 1985). 
This suggests that HaCaT cells were capable of increasing the level of expression of 
ICAM-1 and MHC-II when stimulated with an appropriate stimuli and that tetanus proteins 
alone were not sufficient to activate the expression of these molecules in vitro. A previous 
study has demonstrated that keratinocytes are capable of up-regulating the expression of 
MHC and co-stimulatory molecules and to present antigens to memory but not naïve T-
lymphocytes (Dustin et al., 1988). Presentation of antigens by keratinocytes to naïve T-
lymphocytes usually results in anergy (Laning et al., 1997). As keratinocytes are unable to 
migrate to the local draining lymph nodes they do not encounter naïve T-lymphocytes, but 
are likely to encounter effector or memory cells that are recirculating into the skin (Black 
et al., 2007). Therefore, keratinocytes may play an important role in interacting with T-
lymphocytes following initial priming by TCI. 
 
In contrast to bone marrow DCs, incubation of HaCaT cells with LPS failed to cause an 
up-regulation of any of the activation markers studied or cytokine production. This is in 
contrast to studies with freshly isolated human keratinocytes where incubation with LPS 
caused an increase in the secretion of pro-inflammatory cytokines and chemokines,  in 
addition to upregulation of some activation markers (Song et al., 2002). Recognition of 
LPS by TLR-4 requires the help of a co-receptor and an accessory protein CD14 and MD2, 
respectively (Remer et al., 2003).  Previous studies by Kollisch et al., (2004) showed that 
although HaCaT cells express TLR-4 and CD14 at the mRNA level, they do not react 
when stimulated with LPS in vitro. It was further suggested that this was due to a lack of 
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MD-2 expression. A separate study showed that TLR-4 mediated LPS signaling was 
dependent on the expression of MD-2 (Visintin et al., 2003). Therefore, even in the 
presence of TLR-4 expression, no functional LPS signaling can be expected without 
sufficient expression of MD-2. The inability to respond to LPS stimulation because of a 
defect in the receptor highlights a potential drawback of using immortalized cell lines such 
as HaCaT cells when trying to understand in vivo processes.     
 
In addition to surface marker expression, cytokine secretion by HaCaT cells was also 
measured following incubation with tetanus proteins. Our results showed that no 
measurable IL-1β or TNF-α was detected in the tissue culture supernatant of HaCaT cells 
incubated with tetanus proteins or in control cultures with IFN-γ. This is surprising as 
keratinocytes are capable of secreting both IL-1 and TNF-α upon in vitro stimulation with 
IFN-γ (Pastore et al., 1998). As for the dendritic cells, the failure to detect cytokines in the 
culture medium may be due to technical limitation and lack of sensitivity of the ELISA 
assay used.  
 
Collectively, the results from the in vitro activation studies with bone marrow derived DCs 
and keratinocytes showed that tetanus proteins have limited activity for activating immune 
cells in vitro. Previous studies have suggested that under certain conditions, activation of 
immune cells may depend on the presence of so called danger signals that are present in 
vivo but are absent from in vitro cultures (Matzinger, 1994). The so-called danger model of 
immune cell activation proposes that when cells are stressed or injured they release danger 
signals or ‘alarms’ into the local microenvironment which in turn  can warn and activate 
local APCs to mount an immune response.  These danger signals are present in a number 
of different forms and include intracellular self-molecules such as mitochondria, ATP, 
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heat-shock proteins or extracellular –matrix breakdown products that are released into the 
surrounding environment following tissue damage or injury (Gallucci and Matzinger, 
2001b). It has been suggested that both IL-1β and TNF-α are primarily danger signals that 
are released in vivo in response to tissue damage, irrespective of antigenic challenge. 
Studies by (Zepter et al., 1997) showed that IL-1β is induced in human keratinocytes when 
in contact with inflammatory stimuli. In separate studies, TNF-α was reported to be 
produced when myocardium cells are injured (Azzawi and Hasleton, 1999). Therefore, the 
absence of IL-1 and TNF-α in the culture medium could also be associated with the lack of 
in vitro danger signals in this model. 
 
In light of the in vitro findings from the present study and with the danger model of 
activation in mind, real-time RT-PCR to detect mRNA for IL-1 and TNF was employed to 
investigate the activation of skin cells in vivo following TCI with tetanus proteins.  These 
studies showed an up-regulation of TNF-α mRNA expression in skin samples taken from 
the site of TCI which was not related to the presence of tetanus proteins as the PBS control 
group showed a similar or even higher level of activation. Results from further studies 
showed that in the absence of tetanus proteins, the level of TNF-α mRNA expression was 
increased by shaving alone or shaving together with application of the depilatory cream. 
This implies that shaving alone was sufficient to induce TNF-α mRNA expression in skin 
cells and that the depilatory cream did not have an additional effect on TNF-α mRNA 
expression. This strongly suggests that the increased TNF-α mRNA expression was a result 
of the skin pre-treatment rather than the application of tetanus proteins themselves. In 
contrast to TNF-α mRNA expression, no measurable up-regulation of IL-1α or IL-1β gene 
expression was evident in skin samples following TCI with tetanus proteins. If anything, a 
slight decrease in both IL-1α and IL-1β gene expression was evident for most of the time 
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points. Other studies have illustrated that IL-1α is capable of acting through the IL1-R1 
receptor to provide a similar stimulus to that of IL-1β for LC migration (Shornick et al., 
2001). Furthermore, it has been proposed that IL-lα can be associated with activation and 
migration of LCs in the presence of topically applied non-contact sensitising agents (Enk 
and Katz, 1992) and may therefore be more relevant than IL-1β to the immune response 
generated after TCI.  The results presented in this study are consistent with previously 
published data, which suggest that any cutaneous trauma of significant magnitude, 
regardless of an antigenic challenge, induces or enhances the secretion of pro-
inflammatory cytokines such as TNF-α (Schreiber et al., 1992). Consistent with these 
results, previous studies have showed an association between significant skin trauma 
caused through contact sensitisation, skin irritation or exposure to ultraviolet B light 
(UVB) with TNF-α gene activation (Kimber & Cumberbatch., 1992; Moodycliffe et al., 
1992) . Therefore, the increase in TNF-α mRNA expression in skin samples may be caused 
by the physical trauma of shaving rather than through the actions of the tetanus proteins. A 
possible reason for not detecting an increase in IL-1 mRNA expression could be due to IL-
1 mRNA stability. In all cells, mRNA has a limited lifetime (stability) before it is 
degraded. In mammalian cells, the presence of AU rich elements tends to destabilize 
mRNA transcripts through the actions of cellular proteins that bind to these motifs, and this 
may act as a crucial mechanisms for preventing the overproduction of potent inflammatory 
cytokines such as TNF or IL-1 (Shaw and Kamen, 1986). Therefore, it is possible that IL-
1α and IL-1β transcripts are less stable and are degraded faster than TNF-α mRNA. 
However, the stability of IL-1 mRNA in the context of this experiment was not studies.  In 
the present study, real-time RT-PCR data showed that IL-1β and IL-1α transcripts were 
present in unshaved normal mouse skin samples, suggesting that low constitutive levels of 
these cytokines may be produced in normal mice. It is possible that this low level of IL-1α 
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or IL-1β is sufficient to provide the second signal for promotion of LC translocation and 
migration out of the epidermis. Alternatively, it has been suggested that when 
keratinocytes are damaged, for example by shaving, IL-1α may be released from 
keratinocytes into the surrounding environment (Wood et al., 1996; Lee et al., 1997) which 
in turn may facilitate the translocation of LC trafficking out of the draining lymph nodes. 
The mechanisms whereby LCs are activated by cytokines is not yet fully understood but 
remains an interesting area for future studies particularly with the development of murine 
cytokine knockout model systems (Wang et al., 2003). 
 
In addition to IL-1 and TNF-α, other cytokines or molecules may also be involved in the 
initiation of LCs activation and migration from the epidermis following TCI. IL-18, for 
example, has been shown to be important for initiation of LC activation and migration in 
mouse models (Cumberbatch et al., 2001;(Wang et al., 2003) and an up regulation in 
chemokine receptor CCR7, which may be involved in the homing of antigen loaded LCs to 
paracortex region of the lymph node (Cumberbatch et al., 1991). Furthermore, in the 
present set of the in vivo experiments, it was not possible to determine which skin cells 
were responsible for increasing the TNF-α gene expression in the context of TCI. Skin 
samples contained all layers and therefore all epidermal cell mRNA transcripts. Previous 
studies have demonstrated that both keratinocytes and LCs can express IL-1α and IL-1β in 
human skin (Kupper et al., 1986) whereas in mice, keratinocytes and LCs are the primary 
source of TNF-α/ IL-1α, and IL-1β respectively (Schreiber et al., 1992b). Interestingly, IL-
1β can be produced from other cells of the skin. For example, in situ hybridization studies 
have shown that dermal cells, which were morphologically consistent with dermal 
macrophages or dermal DCs, were the predominant IL-1β expressing cells (Shornick et al., 
2001). Conducting in situ hybridization experiments with a labeled probe specific for 
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detection of cytokines such as IL-1β together with immunohistochemistry using lineage 
specific markers for phenotype analysis may help identify cell subsets that can secrete 
cytokine. 
 
In vivo cytokine study suggests that the depilatory cream did not have any additional 
stimulatory effect to that caused by shaving alone. Therefore, it is possible that application 
of depilatory cream played another role in TCI, probably in aiding the translocation of 
tetanus proteins through the skin. Immunohistochemistry staining studies showed that the 
majority of topically applied HCWT protein remained within the outer keratin layers of the 
skin when applied onto the shaved skin. In contrast, when HCWT protein was applied onto 
skin, which had been shaved and treated with depilatory cream, a steady translocation of 
protein was evident through the epidermis and into the dermis over a period of 2 hours. 
Thus, application of the hair removing cream appears to increase the opportunity for 
topically applied protein antigens to interact with the underlying epidermal layers of the 
skin. This is probably due to the actions of removing residual hair and the thick waxy outer 
stratum corneum layer that lies on top of the immunologically active epidermal cells. This 
finding provide possible explanation for the lack of a significant immune response 
following TCI with tetanus proteins onto shaved skin in the absence of depilatory cream 
treatment, as presented in Chapter 4.   
 
The recombinant HCWT fragment in its native form has a molecular mass of 50kDa 
whereas the TTxd is a larger molecule of 170 to 200kDa. Furthermore, formaldehyde 
treatment during the production of TTxd causes cross-linking of amide groups and 
therefore creates an even bulkier, protein molecule. One possible explanation for the 
increased immunogenicity of HCWT compared to TTxd by TCI is that because of the 
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smaller size of the toxin fragment it was more efficient at gaining access to the 
immunologically active layers of the skin when compared to the larger TTxd.  
Unfortunately, it was not possible to compare the translocation of HCWT protein with 
TTxd through the epidermis in this study as attempts to effectively detect TTxd in skin 
samples taken from the site of TCI using the anti- HCWT antibody were unsuccessful. 
Immunohistochemistry staining with the rabbit anti-HC antibody was weak and in some 
cases comparable to that of the negative controls.  Further immunohistology studies with 
different antibodies are required to compare the translocation of TTxd with that of HCWT, 
and may help to gain insight into the differences in immunogenicity of the two proteins 
when administered via the skin.  
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Chapter 6: General discussion 
Needle-free vaccination delivery methods have become an attractive concept in attempts to 
avoid potential discomfort and spread of blood borne infections caused through the use of 
needles during routine vaccinations. Furthermore, the development of efficient and 
economical methods for production of highly purified vaccine antigens has provided an 
excellent opportunity to explore new needle-free delivery routes for immunisation against 
infectious diseases. TCI through the topical administration of vaccine candidates directly 
onto intact skin is a promising vaccine delivery method that targets potent immune cells 
residing within the outer regions of the skin. The overall aim of this thesis was to compare 
the immunogenicity of potential future tetanus vaccine candidate HCWT and a double-
point mutant derivative HCM115 with that of TTxd, the current vaccine component 
following TCI in a mouse model. Collectively, we demonstrated that TCI with HCWT 
induces a superior TeNT neutralising antibody response compared to immunisation with 
TTxd (Johnston et al., 2009). In addition, this study sought to gain insight into the 
underlying immune mechanisms involved in the initiation of immune responses following 
TCI by using these tetanus proteins as models to study the in vitro and in vivo interactions 
with immune skin cells. 
 
Collectively, the results presented in this thesis suggest that there are two main factors that 
need to be considered to fully exploit TCI as an effective method of vaccine delivery; (1) 
enhancing the translocation of topically applied antigens across the usually impermeable 
skin barrier and (2) promoting the appropriate stimulation of the underlying immune cells.  
For successful uptake of topically applied antigens, it may be important to consider the size 
of the vaccine candidate. Results presented in this study showed that HCWT entered the 
underlying layers of the skin within 10 minutes post-application, suggesting that HCWT 
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fragment may be better that TTxd for TCI due to its much smaller size and therefore better 
access to APCs in the underlying epidermal layers. Interestingly, results from a recent 
study by (Naito et al., 2007) showed that in the absence of adjuvant, TeNT neutralising 
antibodies could be induced following prolonged topical application of TTxd (≥ 16 hours). 
The authors in this study applied the antigen using a patch as opposed to directly in 
solution, which could have enhanced the uptake and absorption by keeping the skin moist 
and the antigen concentrated in one area for a longer period. This indicates that for 
successful TCI for large molecules, such as TTxd, there might be a need to prolong the 
contact of the antigen with the surface of the skin, and that smaller molecules can 
translocate into the underlying layers and be expected to induce more efficient immune 
responses, as confirmed in this study.  
  
In this study, no measurable immune response could be detected following topical 
application of vaccine antigens directly onto shaved skin. This finding, in addition to the 
limited uptake of antigen in those animals, suggests that the weak antibody response was 
primarily caused by poor uptake of antigen due to inadequate disruption of the outer skin 
barrier. Upon application of the depilatory cream, residual hair left behind following 
shaving was removed and disruption of the outer skin barrier increased the uptake of 
topically applied antigens into the underlying layers. Therefore, in addition to considering 
the size, type and duration of antigen exposure to skin cells when carrying out TCI, it may 
also be important to ensure that the correct skin pre-treatment is applied for adequate 
antigen delivery. To overcome the outer barrier layer a number of antigen delivery 
techniques have been developed including delivery of vaccine antigens via elastic 
liposomes (Mishra et al., 2006),  pre-treating skin with microneedles (Qiu et al., 2008) or 
through use of ultrasound  (Tezel et al., 2005a). Results from these studies indicate that 
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TCI using such methods can readily induce both mucosal and systemic immune responses 
against co-applied or encapsulated antigens due to efficient translocation and delivery to 
underlying immune cells. Future studies may focus on comparing the effect of  different 
methods of barrier disruption on the immune response to tetanus antigens such as low 
frequency ultrasound combined with SDS, which has been known to increase skin 
permeability and enhance delivery.  
 
In addition to enhance the uptake of antigen, it is also important that the appropriate skin 
pre-treatment is carried out for effective stimulation of the underlying immune cells. 
Previous TCI studies which have shown that disruption of the skin barrier by abrasion, tape 
stripping (Glenn et al., 2007; Godefroy et al., 2005) or external stimulations such as low 
frequency ultrasound (Tezel et al., 2005) or local hyperthermia (Upadhyay, 2006) can 
increase immunogenicity of topically applied antigens.  In addition, recent studies by 
Godefroy et al., (2005) have also showed that the generation of protective immune 
responses by topical application of CRM197 is influenced by the skin pre-treatment. For 
example, when applied to untreated skin, CRM197 induced considerably lower protective 
immune responses in comparison to skin that had been damaged by tape stripping or mild 
abrasion. It is possible that the more aggressive skin pre-treatment led to the initiation of 
endogenous danger signals, which have been shown to be released in tissues that are 
undergoing stress or damage from trauma or chemical modification (Gallucci and 
Matzinger, 2001). These danger signals can subsequently act as co-stimulatory signals that 
aid in the initiation of activation and maturation of LCs or keratinocytes (Peachman et al., 
2003). The absence of the danger signal, in the in vitro cell culture with tetanus proteins 
may explain the low in vitro stimulation of DCs and keratinocytes observed in this study. 
This suggests that while effectively bringing the tetanus antigens into contact with cells in 
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the epidermis is necessary for generation of immune responses in vivo, the antigens are not 
by themselves efficient at activating immune cells and that other in vivo factors may 
contribute to this.  
 
In this thesis, studies have been carried out in an attempt to understand the roles of LC and 
keratinocytes in the generation of immune response following TCI. Although in vitro 
studies showed limited stimulation of both keratinocyte and bone marrow DC when 
incubated with tetanus proteins an increase in TNF-α mRNA was readily detectable in vivo 
after shaving of the skin. However, the type of cells or mechanism responsible for such 
increases was not determined in this study. Future work should try to address the roles 
played by different immune cells during TCI. The epidermis is a complex system 
containing, in addition to LC and keratinocytes, other cell types such as granulocytes, 
dermal dendritic cells, mast cells or γ/δ T-cells (Loser and Beissert, 2007;Metz et al., 
2008) which may play a significant role in the development of local cutaneous and 
systemic immune responses following TCI. A recent study by (Fukunaga et al., 2008b), for 
example, showed that dermal DCs rather than LCs isolated from draining lymph nodes 
following application of a hapten could activate T-cells which suggests that LCs may not 
be the only APC involved in skin immunity. The lack of a clear cut marker for the reliable 
discrimination between LCs and other cells have left the question of to what extent other 
cell types are involved in the generation of immune responses following TCI unanswered. 
Interestingly,  a number of murine model systems have been developed in which LCs can 
be depleted (Bennett et al., 2005;Kaplan et al., 2005;Kissenpfennig et al., 2005). Such 
models could be useful for future studies to determine to what extent LCs contribute to 
TCI responses.   
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Increasing the knowledge on how to modulate the response of cutaneous immune cells will 
be beneficial for the rational design of innovative approaches, which promote successful 
delivery of antigen by the transcutaneous route.  Contribution of each cell type for 
inducing TH-1 or TH-2 responses could be exploited to achieve a well-defined immune 
response. 
 
In summary, the results presented in this thesis have demonstrated that recombinant HCWT 
protein is a promising potential novel vaccine candidate, which can elicit a potent TeNT 
neutralising antibody response following TCI in mice (Johnston et al., 2009). Although the 
exact mechanisms involved in generating immune responses following TCI have yet to be 
fully determined, they seem to require a means of overcoming the physical barrier caused 
by the stratum corneum, and the appropriate activation of immune cells in the epidermis. 
Future research efforts should focus of optimising mechanisms of barrier disruption and 
delivery methods for effective antigen uptake together with selection of appropriate 
vaccine formulations and adjuvants. There is currently a need to understand the relative 
contribution of each cell type to the generation of the appropriate local and systemic 
immune response. This in turn could lead to the development of a simple and novel 
vaccination strategy that can be tailored to modulate immune responses towards topically 
applied antigens. 
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